<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Phlebotonics for venous insufficiency - Martinez-Zapata, MJ - 2020 | Cochrane Library</title> <meta content="Phlebotonics for venous insufficiency - Martinez-Zapata, MJ - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003229.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Phlebotonics for venous insufficiency - Martinez-Zapata, MJ - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003229.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003229.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Phlebotonics for venous insufficiency" name="citation_title"/> <meta content="Maria José Martinez-Zapata" name="citation_author"/> <meta content="CIBER Epidemiología y Salud Pública (CIBERESP)" name="citation_author_institution"/> <meta content="mmartinezz@santpau.cat" name="citation_author_email"/> <meta content="Robin WM Vernooij" name="citation_author"/> <meta content="University Medical Center Utrecht" name="citation_author_institution"/> <meta content="Daniel Simancas-Racines" name="citation_author"/> <meta content="Universidad Tecnológica Equinoccial" name="citation_author_institution"/> <meta content="Sonia Maria Uriona Tuma" name="citation_author"/> <meta content="Vall Hebron University Hospital" name="citation_author_institution"/> <meta content="Airton T Stein" name="citation_author"/> <meta content="Universidade Federal de Ciências da Saúde" name="citation_author_institution"/> <meta content="Rosa Maria M Moreno Carriles" name="citation_author"/> <meta content="Universitary Hospital La Princesa" name="citation_author_institution"/> <meta content="Emilio Vargas" name="citation_author"/> <meta content="Hospital Clínico San Carlos. Universidad Complutense de Madrid" name="citation_author_institution"/> <meta content="Xavier Bonfill Cosp" name="citation_author"/> <meta content="CIBER Epidemiología y Salud Pública (CIBERESP)" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD003229.pub4" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/11/03" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003229.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003229.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003229.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="4-Aminobenzoic Acid [therapeutic use]; Angioedemas, Hereditary [drug therapy]; Calcium Dobesilate [therapeutic use]; Centella; Chronic Disease; Diosmin [analogs &amp; derivatives, therapeutic use]; Edema [drug therapy]; Hematologic Agents [*therapeutic use]; Leg; Leg Ulcer [drug therapy]; para-Aminobenzoates [therapeutic use]; Phytotherapy [methods]; Pinus; Plant Extracts [*therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic; Rutin [therapeutic use]; Venous Insufficiency [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003229.pub4&amp;doi=10.1002/14651858.CD003229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Ko3zGe0H";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003229\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003229\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003229\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003229\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ms","ja","hr","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003229.pub4",title:"Phlebotonics for venous insufficiency",firstPublishedDate:"Nov 3, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003229.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003229.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003229.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003229.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003229.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003229.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003229.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003229.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003229.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003229.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>17677 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003229.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-sec-0096"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-sec-0013"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-sec-0014"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-sec-0038"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-sec-0090"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/appendices#CD003229-sec-0101"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/supinfo/CD003229StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/supinfo/CD003229StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Phlebotonics for venous insufficiency</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/information#CD003229-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Maria José Martinez-Zapata</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/information#CD003229-cr-0005">Robin WM Vernooij</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/information#CD003229-cr-0006">Daniel Simancas-Racines</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/information#CD003229-cr-0007">Sonia Maria Uriona Tuma</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/information#CD003229-cr-0008">Airton T Stein</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/information#CD003229-cr-0009">Rosa Maria M Moreno Carriles</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/information#CD003229-cr-0010">Emilio Vargas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003229.pub4/information#CD003229-cr-0011">Xavier Bonfill Cosp</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/information/en#CD003229-sec-0107">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 03 November 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003229.pub4">https://doi.org/10.1002/14651858.CD003229.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003229-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003229-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003229-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003229-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003229-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003229-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003229-abs-0001" lang="en"> <section id="CD003229-sec-0001"> <h3 class="title" id="CD003229-sec-0001">Background</h3> <p>Chronic venous insufficiency (CVI) is a condition in which veins are unable to transport blood unidirectionally towards the heart. CVI usually occurs in the lower limbs. It might result in considerable discomfort, with symptoms such as pain, itchiness and tiredness in the legs. Patients with CVI may also experience swelling and ulcers. Phlebotonics are a class of drugs often used to treat CVI. This is the second update of a review first published in 2005. </p> </section> <section id="CD003229-sec-0002"> <h3 class="title" id="CD003229-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of phlebotonics administered orally or topically for treatment of signs and symptoms of lower extremity CVI. </p> </section> <section id="CD003229-sec-0003"> <h3 class="title" id="CD003229-sec-0003">Search methods</h3> <p>The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase, and CINAHL databases and the World Health Organization International Clinical Trials Registry Platform and Clinicaltrials.gov trials register up to 12 November 2019. We searched the reference lists of the articles retrieved by electronic searches for additional citations. We also contacted authors of unpublished studies. </p> </section> <section id="CD003229-sec-0004"> <h3 class="title" id="CD003229-sec-0004">Selection criteria</h3> <p>We included randomised, double‐blind, placebo‐controlled trials (RCTs) assessing the efficacy of phlebotonics (rutosides, hidrosmine, diosmine, calcium dobesilate, chromocarbe, <i>Centella asiatica</i>, disodium flavodate, French maritime pine bark extract, grape seed extract and aminaftone) in patients with CVI at any stage of the disease. </p> </section> <section id="CD003229-sec-0005"> <h3 class="title" id="CD003229-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and assessed the quality of included RCTs. We estimated the effects of treatment by using risk ratios (RRs), mean differences (MDs) and standardized mean differences (SMDs), according to the outcome assessed. We calculated 95% confidence intervals (CIs) and percentage of heterogeneity (I<sup>2</sup>). Outcomes of interest were oedema, quality of life (QoL), assessment of CVI and adverse events. We used GRADE criteria to assess the certainty of the evidence. </p> </section> <section id="CD003229-sec-0006"> <h3 class="title" id="CD003229-sec-0006">Main results</h3> <p>We identified three new studies for this update. In total, 69 RCTs of oral phlebotonics were included, but only 56 studies (7690 participants, mean age 50 years) provided quantifiable data for the efficacy analysis. These studies used different phlebotonics (28 on rutosides, 11 on hidrosmine and diosmine, 10 on calcium dobesilate, two on <i>Centella asiatica</i>, two on aminaftone, two on French maritime pine bark extract and one on grape seed extract). No studies evaluating topical phlebotonics, chromocarbe, naftazone or disodium flavodate fulfilled the inclusion criteria. </p> <p>Moderate‐certainty evidence suggests that phlebotonics probably reduce oedema slightly in the lower legs, compared with placebo (RR 0.70, 95% CI 0.63 to 0.78; 13 studies; 1245 participants); and probably reduce ankle circumference (MD ‐4.27 mm, 95% CI ‐5.61 to ‐2.93 mm; 15 studies; 2010 participants). Moderate‐certainty evidence shows that phlebotonics probably make little or no difference in QoL compared with placebo (SMD ‐0.06, 95% CI ‐0.22 to 0.10; five studies; 1639 participants); and similarly, may have little or no effect on ulcer healing (RR 0.94, 95% CI 0.79 to 1.13; six studies; 461 participants; low‐certainty evidence). Thirty‐seven studies reported on adverse events. Pooled data suggest that phlebotonics probably increase adverse events slightly, compared to placebo (RR 1.14, 95% CI 1.02 to 1.27; 37 studies; 5789 participants; moderate‐certainty evidence). Gastrointestinal disorders were the most frequently reported adverse events. We downgraded our certainty in the evidence from 'high' to 'moderate' because of risk of bias concerns, and further to 'low' because of imprecision. </p> </section> <section id="CD003229-sec-0007"> <h3 class="title" id="CD003229-sec-0007">Authors' conclusions</h3> <p>There is moderate‐certainty evidence that phlebotonics probably reduce oedema slightly, compared to placebo; moderate‐certainty evidence of little or no difference in QoL; and low‐certainty evidence that these drugs do not influence ulcer healing. Moderate‐certainty evidence suggests that phlebotonics are probably associated with a higher risk of adverse events than placebo. Studies included in this systematic review provided only short‐term safety data; therefore, the medium‐ and long‐term safety of phlebotonics could not be estimated. Findings for specific groups of phlebotonics are limited due to small study numbers and heterogeneous results. Additional high‐quality RCTs focusing on clinically important outcomes are needed to improve the evidence base. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003229-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003229-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003229-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003229-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003229-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003229-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003229-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003229-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD003229-abs-0013">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003229-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003229-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003229-abs-0002" lang="en"> <h3>Drugs to improve blood flow for people who have poor blood circulation in the veins of their legs </h3> <p><b>Background</b> </p> <p>In chronic venous insufficiency, veins of the lower limbs are unable to transport blood towards the heart. It might be caused by genetic factors, may occur after trauma, or may result from a blood clot. Poor movement of blood up the legs may cause swelling and puffiness, feelings of heaviness, tingling, cramps, pain, varicose veins and changes in skin pigmentation. If severe insufficient blood circulation occurs, ulcers and skin wasting can develop. Drugs such as natural flavonoids extracted from plants and similar synthetic products may improve blood circulation. These drugs are known collectively as venoactive drugs or phlebotonics. This review examined evidence from randomised controlled clinical trials comparing these drugs versus inactive treatment (placebo), generally given over one to three months. </p> <p><b>Study characteristics and key results</b> </p> <p>We identified three new studies for this update. In total, 69 studies met the eligibility criteria for this review. However, we could only use 56 studies (7690 participants; mean age 50 years) in further analysis. </p> <p>We compared the results and summarised the evidence from the studies. After doing so, we assessed how certain the evidence was. To do this, we considered factors such as the way studies were conducted, study sizes, and consistency of findings across studies. Based on our assessments, we categorised the evidence as potentially being of very low, low, moderate or high certainty. </p> <p>Moderate‐certainty evidence from 13 studies (involving 1245 people) suggests that phlebotonics probably slightly reduce puffiness (oedema) compared with placebo. Moderate‐certainty evidence suggests that there is little or no difference in quality of life for people taking phlebotonics when compared with placebo. Low‐certainty evidence suggests there is little or no difference in the proportion of healed ulcers with phlebotonics, compared with placebo. Moderate‐certainty evidence from 37 studies (involving 5789 people) suggests that phlebotonics probably produce more side effects, especially gastrointestinal disorders. </p> <p><b>Certainty of the evidence</b> </p> <p>All evidence was of moderate or low certainty. Starting from an initial assumption of high certainty, we downgraded the certainty of evidence by one level for each outcome because of the high risk of bias, primarily due to selective outcome reporting and incomplete outcome data. For the outcome of ulcer healing, we downgraded by an additional level due to statistical imprecision (small number of events). With moderate‐certainty evidence, we are moderately confident in the effect estimates for these outcomes. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. With low‐certainty evidence, our confidence in the effect estimate for that outcome is limited. The true effect may be substantially different from the estimate of the effect. </p> <p><b>How‐up‐to date is this review?</b> </p> <p>The evidence in this Cochrane Review is current to November 2019.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003229-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003229-sec-0096"></div> <h3 class="title" id="CD003229-sec-0097">Implications for practice</h3> <section id="CD003229-sec-0097"> <p>Phlebotonics present limited efficacy for oedema and for some signs and symptoms related to chronic venous insufficiency (CVI). </p> <p>There is moderate‐certainty evidence that phlebotonics probably slightly reduce oedema compared to placebo; moderate‐certainty evidence of little or no difference in quality of life (QoL); and low‐certainty evidence indicates that these drugs do not influence ulcer healing. Moderate‐certainty evidence shows that phlebotonics are probably associated with higher risk of adverse events than placebo, especially in the subgroup analysis of rutoside group. Studies included in this Cochrane Review provided only short‐term efficacy and safety data; therefore, the middle‐ and long‐term efficacy and safety of phlebotonics could not be estimated. Based on the results of subgroup analysis some phlebotonics were effective for certain symptoms and signs; however, given the limited number of studies and the discordance in their results, these findings are uncertain. </p> </section> <h3 class="title" id="CD003229-sec-0098">Implications for research</h3> <section id="CD003229-sec-0098"> <p>As a result of the importance of phlebotonics and the limitations of current evidence, high‐quality RCTs are needed to evaluate the efficacy and adverse effects of this group of drugs in an independent and rigorous manner. However, the new studies included in this review have improved methodological aspects and have already considered in a standardized manner the diagnostic classification of participants, measurement of signs and symptoms, larger sample sizes and longer follow‐up, and future trials should continue these recommendations. Additional research regarding QoL and both ulcer healing and trophic disorders is needed, particularly with an accurate definition of the term and the use of objective measurements. More and better assessments of venous ulcers should be made, and QoL surveys specifically validated for CVI should be introduced. Furthermore, currently available data on safety refer to a short administration period; therefore, long‐term observational follow‐up studies are needed to better define the safety profile of each of the phlebotonics and to outline more clearly the risk/benefit ratio. </p> <p>When the efficacy of phlebotonics is investigated, restriction criteria are recommended to avoid situations that are more likely to result in adverse effects, including long‐term administration, important co‐morbidity, leucopenia, ageing and multiple medications. In addition, researchers involved in these trials should make an explicit statement regarding their conflicts of interest. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003229-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003229-sec-0008"></div> <div class="table" id="CD003229-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Do phlebotonics improve signs and symptoms of venous insufficiency when compared with placebo?</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phlebotonics compared with placebo for venous insufficiency</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with venous insufficiency<br/><b>Settings:</b> hospital and ambulatory settings<br/><b>Intervention:</b> phlebotonics<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects *</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(RCTs)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with phlebotonics</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Oedema in the lower legs</b> </p> <p><b>(dichotomous</b> </p> <p><b>variable)</b> </p> <p>Follow‐up: 1‐6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>575 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>403 per 1000</b><br/>(362 to 449) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.70</b> <br/>(0.63 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1245<br/>(13 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phebotonics probably slightly reduce oedema in the lower limb compared to placebo</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Oedema in the lower legs</b> </p> <p><b>(ankle circumference, mm)</b> </p> <p>Follow‐up: 1‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ankle circumference in the lower legs in the phlebotonic groups was <b>4.27 mm lower</b> (5.61 to 2.93 lower) than in the placebo groups </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010<br/>(15 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phlebotonics probably slightly reduce ankle perimeter circumference compared to placebo</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><b>(CIVIQ and other questionnaires)</b> </p> <p>Follow‐up: mean 2‐12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The QoL in the phlebotonic groups was <b>0.06 SMD lower</b> (0.22 lower to 0.1 higher) than in the placebo groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1639<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phebotonics probably make little or no difference to QoL compared with placebo</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulcer healing</b> </p> <p><b>(dichotomous variable)</b> </p> <p>Follow‐up: 1‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>381 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>358 per 1000</b><br/>(301 to 430) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/>(0.79 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>461<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phlebotonics may make little or no difference to ulcer healing compared to placebo</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 1‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>158 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>180 per 1000</b><br/>(161 to 200) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.14</b> <br/>(1.02 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5789<br/>(37 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phlebotonics probably slightly increase adverse events compared to placebo</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>CIVIQ</b> : Chronic Venous Insufficiency International Questionnaire; <b>QoL</b> : quality of life; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The certainty of the evidence was downgraded (1 level) to moderate because of overall risk of bias (10 studies had an unclear risk of bias and two had a high risk of bias)<br/><sup>b</sup>The certainty of the evidence was downgraded (1 level) to moderate because of overall risk of bias (11 studies had an unclear risk of bias and one had a high risk of bias)<br/><sup>c</sup>The certainty of the evidence was downgraded (1 level) to moderate because of overall risk of bias (one study had an unclear risk of bias and two had a high risk of bias)<br/><sup>d</sup>The certainty of the evidence was downgraded (2 levels) to low because of overall risk of bias (four studies had an unclear risk of bias and two had a high risk of bias) and imprecision (low number of events)<br/><sup>e</sup>The certainty of the evidence was downgraded (1 level) to moderate because of overall risk of bias (28 RCTs had unclear risk of bias and four RCTs had high risk of bias) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003229-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003229-sec-0009"></div> <section id="CD003229-sec-0010"> <h3 class="title" id="CD003229-sec-0010">Description of the condition</h3> <p>Chronic venous insufficiency (CVI) is a condition in which veins are unable to transport blood unidirectionally toward the heart with flow adapted to tissue drainage needs, temperature regulation and haemodynamic reserve, regardless of their position and activity. CVI first manifests as an increase in venous tension (venous hypertension, or high blood pressure in the veins) with or without reflux (<a href="./references#CD003229-bbs2-0200" title="KurzX , KahnSR , AbenhaimL , ClementD , NorgrenL , BaccagliniU , et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Venous Insufficiency Epidemiologic and Economic Studies. International Angiology1999;18(2):83-102.">Kurz 1999</a>). Depending on its cause, CVI can be congenital, primary (with undetermined cause) or secondary (post‐thrombotic, post‐traumatic or other). Depending on its pathophysiology, CVI can be related to occlusion (blocked veins), reflux or both. Finally, it might depend on superficial or deep venous systems or on perforator anomalies (<a href="./references#CD003229-bbs2-0207" title="PorterJM , MonetaGL . Reporting standards in venous disease: an update. International Consensus Committee on Chronic Venous Disease. Journal of Vascular Surgery1995;21(4):635-45.">Porter 1995</a>). </p> <p>CVI is an important cause of discomfort and inability to work, and many people find it difficult to live with this condition. Its prevalence has not been clearly determined because available studies regarding this subject are few, and those that are available present limitations. Some studies do not cover the whole pathological spectrum and focus only on varicose veins or ulcers; others do not use standardized definitions of the illness and apply a variety of diagnostic criteria (<a href="./references#CD003229-bbs2-0204" title="Nicolaides AN Cardiovascular Disease Educational and Research Trust European Society of Vascular Surgery The International Angiology Scientific Activity Congress Organization International Union of Angiology Union Internationale de Phlebologie at the Abbaye des Vaux de Cernay. Investigation of chronic venous insufficiency: a consensus statement (France, March 5-9, 1997). Circulation2000;102(20):E126-63.">Nicolaides 2000</a>). As a result, prevalence has been estimated at between 1% and 50% (<a href="./references#CD003229-bbs2-0192" title="EvansCJ , FowkesFG , RuckleyCV , LeeAJ . Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. Journal of Epidemiology and Community Health1999;53(3):149-53.">Evans 1999</a>; <a href="./references#CD003229-bbs2-0213" title="StanhopeJM . Varicose veins in a population of New Guinea. International Journal of Epidemiology1975;4(3):221-5.">Stanhope 1975</a>; <a href="./references#CD003229-bbs2-0215" title="Van den OeverR , HeppB , DebbautB , SimonI . Socio-economic impact of chronic venous insufficiency. An underestimated public health problem. International Angiology1998;17(3):161-7.">Van den Oever 1998</a>). The Framingham Study showed an annual incidence of 2.6% among women and 1.9% among men (<a href="./references#CD003229-bbs2-0183" title="BrandFN , DannenbergAL , AbbottRD , KannelWB . The epidemiology of varicose veins: the Framingham Study. American Journal of Preventive Medicine1988;4(2):96-101.">Brand 1988</a>). In a recent publication of the Edinburgh Vein Study, annual incidence of CVI was reported as 1% among the general population of the UK (<a href="./references#CD003229-bbs2-0210" title="RobertsonLA , EvansCJ , LeeAJ , AllanPL , RuckleyCV , FowkesFG . Incidence and risk factors for venous reflux in the general population: Edinburgh Vein Study. European Journal of Vascular and Endovascular Surgery2014;48(2):208-14.">Robertson 2014</a>). </p> <p>Causes of CVI are unknown, although it has been associated with venous dilation, deformity and valvular venous incompetence. Trophic skin disorders and venous ulcers result from severe varicose illness (<a href="./references#CD003229-bbs2-0184" title="CarpentierPH . Epidemiology and physiopathology of chronic venous leg diseases. Revue du Praticien2000;50(11):1176-81.">Carpentier 2000</a>). Varicose veins have a multi‐factorial origin related to advanced age and certain lifestyles (sedentary life), pregnancy, hereditary factors and obesity. Risk of ulcers may be increased by trauma and previous episodes of deep venous thrombosis (clinical or subclinical) (<a href="./references#CD003229-bbs2-0212" title="ScottTE , LaMorteWW , GorinDR , MenzoainJO . Risk factors for chronic venous insufficiency: a dual case-control study. Journal of Vascular Surgery1995;22(5):622-8.">Scott 1995</a>). </p> <p>Clinical manifestations of CVI differ according to stage of the illness and can include feelings of heaviness in the extremities, paraesthesia (tingling), cramps, pain, oedema (swellings), varicose veins, skin pigmentation, varicose sores and signs of skin atrophy (wasting). Symptoms are frequently related to extent of disease. Underlying venous disease (superficial, deep or both, with or without obstruction) has a major impact on both manifestations of the disease and response to treatment. Since 1994, criteria develop by the International Consensus Committee on Chronic Venous Disease have been used to define and classify CVI in a standardized fashion (<a href="./references#CD003229-bbs2-0207" title="PorterJM , MonetaGL . Reporting standards in venous disease: an update. International Consensus Committee on Chronic Venous Disease. Journal of Vascular Surgery1995;21(4):635-45.">Porter 1995</a>). According to this Consensus, clinical signs (C), aetiology (E), anatomical distribution (A) and physiological conditions (P) ("Clinical‐Etiology‐Anatomy‐Pathophysiology"; CEAP) are used to classify CVI (<a href="./references#CD003229-bbs2-0207" title="PorterJM , MonetaGL . Reporting standards in venous disease: an update. International Consensus Committee on Chronic Venous Disease. Journal of Vascular Surgery1995;21(4):635-45.">Porter 1995</a>). A later revision of the CEAP classification established a means of differentiating between chronic venous disorder (referring to all morphology and functional abnormalities of the venous system) and CVI (reserved for more advanced stages of the disease with oedema, skin changes or venous ulcers) (<a href="./references#CD003229-bbs2-0191" title="EklöfB , RutherfordRB , BerganJJ , CarpentierPH , GloviczkiP , KistnerRL , et al, American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification. Revision of the CEAP classification for chronic venous disorders: consensus statement. Journal of Vascular Surgery2004;40(6):1248-52.">Eklöf 2004</a>). In parallel, a venous clinical severity score (ranging from none (0) to severe (3)) was established to assess pain, varicose veins, venous oedema, skin pigmentation, inflammation, induration, active ulcer (number, duration and size) and use of compression therapy (<a href="./references#CD003229-bbs2-0216" title="VasquezMA , RabeE , McLaffertyRB , ShortellCK , MarstonWA , GillespieD , et al. Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American Venous Forum Ad Hoc Outcomes Working Group. Journal of Vascular Surgery2010;52(5):1387-96.">Vasquez 2010</a>). Recently, a new version of CEAP classification has been published (<a href="./references#CD003229-bbs2-0202" title="LurieF , PassmanM , MeisnerM , DalsingM , MasudaE , WelchH , et al. The 2020 update of the CEAP classification system and reporting standards. Journal of Vascular Surgery2020;8(3):342-352.">Lurie 2020</a>), in which Corona phlebectatica was added as a C4c clinical subclass, the modifier “r” introduced for recurrent varicose veins and recurrent venous ulcers and numeric descriptions of the venous segments replaced by their common abbreviations (<a href="./references#CD003229-bbs2-0202" title="LurieF , PassmanM , MeisnerM , DalsingM , MasudaE , WelchH , et al. The 2020 update of the CEAP classification system and reporting standards. Journal of Vascular Surgery2020;8(3):342-352.">Lurie 2020</a>). </p> </section> <section id="CD003229-sec-0011"> <h3 class="title" id="CD003229-sec-0011">Description of the intervention</h3> <p>Surgery, sclerotherapy and mechanical compression are generally the preferred treatments for CVI. However, pharmacological treatments or phlebotonics are often used because they are easy to administer, and because compliance with compressive treatments (such as elastic stockings) is often poor. </p> <p>Phlebotonics represent a heterogeneous group of medications used to treat CVI. Most of these drugs are natural flavonoids extracted from plants. Synthetic products with flavonoid‐like properties are also used to treat venous disorders. In the Anatomical Therapeutic Chemical (ATC) system, phlebotonics are classified as vasoprotective agents (<a href="./references#CD003229-bbs2-0179" title="Anatomical Therapeutic Chemical (ATC) system classification. http://www.whocc.no/atc_ddd_index/?code=C05 (accessed December 2015).">ATC 2015</a>). Within this classification system, active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties. Phlebotonics are known as venoactive drugs whose mechanism of action is not scientifically well established despite the availability of numerous studies examining their pharmacological and clinical properties. These medications are associated with effects on macrocirculation (e.g. they may improve venous tone) (<a href="./references#CD003229-bbs2-0214" title="TsouredosY . Venous tone: are the phlebotonics properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg. Zeitschrift fur Kardiologie1991;80 Suppl 7:95-101.">Tsouderos 1991</a>) and on microcirculatory parameters (e.g. they may decrease capillary hyperpermeability) (<a href="./references#CD003229-bbs2-0181" title="BeharA , LagrueG , Cohen-BoulakiaF , BailletJ . Capillary filtration in idiopathic cyclic edema - effects of Daflon 500 mg. Nuklearmedizin1988;27(3):105-7.">Behar 1988</a>). </p> </section> <section id="CD003229-sec-0012"> <h3 class="title" id="CD003229-sec-0012">Why it is important to do this review</h3> <p>Lower limb CVI affects a predominantly adult population and it is a frequent cause for a referral from primary to secondary care (<a href="./references#CD003229-bbs2-0217" title="Venous Forum of the Royal Society of Medicine, BerridgeD , BradburyAW , DaviesAH , GohelM , NyamekyeI , et al. Recommendations for the referral and treatment of patients with lower limb chronic venous insufficiency (including varicose veins). Phlebology2011;26(3):91-3.">Venous Forum 2011</a>). Although phlebotonics are commercialised in many countries, in others they are not widely available. In some countries, such as Spain, for certain phlebotonics (calcium dobesilate, chromocarbe and naftazone) the CVI indication has been withdrawn, and for several other phlebotonics, such as aminaftone, diosmine, hidrosmine, escin and some rutosides, conditions of use during exacerbations of CVI have been limited to two or three months by the Spanish Ministry of Health (<a href="./references#CD003229-bbs2-0178" title="Agencia Española del Medicamento (2002). Re-evaluation of the risk-benefit relationship of oral phlebotonic agents [Re-evaluación de la relación beneficio-riesgo de los agentes flebotónicos para administración por via oral]. https://www.aemps.gob.es/informa/notasinformativas/medicamentosusohumano-3/seguridad-1/2002/ni_2002-09_flebotonicos/ (accessed 27 March 2020).">AEM 2002</a>). </p> <p>Controversy surrounds the clinical relevance of the efficacy and benefit‐risk balance of phlebotonics. Case‐control studies have found that risk of agranulocytosis (reduced numbers of white blood cells, mainly neutrophils) is associated with some phlebotonics (<a href="./references#CD003229-bbs2-0195" title="IbañezL , BallarínE , VidalX , LaporteJR . Agranulocytosis associated with calcium dobesilate. Clinical course and risk estimation with the case-control and the case-population approaches. European Journal of Clinical Pharmacology2000;56(9-10):763-7.">Ibañez 2000</a>; <a href="./references#CD003229-bbs2-0196" title="IbáñezL , VidalX , BallarínE , LaporteJR . Population-based drug-induced agranulocytosis. Archives of Internal Medicine2005;165(8):869-74.">Ibáñez 2005</a>; <a href="./references#CD003229-bbs2-0199" title="KaufmanDW , KellyJP , Levy ShapiroS . The Drug Etiology of Agranulocytosis and Aplastic Anemia. New York: Oxford University Press, 1991.">Kaufman 1991</a>). As efficacy is not well defined and serious harmful effects have been associated with phlebotonics, an evaluation of available evidence is needed. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003229-sec-0013" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003229-sec-0013"></div> <p>To assess the efficacy and safety of phlebotonics administered orally or topically for treatment of signs and symptoms of lower extremity CVI. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003229-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003229-sec-0014"></div> <section id="CD003229-sec-0015"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003229-sec-0016"> <h4 class="title">Types of studies</h4> <p>We included randomised, double‐blind, controlled trials assessing the efficacy and/or safety of phlebotonics compared with placebo in patients with chronic venous insufficiency (CVI) at any stage of the disease. We did not include studies which were not RCTs or double‐blind. We did not choose specific diagnostic classifications of CVI a priori because most of the studies were carried out before 1994, before the international diagnostic consensus of CVI. Therefore, we included RCTs with different diagnostic criteria. We included studies in which use of compression measures (support tights) was similar across groups. </p> </section> <section id="CD003229-sec-0017"> <h4 class="title">Types of participants</h4> <p>We included both male and female participants who were 18 years of age and older, suffering from any type of CVI. CVI could be diagnosed according to explicit clinical criteria and/or by objective instruments. Participant background, ethnicity and medical co‐morbidities at the beginning of the study did not influence the decision to include or exclude the study. We excluded studies that included participants with active thrombophlebitis and those including pregnant women. </p> </section> <section id="CD003229-sec-0018"> <h4 class="title">Types of interventions</h4> <p>We considered the following interventions to treat CVI acceptable for inclusion: treatments including venoactive drugs or phlebotonics, administered orally or topically, at any dosage and independently of the duration of treatment, compared with placebo. We excluded studies that compared phlebotonics among themselves or with any other therapeutic method (i.e. support tights or surgery). </p> <p> <ul id="CD003229-list-0001"> <li> <p>Natural products</p> <ul id="CD003229-list-0002"> <li> <p>Flavonoids: rutoside, French maritime pine bark extract (also known as pycnogenol), grape seed extract, diosmine and hidrosmine, disodium flavodate </p> </li> <li> <p>Saponosides: <i>Centella asiatica</i> </p> </li> </ul> </li> <li> <p>Synthetic products</p> <ul id="CD003229-list-0003"> <li> <p>Calcium dobesilate, naftazone, aminaftone, chromocarbe</p> </li> </ul> </li> </ul> </p> <p>We excluded escin (horse chestnut seed extract), as it is covered in another Cochrane Review (<a href="./references#CD003229-bbs2-0206" title="PittlerMH , ErnstE . Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD003230. [DOI: 10.1002/14651858.CD003230.pub4]">Pittler 2012</a>). </p> <p>Pentoxifylline is classified as a peripheral vasodilator, not as a vasoprotective agent (<a href="./references#CD003229-bbs2-0179" title="Anatomical Therapeutic Chemical (ATC) system classification. http://www.whocc.no/atc_ddd_index/?code=C05 (accessed December 2015).">ATC 2015</a>); therefore, we excluded it from this review. </p> </section> <section id="CD003229-sec-0019"> <h4 class="title">Types of outcome measures</h4> <p>We included studies that assessed any of the following outcome measures.</p> <section id="CD003229-sec-0020"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003229-list-0004"> <li> <p>Oedema in the lower limb measured by the dichotomous variable 'oedema' and the continuous variables 'ankle perimeter circumference' and 'volume of the leg' </p> </li> <li> <p>Specific quality of life (QoL) scales (e.g. Chronic Venous Insufficiency International Questionnaire (CIVIQ)) </p> </li> </ul> </p> </section> <section id="CD003229-sec-0021"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003229-list-0005"> <li> <p>Assessment of CVI: objective signs</p> <ul id="CD003229-list-0006"> <li> <p>Skin manifestations including venous ulcer healing and trophic alterations (e.g. lipodermatosclerosis (hardening of the skin that may cause red/brown pigmentation and is accompanied by wasting of subcutaneous fat), telangiectasia (tiny blood vessels cause threadlike red lines or patterns on the skin), reticular veins (dilated veins that show as a net‐like pattern on the skin), varicose veins (permanently dilated veins) </p> </li> </ul> </li> <li> <p>Assessment of CVI: subjective symptoms</p> <ul id="CD003229-list-0007"> <li> <p>Pain in the lower legs</p> </li> <li> <p>Cramps in the lower legs</p> </li> <li> <p>Restless legs</p> </li> <li> <p>Itching in the lower legs</p> </li> <li> <p>Feeling of heaviness in the lower legs</p> </li> <li> <p>Swelling in the lower legs</p> </li> <li> <p>Paraesthesias (abnormal sensations, such as prickling, burning, tingling) in the lower legs </p> </li> <li> <p>Participant satisfaction</p> </li> </ul> </li> <li> <p>Adverse events</p> <ul id="CD003229-list-0008"> <li> <p>Adverse reactions experienced by participants during the trial, as reported by questionnaire or related by participants and specified within the publication </p> </li> </ul> </li> </ul> </p> </section> </section> </section> <section id="CD003229-sec-0022"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003229-sec-0023"> <h4 class="title">Electronic searches</h4> <p>For this update, the Cochrane Vascular Information Specialist conducted systematic searches of the following databases for randomised controlled trials and controlled clinical trials without language, publication year or publication status restrictions: </p> <p> <ul id="CD003229-list-0009"> <li> <p>the Cochrane Vascular Specialised Register via the Cochrane Register of Studies (CRS‐Web searched on 12 November 2019); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) Cochrane Register of Studies Online (CRSO 2019, issue 10); </p> </li> <li> <p>MEDLINE (Ovid MEDLINE® Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE® Daily and Ovid MEDLINE®) (searched from 1 January 2017 to 12 November 2019); </p> </li> <li> <p>Embase Ovid (searched from 1 January 2017 to 12 November 2019);</p> </li> <li> <p>CINAHL Ebsco (searched from 1 January 2017 to 12 November 2019); and</p> </li> <li> <p>AMED Ovid (searched from 1 January 2017 to 12 November 2019).</p> </li> </ul> </p> <p>The Information Specialist modelled search strategies for other databases on the search strategy designed for CENTRAL. Where appropriate, strategies were combined with adaptations of the highly sensitive search strategy designed by the Cochrane Collaboration for identifying randomised controlled trials and controlled clinical trials (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Chapter 6, <a href="./references#CD003229-bbs2-0201" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6. Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from handbook.cochrane.org2011.">Lefebvre 2011</a>). Search strategies for major databases are provided in <a href="./appendices#CD003229-sec-0102">Appendix 1</a>. </p> <p>The Information Specialist searched the following trials registries on 12 November 2019: </p> <p> <ul id="CD003229-list-0010"> <li> <p>the World Health Organization International Clinical Trials Registry Platform (<a href="https://apps.who.int/trialsearch/" target="_blank">who.int/trialsearch</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>). </p> </li> </ul> </p> </section> <section id="CD003229-sec-0024"> <h4 class="title">Searching other resources</h4> <p>For this update, we searched the reference lists of articles retrieved by electronic searches for additional citations. </p> </section> </section> <section id="CD003229-sec-0025"> <h3 class="title" id="CD003229-sec-0025">Data collection and analysis</h3> <section id="CD003229-sec-0026"> <h4 class="title">Selection of studies</h4> <p>For this update, two review authors (RV and DS) independently assessed the eligibility of new studies identified by the searches. A third review author (MMZ) helped to resolve disagreements by discussion. </p> </section> <section id="CD003229-sec-0027"> <h4 class="title">Data extraction and management</h4> <p>For this update, two review authors (RV and MMZ) independently extracted data from new studies and entered them to a previously tested standardized form. A consensus between reviewers were reached if any data extraction discrepancies occurred. We collected information including characteristics of study participants, characteristics of intervention and control groups and outcome characteristics of every group of participants. For cross‐over studies, we extracted and analyzed only data related to the first period of treatment. </p> </section> <section id="CD003229-sec-0028"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For this update, two review authors (RV and MJMZ) independently assessed the risk of bias of the newly included studies. A consensus between review authors was reached by discussion when there was any disagreement. We specifically assessed the randomisation method (sequence generation and allocation concealment); blinding of participants, caregivers/study researchers and outcome assessors to the intervention; whether outcome data were incomplete; and presence of selection bias. Once this information was gathered, review authors classified each study into one of three levels of risk of bias: low, unclear or high, based on the criteria specified in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003229-bbs2-0194" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD003229-sec-0029"> <h4 class="title">Measures of treatment effect</h4> <p>We estimated effects of treatment with phlebotonics by using risk ratios (RRs) for dichotomous variables and mean differences (MDs) or standardized mean differences (SMDs) for continuous variables, along with their corresponding 95% confidence intervals (CIs). We calculated SMDs when studies used different instruments to measure the same variable. </p> </section> <section id="CD003229-sec-0030"> <h4 class="title">Unit of analysis issues</h4> <p>We took the unit of analysis to be the individual participant. For cross‐over studies, we extracted and analyzed only data related to the first period of treatment. </p> </section> <section id="CD003229-sec-0031"> <h4 class="title">Dealing with missing data</h4> <p>We analyzed dichotomous variables by applying the intention‐to‐treat (ITT) principle to analyze every individual in the randomly assigned treatment group regardless of whether individuals completed treatment or withdrew prematurely from the study. We included in the ITT analysis only studies that provided data from all randomised participants, or that stated the number of participants lost during follow‐up. We numerically imputed missing values due to withdrawal of participants or loss to follow‐up as therapeutic failures in both comparative groups. For continuous variables, we analyzed data as provided by study authors, either per protocol or as ITT values. </p> </section> <section id="CD003229-sec-0032"> <h4 class="title">Assessment of heterogeneity</h4> <p>We carried out an analysis to detect the presence of heterogeneity by using the I<sup>2</sup> statistic before obtaining global effect estimators. The I<sup>2</sup> statistic describes the percentage of total variation across studies that is due to heterogeneity rather than to sampling error (<a href="./references#CD003229-bbs2-0188" title="DeeksJJ , HigginsJPT , AltmanDG , on behalf of the Cochrane Statistical Methods Group (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.">Deeks 2011</a>). When statistical heterogeneity was high (I<sup>2</sup> &gt; 75%), we did not pool studies. For levels of I<sup>2</sup> less than 50%, we applied a fixed‐effect model; for levels of I<sup>2</sup> greater than 50% but less than 75%, we applied a random‐effects model (<a href="./references#CD003229-bbs2-0189" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7(3):177-88.">DerSimonian 1986</a>). </p> </section> <section id="CD003229-sec-0033"> <h4 class="title">Assessment of reporting biases</h4> <p>We constructed a funnel plot to assess whether the outcome of oedema (dichotomous variable) was subject to publication bias (<a href="#CD003229-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD003229-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Phlebotonics vs placebo, outcome: 1.1 Oedema in the lower legs (dichotomous variable)." data-id="CD003229-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Phlebotonics vs placebo, outcome: 1.1 Oedema in the lower legs (dichotomous variable). </p> </div> </div> </div> </section> <section id="CD003229-sec-0034"> <h4 class="title">Data synthesis</h4> <p>We obtained data from the included studies for variables evaluated at the end of treatment. In addition, we obtained data from measures of change when no significant baseline differences were evident between compared groups. We then pooled these together with other similar continuous outcomes. </p> <p>We split the outcomes of variables measured by ordinal categorical scales into two groups of response. We considered one group as showing success (no signs or symptoms or mild manifestations) and the other as showing failure (moderate, severe or very severe persistence of signs and symptoms). </p> </section> <section id="CD003229-sec-0035"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We carried out subgroup analyses in addition to the overall analysis of phlebotonics. These included looking at the effects of the following phlebotonics: rutosides, hidrosmine, diosmine, calcium dobesilate, disodium flavodate, grape seed extract, French maritime pine bark extract, chromocarbe and aminaftone. </p> </section> <section id="CD003229-sec-0036"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses to assess the influence on data of assumptions and decisions of review authors during the review process. We re‐analysed data by: </p> <p> <ul id="CD003229-list-0011"> <li> <p>excluding studies that used compression measures;</p> </li> <li> <p>excluding unpublished studies; and</p> </li> <li> <p>excluding studies with high or unclear risk of bias in at least one domain.</p> </li> </ul> </p> <section id="CD003229-sec-0037"> <h5 class="title">Summary of findings and assessment of certainty of the evidence</h5> <p>We created one 'Summary of findings' table to present the main findings for 'Phlebotonics compared with placebo for venous insufficiency' using GRADE profiler software (<a href="./references#CD003229-bbs2-0193" title="GRADEpro Version 3.2 for Windows [GRADEpro. www.gradepro.org].]. BrozekJ , OxmanA , SchünemannH . Ontario, Canada: McMaster University, 2008.">GRADEpro 2008</a>). See <a href="./full#CD003229-tbl-0001">summary of findings Table 1</a>. We used the principles of the GRADE system to assess the certainty of the body of evidence associated with the main outcomes listed below. The GRADE approach appraises the certainty of a body of evidence according to the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. Evaluation of the certainty of a body of evidence considers within‐study risk of bias, indirectness of the evidence, inconsistency (heterogeneity in the data), imprecision (precision of effect estimates) and publication bias (<a href="./references#CD003229-bbs2-0211" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and “Summary of findings” tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of interventions Version 5.1.0. London, UK: The Cochrane Collaboration. www.cochrane-handbook.org, 2011.">Schünemann 2011</a>). </p> <p>Two review authors (DS and RV) independently assessed the certainty of the body of evidence for the following outcomes. </p> <p> <ul id="CD003229-list-0012"> <li> <p>Oedema in the lower legs (dichotomous variable)</p> </li> <li> <p>Oedema in the lower legs (circumference mm)</p> </li> <li> <p>QoL</p> </li> <li> <p>Ulcer healing</p> </li> <li> <p>Adverse events</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003229-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003229-sec-0038"></div> <section id="CD003229-sec-0039"> <h3 class="title">Description of studies</h3> <section id="CD003229-sec-0040"> <h4 class="title">Results of the search</h4> <p>For this update we identified three new included studies (<a href="./references#CD003229-bbs2-0041" title="NCT01848210. Efficacy and safety of coumarin and troxerutin in the symptomatic treatment of chronic venous insufficiency. clinicaltrials.gov/ct2/show/NCT01848210 (first posted 7 May 2013). ">NCT01848210</a>; <a href="./references#CD003229-bbs2-0053" title="RabeE , AgusGB , RoztocilK . Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. International Angiology2015;34(5):428-36. ">Rabe 2015</a>; <a href="./references#CD003229-bbs2-0054" title="RabeE , BallariniS , LehrL , Doxium EDX09/01 Study Group. A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology2016;31(4):264-74. ">Rabe 2016</a>); two new ongoing studies (<a href="./references#CD003229-bbs2-0174" title="BarattiniDF , DogaruDE . Clinical trial to assess the efficacy of μSmin® Plus. clinicaltrials.gov/ct2/show/NCT04101201 (first posted 24 September 2019). ">Barattini 2019</a>; <a href="./references#CD003229-bbs2-0177" title="NCT03833024. The MUFFIN-PTS Trial (MUFFIN-PTS). clinicaltrials.gov/ct2/show/NCT03833024 (first posted 6 February 2019). ">NCT03833024</a>); and two new studies were excluded (<a href="./references#CD003229-bbs2-0113" title="EudraCT2009-014681-25. Pharmacodynamic and clinical assessment of DC 982 GE (2,4 or 6 capsules per day) in patients with chronic venous disorders: randomised, placebo-controlled, dose effect, double blind, parallel group study. clinicaltrialsregister.eu/ctr-search/search?query=2009-014681-25 (first posted 21 October 2009). ">EudraCT2009‐014681‐25</a>; <a href="./references#CD003229-bbs2-0125" title="ISRCTN54360155. A 3 month clinical trial of herbal medicine combination intended for topical application in patients with leg symptoms complaints due to chronic venous insufficiency: a double-blind randomized controlled trial. www.isrctn.com/ISRCTN54360155 (first posted 5 January 2015). ">ISRCTN54360155</a>). See <a href="#CD003229-fig-0002">Figure 2</a>. Details of all studies are provided in the <a href="./references#CD003229-sec-0113" title="">Characteristics of included studies</a>, <a href="./references#CD003229-sec-0115" title="">Characteristics of ongoing studies</a> and <a href="./references#CD003229-sec-0114" title="">Characteristics of excluded studies</a> tables. </p> <div class="figure" id="CD003229-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003229-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD003229-sec-0041"> <h4 class="title">Included studies</h4> <p>For this update, we identified three new included studies (<a href="./references#CD003229-bbs2-0041" title="NCT01848210. Efficacy and safety of coumarin and troxerutin in the symptomatic treatment of chronic venous insufficiency. clinicaltrials.gov/ct2/show/NCT01848210 (first posted 7 May 2013). ">NCT01848210</a>; <a href="./references#CD003229-bbs2-0053" title="RabeE , AgusGB , RoztocilK . Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. International Angiology2015;34(5):428-36. ">Rabe 2015</a>; <a href="./references#CD003229-bbs2-0054" title="RabeE , BallariniS , LehrL , Doxium EDX09/01 Study Group. A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology2016;31(4):264-74. ">Rabe 2016</a>). In total with those identified in earlier versions, we included 69 studies. See <a href="./references#CD003229-sec-0113" title="">Characteristics of included studies</a> tables. </p> <p>Most studies were published in English, but four were published in German (<a href="./references#CD003229-bbs2-0007" title="BilandL , BlättlerP , ScheiblerP , StuderS , WidmerK . Zur therapie sogenannt venosër beinsbeschwerden. Vasa1982;11(1):53-8. ">Biland 1982</a>; <a href="./references#CD003229-bbs2-0029" title="KiesewetterH , KoscielnyJ , GrütznerK , MüllerA , HoffmannKH , BirkA . Buckwheat herb/troxerutin-combination for the treatment of chronic venous insufficiency. Zeitschrift für Phytotherapie1997;18(6):341-6. ">Kiesewetter 1997</a>; <a href="./references#CD003229-bbs2-0031" title="KoscielnnyJ , RadtkeH , Hoffmann, JungF , MüllerA , GrütznerKI , et al. Fagorutin buckwheat herb tea in chronic venous insufficiency. Zeitschrift für Phytotherapie1996;17(3):147-59. ">Koscielnny 1996</a>; <a href="./references#CD003229-bbs2-0046" title="PedersenFM , HambergO , SorensenMD , NelandK . The effect of O-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs. Ugeskrift for Laeger1992;154(38):2561-3. ">Pedersen 1992</a>), seven in French (<a href="./references#CD003229-bbs2-0011" title="Van CauwenbergeH . Double-blind clinical trial to assess the efficacy of 0-(b-hidroxy-ethyl)-rutosides in the treatment of venous disorders [Etude en double aveugle de l'efficacité de l'0-(b-hidroxyéthyl)-rutosides dans le traitement des affections veineuses]. Mèdicine et Hygiène1978;35:4175-7. ">Cauwenberge 1978</a>; <a href="./references#CD003229-bbs2-0013" title="ChassignolleJF , AmielM , LanfranchiG , BarbeR . Activite therapeutique de daflon 500 mg dans l'insuffisance veineuse fonctionnelle. Journal International de Medicine1994;Suppl 99:32-5. ">Chassignolle 1994</a>; <a href="./references#CD003229-bbs2-0048" title="PlanchonB . Venous insufficiency and Daflon 500 mg [Insuffisance veineuse et Daflon 500 mg]. Artères et Veines1990;IX(4):376-80. ">Planchon 1990</a>; <a href="./references#CD003229-bbs2-0061" title="ThebautJF , ThebautP , VinF . Trial of vasculoprotective agent (plant products of the flavan class) in functional manifestations of peripheral venous insufficiency (double-blind trial in 92 cases). Gazette Medicale1985;92(12):96-100. ">Thebaut 1985</a>; <a href="./references#CD003229-bbs2-0066" title="VinE , ChabanelA , TaccoenA , DucrosJ , GrufazJ , HutinelB , et al. Action of Veinamitol 3500 mg on clinical and hemorheological data in CVI. International Angiology1995;14(Suppl 1):99. VinF , ChabanelA , TaccoenA , DucrosJ , GruffazJ , HutinelB , et al. Action de la troxérutine sur les paramètres cliniques, pléthysmographiques et rhéologiques de l'insuffisance veineuse des membres inférieurs. Etude contrôlée contre placebo. Artères et Veines1992;XI:333-42. VinF , ChabanelA , TaccoenA , DucrosJ , GruffazJ , HutinelB , et al. Double-blind trial of the efficacy of troxerutin in chronic venous insufficiency. Phlebology1994;9(2):71-6. ">Vin 1994</a>; <a href="./references#CD003229-bbs2-0067" title="WelchW , MoriauM , vanGyselJP . A double-blind, placebo controlled trial of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Novartis1985. ">Welch 1985</a>; <a href="./references#CD003229-bbs2-0069" title="ZucarelliF . Clinical efficacy and tolerability of rutin. Double blind, placebo controlled clinical trial. [Efficacité clinique et tolerance de la coumarine rutine. Étude controlée en double aveugle versus placebo]. Gazette Médicale1987;94(32):80-6. ">Zucarelli 1987</a>), four in Spanish (<a href="./references#CD003229-bbs2-0022" title="Flota-CerveraF ,  Flota-RuizC ,  TreviñoC ,  BerberA . Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology2008;59(3):352-6. FlotaLF . Prospective, randomised, double-blind, placebo controlled, clinical trial that assesses the efficacy of calcium dobesilate in the limphoedema by varicose disease [Estudio clínico prospectivo aleatorizado, doble ciego, con control placebo, para evaluar la eficacia en la resolución del edema de origen lifático, del dobesilato de calcio en pacientes con enfermedad varicosa]. Knoll de Mexico S.A. Laboratorios Dr. Esteve. No de proyec. Knoll-mex-02-99, 003/MEX, 99. ">Flota‐Cervera 2008</a>; <a href="./references#CD003229-bbs2-0030" title="KlükenN . Double-blind clinical trial to assess the therapy with drugs for venous disorders [Estudio clínico doble ciego para tratar de objetivar la terapéutica con venofármacos]. Therapiewoche1971;21:1. ">Klüken 1971</a>; <a href="./references#CD003229-bbs2-0039" title="MarinelloJ , et al. Multicentric, randomised, double-blind, placebo controlled, clinical trial that assess the efficacy of calcium dobesilate in the treatment of venous hypertension in patients with chronic venous insufficiency [Ensayo clínico multicéntrico, doble ciego, aleatorizado, controlado con placebo sobre la eficacia de dobesilato de calcio en el tratamiento de la hipertensión venosa en pacientes afectos de insuficiencia venosa crónica en sus extremidades inferiores. Código: ESCLIN-004/99]. Laboratorios Dr. Esteve. MarinelloJ , VidelaS . Chronic venous insufficiency of the lower limbs: suitability of transcutaneous blood gas monitoring as an endpoint to evaluate the outcome of pharmacological treatment with calcium dobesilate. Methods and Findings in Experimental and Clinical Pharmacology2004;26(10):775-80. ">Marinello 2002</a>; <a href="./references#CD003229-bbs2-0060" title="SerraldeCF , AcevesAQ . Clinical trial of the O-(β-hydroxy-ethyl-rutosides) in patients with chronic venous insufficiency [Ensayo clínico de o-(beta-hidroxietil-rutósidos) en pacientes con insuficiencia venosa crónica]. Revista Médica del Hospital General de México1990;53(2):102-6. ">Serralde 1990</a>), three in Italian (<a href="./references#CD003229-bbs2-0001" title="Allegra C Pollari G, CriscuoloA , BonifacioM , TabassiD . Centella asiatica extract in venous disorders of the lower limbs. Comparative clinico-instrumental studies with a placebo. Clinica Terapeutica1981;99(5):507-13. ">Allegra 1981</a>; <a href="./references#CD003229-bbs2-0036" title="LazzariniA , DanieliL . Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers [Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche]. Rassegna Internazionale di Clinica e Terapia1982;62(12):825-44. ">Lazzarini 1982</a>; <a href="./references#CD003229-bbs2-0045" title="PecchiS , De FrancoV , DamianiP , GuerriniM , Di PerriT . Calcium dobesilate in the treatment of primary venous insufficiency of the lower limbs. A controlled clinical study [Il dobesilato di calcio nel trattamento del l´insufficienza venosa primitiva degli arti inferiori]. Clinica Terapeutica1990;132(6):409-17. ">Pecchi 1990</a>), and one in Spanish, French and Dutch (<a href="./references#CD003229-bbs2-0043" title="PadrósW . Controlled study of the effect of calcium dobesilate on syndromes of venous insufficiency. Medicina Clínica1972;58(6):515-9. PadrosW . Double blind investigation of clinical effectiveness of calcium dobesilate in the venous insufficiency syndrome (Dutch). Ars Medici Internationaal Tijdschrift voor Praktische Therapie1977;6(8):777-84. PadrosW . Double blind study of the action of calcium dobesilate on venous insufficiency syndromes. Ars Medici Revue Internationale de Therapie Pratique1977;32(8):783-90. ">Padrós 1972</a>). </p> <p>Of the 69 included double‐blind, placebo‐controlled clinical trials, we did not include 13 studies in the efficacy analysis. Of these, 10 studies corresponded to the rutoside group (<a href="./references#CD003229-bbs2-0006" title="BerqvistD , HallböökT , LindbladB , LindhagenA . A double-blind trial of O-(beta-hydroxyethyl)-rutoside in patients with chronic venous insufficiency. Vasa1981;10(3):253-60. ">Bergqvist 1981</a>; <a href="./references#CD003229-bbs2-0014" title="CloarecM , ClementR , GritonP , GuillouGB , GoldenG . A double blind three centre trial on efficacy of o-(beta-hydroxyethyl) rutosides in patients with venous insufficiency. International Angiology1994;13 Suppl 1(2):74. ">Cloarec 1994</a>; <a href="./references#CD003229-bbs2-0027" title="De JongsteAB , Ten CateJW , HuismanMV . The effectiveness of o-(b-hydroxyethyl)-rutosides (HR) in the post-thrombotic syndrome (PTS). Phlebology1986;85 Suppl 285:837-9. ">Jongste 1986</a>; <a href="./references#CD003229-bbs2-0038" title="MannRJ . A double-blind trial of oral O-beta-hydroxyethyl rutosides for stasis leg ulcers. British Journal of Clinical Practice1981;35:79-81. ">Mann 1981</a>; <a href="./references#CD003229-bbs2-0042" title="NockerW , DiebschlagW , LehmacherW . Clinical trials of the dose-related effects of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Phlebology1990;5 Suppl 1:23-6. NockerW , DiebschlagW , LehmacherW . Three-month, randomized, double-blind, dose-response study with O-(beta-hydroxyethyl)-rutosides drinking solution. Vasa1989;18(3):235-8. NockerW , DiebschlagW . An investigation of dosage effects with drinking solutions of o-(beta hydroxyethyl)-rutosides. Vasa1987;16:365-9. ">Nocker 1990</a>; <a href="./references#CD003229-bbs2-0050" title="PrerovskyI , RoztocilK , HlavovaA , KoleilatZ , RazgovaL , OlivaI . The effects of hydroxyethylrutosides after acute and chronic oral administration in patients with venous diseases. A double blind study. Angiologica1972;9(3-6):408-14. ">Prerovsky 1972</a>; <a href="./references#CD003229-bbs2-0055" title="RentonS , LeonM , BelcaroG , NicolaidesAN . The effect of hydroxyethylrutosides on capillary filtration in moderate venous hypertension: a double blind study. International Angiology1994;13(3):259-62. ">Renton 1994</a>; <a href="./references#CD003229-bbs2-0056" title="RoseSS . A report on the use of an hydroxyethylrutoside in symptoms due to venous back pressure and allied conditions in the lower limbs. British Journal of Clinical Practice1970;24(4):161-4. ">Rose 1970</a>; <a href="./references#CD003229-bbs2-0057" title="RudofskyG , DiehmC , GrubJ , HartmannM , Schultz-EhrenburgHU , BislerH . Ruscus saponines and the flavonoid hesperidinmethylchalcone in the treatment of chronic venous insufficiency. In: DavyA , StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. London and Paris: John Libbey Eurotext Ltd, 1989:728-30. RudofskyG , DiehmC , GrussJD , HartmanM , Schultz-EhrenburgHK , BislerH . Chronic venous insufficiency: treatment with Ruscus extract and trimethyl hesperidine chalcone. Münchener Medizinische Wochenschrift1990;132(13):205-10. ">Rudofsky 1989</a>; <a href="./references#CD003229-bbs2-0059" title="SentouY . Double blind study of the activity of Cyclo 3 in man. International Angiology1984;3:106-9. ">Sentou 1984</a>), two corresponded to calcium dobesilate (<a href="./references#CD003229-bbs2-0043" title="PadrósW . Controlled study of the effect of calcium dobesilate on syndromes of venous insufficiency. Medicina Clínica1972;58(6):515-9. PadrosW . Double blind investigation of clinical effectiveness of calcium dobesilate in the venous insufficiency syndrome (Dutch). Ars Medici Internationaal Tijdschrift voor Praktische Therapie1977;6(8):777-84. PadrosW . Double blind study of the action of calcium dobesilate on venous insufficiency syndromes. Ars Medici Revue Internationale de Therapie Pratique1977;32(8):783-90. ">Padrós 1972</a>; <a href="./references#CD003229-bbs2-0045" title="PecchiS , De FrancoV , DamianiP , GuerriniM , Di PerriT . Calcium dobesilate in the treatment of primary venous insufficiency of the lower limbs. A controlled clinical study [Il dobesilato di calcio nel trattamento del l´insufficienza venosa primitiva degli arti inferiori]. Clinica Terapeutica1990;132(6):409-17. ">Pecchi 1990</a>) and another corresponded to French bark pine extract (<a href="./references#CD003229-bbs2-0047" title="PetrassiC , MastromarinoA , SparteraC . Pycnogenol in chronic venous insufficiency. Phytomedicine2000;7(5):383-8. ">Petrassi 2000</a>). </p> <p>We excluded these studies from the efficacy analysis for the following reasons.</p> <p> <ul id="CD003229-list-0013"> <li> <p>Only mean data were provided without standard deviations (SDs) or standard errors (SEs) (<a href="./references#CD003229-bbs2-0059" title="SentouY . Double blind study of the activity of Cyclo 3 in man. International Angiology1984;3:106-9. ">Sentou 1984</a>). </p> </li> <li> <p>Medians were provided instead of means (<a href="./references#CD003229-bbs2-0055" title="RentonS , LeonM , BelcaroG , NicolaidesAN . The effect of hydroxyethylrutosides on capillary filtration in moderate venous hypertension: a double blind study. International Angiology1994;13(3):259-62. ">Renton 1994</a>). </p> </li> <li> <p>Outcomes were reported by graph only (<a href="./references#CD003229-bbs2-0042" title="NockerW , DiebschlagW , LehmacherW . Clinical trials of the dose-related effects of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Phlebology1990;5 Suppl 1:23-6. NockerW , DiebschlagW , LehmacherW . Three-month, randomized, double-blind, dose-response study with O-(beta-hydroxyethyl)-rutosides drinking solution. Vasa1989;18(3):235-8. NockerW , DiebschlagW . An investigation of dosage effects with drinking solutions of o-(beta hydroxyethyl)-rutosides. Vasa1987;16:365-9. ">Nocker 1990</a>; <a href="./references#CD003229-bbs2-0056" title="RoseSS . A report on the use of an hydroxyethylrutoside in symptoms due to venous back pressure and allied conditions in the lower limbs. British Journal of Clinical Practice1970;24(4):161-4. ">Rose 1970</a>; <a href="./references#CD003229-bbs2-0057" title="RudofskyG , DiehmC , GrubJ , HartmannM , Schultz-EhrenburgHU , BislerH . Ruscus saponines and the flavonoid hesperidinmethylchalcone in the treatment of chronic venous insufficiency. In: DavyA , StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. London and Paris: John Libbey Eurotext Ltd, 1989:728-30. RudofskyG , DiehmC , GrussJD , HartmanM , Schultz-EhrenburgHK , BislerH . Chronic venous insufficiency: treatment with Ruscus extract and trimethyl hesperidine chalcone. Münchener Medizinische Wochenschrift1990;132(13):205-10. ">Rudofsky 1989</a>). </p> </li> <li> <p>First period data were not provided in studies of cross‐over design (<a href="./references#CD003229-bbs2-0043" title="PadrósW . Controlled study of the effect of calcium dobesilate on syndromes of venous insufficiency. Medicina Clínica1972;58(6):515-9. PadrosW . Double blind investigation of clinical effectiveness of calcium dobesilate in the venous insufficiency syndrome (Dutch). Ars Medici Internationaal Tijdschrift voor Praktische Therapie1977;6(8):777-84. PadrosW . Double blind study of the action of calcium dobesilate on venous insufficiency syndromes. Ars Medici Revue Internationale de Therapie Pratique1977;32(8):783-90. ">Padrós 1972</a>; <a href="./references#CD003229-bbs2-0050" title="PrerovskyI , RoztocilK , HlavovaA , KoleilatZ , RazgovaL , OlivaI . The effects of hydroxyethylrutosides after acute and chronic oral administration in patients with venous diseases. A double blind study. Angiologica1972;9(3-6):408-14. ">Prerovsky 1972</a>). </p> </li> <li> <p>No data were provided for any variable (<a href="./references#CD003229-bbs2-0006" title="BerqvistD , HallböökT , LindbladB , LindhagenA . A double-blind trial of O-(beta-hydroxyethyl)-rutoside in patients with chronic venous insufficiency. Vasa1981;10(3):253-60. ">Bergqvist 1981</a>; <a href="./references#CD003229-bbs2-0014" title="CloarecM , ClementR , GritonP , GuillouGB , GoldenG . A double blind three centre trial on efficacy of o-(beta-hydroxyethyl) rutosides in patients with venous insufficiency. International Angiology1994;13 Suppl 1(2):74. ">Cloarec 1994</a>; <a href="./references#CD003229-bbs2-0027" title="De JongsteAB , Ten CateJW , HuismanMV . The effectiveness of o-(b-hydroxyethyl)-rutosides (HR) in the post-thrombotic syndrome (PTS). Phlebology1986;85 Suppl 285:837-9. ">Jongste 1986</a>). </p> </li> <li> <p>Measured changes were reported when significant differences in baseline were noted between compared groups (<a href="./references#CD003229-bbs2-0038" title="MannRJ . A double-blind trial of oral O-beta-hydroxyethyl rutosides for stasis leg ulcers. British Journal of Clinical Practice1981;35:79-81. ">Mann 1981</a>; <a href="./references#CD003229-bbs2-0047" title="PetrassiC , MastromarinoA , SparteraC . Pycnogenol in chronic venous insufficiency. Phytomedicine2000;7(5):383-8. ">Petrassi 2000</a>). </p> </li> <li> <p>A quasi‐randomisation method was used in which treatments were alternatively allocated depending on participants' order of arrival (<a href="./references#CD003229-bbs2-0045" title="PecchiS , De FrancoV , DamianiP , GuerriniM , Di PerriT . Calcium dobesilate in the treatment of primary venous insufficiency of the lower limbs. A controlled clinical study [Il dobesilato di calcio nel trattamento del l´insufficienza venosa primitiva degli arti inferiori]. Clinica Terapeutica1990;132(6):409-17. ">Pecchi 1990</a>). </p> </li> <li> <p>At baseline, a significant imbalance in the ulcer area was evident between groups (1130 mm<sup>2</sup> in the rutoside group vs 430 mm<sup>2</sup> in the placebo group; P = 0.039) (<a href="./references#CD003229-bbs2-0038" title="MannRJ . A double-blind trial of oral O-beta-hydroxyethyl rutosides for stasis leg ulcers. British Journal of Clinical Practice1981;35:79-81. ">Mann 1981</a>). </p> </li> </ul> </p> <p>Of the 56 studies with oral phlebotonics included in the efficacy analysis, studied phlebotonics corresponded to 28 studies of rutosides (<a href="./references#CD003229-bbs2-0004" title="BalmerA , LimoniC . Clinical, placebo-controlled double-blind study of venoruton in the treatment of chronic venous insufficiency. Importance of the selection of patients. Vasa1980;9(1):76-82. BlumeJ . Therapy of venous oedemas [Tratamento do edema de origem venosa]. Revista Brasileira de Medicina1994;51(3):283-8. ">Balmer 1980</a>; <a href="./references#CD003229-bbs2-0008" title="BurnandKG , PowellS , BishopC , StaceyM , PulvertaftT . Effect of Paroven on skin oxygenation in patients with varicose veins. Phlebologie1989;4(1):15-22. ">Burnand 1989</a>; <a href="./references#CD003229-bbs2-0015" title="CloarecM , ClémentR , GritonP . A double-blind clinical trial of hydroxyethylrutosides in the treatment of the symptoms and signs of chronic venous insufficiency. Phlebology1996;11(2):76-82. ">Cloarec 1996</a>; <a href="./references#CD003229-bbs2-0010" title="Van CauwenbergeH . Double-blind study of the efficacy of a soluble rutoside derivative in the treatment of venous disease. Archives of Internal Pharmacodynamics and Therapeutics1972;196(Suppl 196):122-5. ">Cauwenberge 1972</a>; <a href="./references#CD003229-bbs2-0011" title="Van CauwenbergeH . Double-blind clinical trial to assess the efficacy of 0-(b-hidroxy-ethyl)-rutosides in the treatment of venous disorders [Etude en double aveugle de l'efficacité de l'0-(b-hidroxyéthyl)-rutosides dans le traitement des affections veineuses]. Mèdicine et Hygiène1978;35:4175-7. ">Cauwenberge 1978</a>; <a href="./references#CD003229-bbs2-0012" title="CesaroneMR , IncandelaL , DeSanctisMT , BelcaroG , GriffinM , IppolitoE , et al. Treatment of edema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton; O-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized, dose-ranging trial. Journal of Cardiovascular Pharmacology and Therapeutics2002;7 Suppl 1:S21-4. ">Cesarone 2002</a>; <a href="./references#CD003229-bbs2-0016" title="Cornu-ThenardA , DahanB , De ParadesB . Study of the action in venous insufficiency of the legs. Pierre Fabre Medicament Laboratoires (Novartis). Report no. DC982GEC51(2),1985. ">Cornu‐Thenard 1985</a>; <a href="./references#CD003229-bbs2-0018" title="DiebschlagW , NockerW , LehmacherW , RehnD . A clinical comparison of two doses of O-(beta-hydroxyethyl) rutosides (oxerutins) in patients with chronic venous insufficiency. Journal of Pharmaceutical Medicine1994;4(1):7-14. ">Diebschlag 1994</a>; <a href="./references#CD003229-bbs2-0026" title="IhmeN , KiesewetterH , JungF , HoffmannKH , BirkA , MüllerA , et al. Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomized, double-blind, placebo-controlled clinical trial. European Journal of Clinical Pharmacology1996;50(6):443-7. ">Ihme 1996</a>; <a href="./references#CD003229-bbs2-0027" title="De JongsteAB , Ten CateJW , HuismanMV . The effectiveness of o-(b-hydroxyethyl)-rutosides (HR) in the post-thrombotic syndrome (PTS). Phlebology1986;85 Suppl 285:837-9. ">Jongste 1986</a>; <a href="./references#CD003229-bbs2-0028" title="JongsteAB , JonkerJJC , HuismanMV , CateJW , AzarAJ . A double-blind trial on the short-term efficacy of HR in patients with the post-thrombotic syndrome. Phlebology1990;5(Suppl 1):21-2. JongsteAB , JonkerJJC , HuismanMV , den CateJW , AzarAJ . A double-blind three center clinical trial on the short-term efficacy of O-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome. Thrombosis and Haemostasis1989;62(3):826-9. ">Jongste 1989</a>; <a href="./references#CD003229-bbs2-0029" title="KiesewetterH , KoscielnyJ , GrütznerK , MüllerA , HoffmannKH , BirkA . Buckwheat herb/troxerutin-combination for the treatment of chronic venous insufficiency. Zeitschrift für Phytotherapie1997;18(6):341-6. ">Kiesewetter 1997</a>; <a href="./references#CD003229-bbs2-0031" title="KoscielnnyJ , RadtkeH , Hoffmann, JungF , MüllerA , GrütznerKI , et al. Fagorutin buckwheat herb tea in chronic venous insufficiency. Zeitschrift für Phytotherapie1996;17(3):147-59. ">Koscielnny 1996</a>; <a href="./references#CD003229-bbs2-0030" title="KlükenN . Double-blind clinical trial to assess the therapy with drugs for venous disorders [Estudio clínico doble ciego para tratar de objetivar la terapéutica con venofármacos]. Therapiewoche1971;21:1. ">Klüken 1971</a>; <a href="./references#CD003229-bbs2-0032" title="KrinerE , BraunR , HircheH , Van LaakHH . Treatment of venous insufficiency. A double-blind trial with Phlebodril. Zeitschrift für Allgemeinmedizin1985;61(9):309-13. ">Kriner 1985</a>; <a href="./references#CD003229-bbs2-0034" title="LanguillatN . Trial of Cyclo 3 Fort in venous insufficiency of the lower limbs: Xenon 133 functional investigation of venous circulatory velocity. Pierre Fabre Medicament Laboratories (Novartis). No. Report DC982GEC130(2),1988. ">Languillat 1988</a>; <a href="./references#CD003229-bbs2-0035" title="LaurentR , GillyR , FrileuxC . Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg. International Angiology1988;7(2 Suppl):39-43. ">Laurent 1988</a>; <a href="./references#CD003229-bbs2-0037" title="DiklandWJ . A clinical trial on the effect of hydroxyethylrutosides on venous refilling time as measured by light reflection rheography. Scripta Phlebologica1995;3:4-7. MacLennanWJ , WilsonJ , RattenhuberV , DiklandWJ , VanerdoncktJ , MoriauM . Hydroxyethylrutosides in elderly patients with chronic venous insufficiency. Its efficacy and tolerability. Gerontology1994;40(1):45-52. ">MacLennan 1994</a>; <a href="./references#CD003229-bbs2-0041" title="NCT01848210. Efficacy and safety of coumarin and troxerutin in the symptomatic treatment of chronic venous insufficiency. clinicaltrials.gov/ct2/show/NCT01848210 (first posted 7 May 2013). ">NCT01848210</a>; <a href="./references#CD003229-bbs2-0044" title="ParradoF , BuzziA . A study of the efficacy and tolerability of a preparation containing Ruscus aculeatus in the treatment of chronic venous insufficiency of the lower limbs. Clinical Drug Investigation1999;18(4):255-61. ">Parrado 1999</a>; <a href="./references#CD003229-bbs2-0046" title="PedersenFM , HambergO , SorensenMD , NelandK . The effect of O-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs. Ugeskrift for Laeger1992;154(38):2561-3. ">Pedersen 1992</a>; <a href="./references#CD003229-bbs2-0051" title="PulvertaftTB . General practice treatment of symptoms of venous insufficiency with oxerutins. Results of a 660 patient multicentre study in the UK. Vasa1983;12(4):373-6. PulvertaftTB . Paroven in the treatment of chronic venous insufficiency. Practitioner1979;223(1338):838-41. ">Pulvertaft 1983</a>; <a href="./references#CD003229-bbs2-0058" title="Schultz-EhrenburgU , MüllerB . Two multicentre clinical trials of two different dosages of O-(beta-hydroxyethyl)-rutosides in the treatment of leg ulcers. Phlebology1993;8 Suppl 1:29-30. ">Schultz‐Ehrenburg 1993</a>; <a href="./references#CD003229-bbs2-0060" title="SerraldeCF , AcevesAQ . Clinical trial of the O-(β-hydroxy-ethyl-rutosides) in patients with chronic venous insufficiency [Ensayo clínico de o-(beta-hidroxietil-rutósidos) en pacientes con insuficiencia venosa crónica]. Revista Médica del Hospital General de México1990;53(2):102-6. ">Serralde 1990</a>; <a href="./references#CD003229-bbs2-0063" title="UnkaufM , RehnD , KlingerJ , MotteS , GrobmannK . Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings. Arzneimittel-Forschung1996;46(5):478-82. ">Unkauf 1996</a>; <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>; <a href="./references#CD003229-bbs2-0065" title="VanscheidtW , JostV , WolnaP , LückerA , MullerA , TheurerC , et al. Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittel-Forschung2002;52(4):243-50. ">Vanscheidt 2002b</a>; <a href="./references#CD003229-bbs2-0066" title="VinE , ChabanelA , TaccoenA , DucrosJ , GrufazJ , HutinelB , et al. Action of Veinamitol 3500 mg on clinical and hemorheological data in CVI. International Angiology1995;14(Suppl 1):99. VinF , ChabanelA , TaccoenA , DucrosJ , GruffazJ , HutinelB , et al. Action de la troxérutine sur les paramètres cliniques, pléthysmographiques et rhéologiques de l'insuffisance veineuse des membres inférieurs. Etude contrôlée contre placebo. Artères et Veines1992;XI:333-42. VinF , ChabanelA , TaccoenA , DucrosJ , GruffazJ , HutinelB , et al. Double-blind trial of the efficacy of troxerutin in chronic venous insufficiency. Phlebology1994;9(2):71-6. ">Vin 1994</a>), 11 of hidrosmine and diosmine (<a href="./references#CD003229-bbs2-0013" title="ChassignolleJF , AmielM , LanfranchiG , BarbeR . Activite therapeutique de daflon 500 mg dans l'insuffisance veineuse fonctionnelle. Journal International de Medicine1994;Suppl 99:32-5. ">Chassignolle 1994</a>; <a href="./references#CD003229-bbs2-0017" title="DanielssonG , JungbeckC , PetersonK , NorgrenL . A randomised controlled trial of micronised purified flavonoid fraction versus placebo in patients with chronic venous disease. European Journal of Vascular and Endovascular Surgery2002;23(1):73-6. ">Danielsson 2002</a>; <a href="./references#CD003229-bbs2-0020" title="DominguezC , BrautighamI , GonzálezE , GonzálezJA , NazcoJ , ValienteR , et al. Therapeutic effects of hidrosmin on chronic venous insufficiency of the lower limbs. Current Medical Research and Opinion1992;12(10):623-30. ">Dominguez 1992</a>; <a href="./references#CD003229-bbs2-0021" title="FermosoJ , LegidoAG , Del PinoJ , ValienteR . Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Current Therapeutic Research, Clinical and Experimental1992;52(1):124-34. ">Fermoso 1992</a>; <a href="./references#CD003229-bbs2-0023" title="FrileuxC , GillyR . Activité thérapeutic de Daflon 500 mg dans l'insuffisance veineuse chronique des membres inférieurs. Journal Internationale de Medicine1994;Suppl 99:36-9. GillyR , PillionG , FrileuxC . Evaluation of a new venactive micronized flavonoid fraction (S5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology1994;9(2):67-70. ThiolletM , FrileuxC , GillyR . Evaluation of a new micronized diosmin in the treatment of chronic venous incompetence: a double-blind, placebo controlled trial. Journal of Vascular Surgery1992;15(2):447. ">Gilly 1994</a>; <a href="./references#CD003229-bbs2-0024" title="GuilhouJJ , DereureO , MarzinL , OuvryP , ZuccarelliF , DebureC , et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomised, controlled versus placebo trial in 107 patients. Angiology1997;48(1):77-85. ">Guilhou 1997</a>; <a href="./references#CD003229-bbs2-0048" title="PlanchonB . Venous insufficiency and Daflon 500 mg [Insuffisance veineuse et Daflon 500 mg]. Artères et Veines1990;IX(4):376-80. ">Planchon 1990</a>; <a href="./references#CD003229-bbs2-0053" title="RabeE , AgusGB , RoztocilK . Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. International Angiology2015;34(5):428-36. ">Rabe 2015</a>; <a href="./references#CD003229-bbs2-0061" title="ThebautJF , ThebautP , VinF . Trial of vasculoprotective agent (plant products of the flavan class) in functional manifestations of peripheral venous insufficiency (double-blind trial in 92 cases). Gazette Medicale1985;92(12):96-100. ">Thebaut 1985</a>; <a href="./references#CD003229-bbs2-0067" title="WelchW , MoriauM , vanGyselJP . A double-blind, placebo controlled trial of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Novartis1985. ">Welch 1985</a>; <a href="./references#CD003229-bbs2-0069" title="ZucarelliF . Clinical efficacy and tolerability of rutin. Double blind, placebo controlled clinical trial. [Efficacité clinique et tolerance de la coumarine rutine. Étude controlée en double aveugle versus placebo]. Gazette Médicale1987;94(32):80-6. ">Zucarelli 1987</a>), 10 of calcium dobesilate (<a href="./references#CD003229-bbs2-0009" title="Casley-SmithJR . A double-blind, placebo -controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. In: Davy A and StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. London and Paris: John Libbey Eurotext Ltd, 1989. Casley-SmithJR . A double-blind, placebo-controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. Phlebologie1989;2:709-11. Casley-SmithJR . A double-blind trial of calcium dobesilate in chronic venous insufficiency. Angiology1988;39(10):853-7. ">Casley‐Smith 1988</a>; <a href="./references#CD003229-bbs2-0019" title="Fundación Iberoamericana Itaca. Randomized, double-blind multicenter clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of ulcer secondaries to chronic venous disease. ClinicalTrials.gov2009. ">DOBESILATO500/2</a>; <a href="./references#CD003229-bbs2-0022" title="Flota-CerveraF ,  Flota-RuizC ,  TreviñoC ,  BerberA . Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology2008;59(3):352-6. FlotaLF . Prospective, randomised, double-blind, placebo controlled, clinical trial that assesses the efficacy of calcium dobesilate in the limphoedema by varicose disease [Estudio clínico prospectivo aleatorizado, doble ciego, con control placebo, para evaluar la eficacia en la resolución del edema de origen lifático, del dobesilato de calcio en pacientes con enfermedad varicosa]. Knoll de Mexico S.A. Laboratorios Dr. Esteve. No de proyec. Knoll-mex-02-99, 003/MEX, 99. ">Flota‐Cervera 2008</a>; <a href="./references#CD003229-bbs2-0025" title="HachenHJ , LorenzP . Double-blind clinical and plethysmographic study of calcium dobesilate in patients with peripheral microvascular disorders. Angiology1982;33(7):480-8. ">Hachen 1982</a>; <a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a>; <a href="./references#CD003229-bbs2-0039" title="MarinelloJ , et al. Multicentric, randomised, double-blind, placebo controlled, clinical trial that assess the efficacy of calcium dobesilate in the treatment of venous hypertension in patients with chronic venous insufficiency [Ensayo clínico multicéntrico, doble ciego, aleatorizado, controlado con placebo sobre la eficacia de dobesilato de calcio en el tratamiento de la hipertensión venosa en pacientes afectos de insuficiencia venosa crónica en sus extremidades inferiores. Código: ESCLIN-004/99]. Laboratorios Dr. Esteve. MarinelloJ , VidelaS . Chronic venous insufficiency of the lower limbs: suitability of transcutaneous blood gas monitoring as an endpoint to evaluate the outcome of pharmacological treatment with calcium dobesilate. Methods and Findings in Experimental and Clinical Pharmacology2004;26(10):775-80. ">Marinello 2002</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0054" title="RabeE , BallariniS , LehrL , Doxium EDX09/01 Study Group. A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology2016;31(4):264-74. ">Rabe 2016</a>; <a href="./references#CD003229-bbs2-0068" title="WidmerL , BilandL , BarrasJP . Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study. International Angiology1990;9(2):105-10. ">Widmer 1990</a>), two of <i>Centella asiatica</i> (<a href="./references#CD003229-bbs2-0001" title="Allegra C Pollari G, CriscuoloA , BonifacioM , TabassiD . Centella asiatica extract in venous disorders of the lower limbs. Comparative clinico-instrumental studies with a placebo. Clinica Terapeutica1981;99(5):507-13. ">Allegra 1981</a>; <a href="./references#CD003229-bbs2-0049" title="PointelJP , BoccalonH , CloarecM , Le DevehatC , JoubertM . Titrated extract of Centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology1987;38(1 Pt 1):46-50. PointelJP . Titrated extract of centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology1986;37(5):420-1. ">Pointel 1986</a>), two of aminaftone (<a href="./references#CD003229-bbs2-0005" title="BelczakSQ , SincosIR , CamposW , BeserraJ , NeringG , AunR . Veno-active drugs for chronic venous disease: a randomized, double-blind, placebo-controlled parallel-design trial. Phlebology2014;29(7):454-60. ">Belczak 2014</a>; <a href="./references#CD003229-bbs2-0036" title="LazzariniA , DanieliL . Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers [Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche]. Rassegna Internazionale di Clinica e Terapia1982;62(12):825-44. ">Lazzarini 1982</a>), two of French maritime pine bark extract (<a href="./references#CD003229-bbs2-0003" title="ArcangeliP . Pycnogenol in chronic venous insufficiency. Fitoterapia2000;71(3):236-44. ">Arcangeli 2000</a>; <a href="./references#CD003229-bbs2-0047" title="PetrassiC , MastromarinoA , SparteraC . Pycnogenol in chronic venous insufficiency. Phytomedicine2000;7(5):383-8. ">Petrassi 2000</a>) and one of grape seed extract (<a href="./references#CD003229-bbs2-0061" title="ThebautJF , ThebautP , VinF . Trial of vasculoprotective agent (plant products of the flavan class) in functional manifestations of peripheral venous insufficiency (double-blind trial in 92 cases). Gazette Medicale1985;92(12):96-100. ">Thebaut 1985</a>). No studies using topical phlebotonics or chromocarbe or naftazone or disodium flavodate fulfilled the inclusion criteria. Length of treatment and participant follow‐up ranged from 28 days to four months, except for three studies, in which follow‐up lasted six months or more (<a href="./references#CD003229-bbs2-0019" title="Fundación Iberoamericana Itaca. Randomized, double-blind multicenter clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of ulcer secondaries to chronic venous disease. ClinicalTrials.gov2009. ">DOBESILATO500/2</a>; <a href="./references#CD003229-bbs2-0037" title="DiklandWJ . A clinical trial on the effect of hydroxyethylrutosides on venous refilling time as measured by light reflection rheography. Scripta Phlebologica1995;3:4-7. MacLennanWJ , WilsonJ , RattenhuberV , DiklandWJ , VanerdoncktJ , MoriauM . Hydroxyethylrutosides in elderly patients with chronic venous insufficiency. Its efficacy and tolerability. Gerontology1994;40(1):45-52. ">MacLennan 1994</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>). </p> <p>Overall, we included 7690 participants in the meta‐analysis; 83% were female and 17% were male; mean age was 50 years (range 32 to 62 years). The mean number of participants included per clinical trial was 150 (range 20 to 1137). All participants met the respective CVI criteria of every study, although we noted variation between studies in degree of progression to CVI, as well as in diagnostic classification criteria applied. Only 22% of studies reported the diagnostic classification used. Among studies that did report on the diagnostic classification of CVI, the CEAP classification was used most often (<a href="./references#CD003229-bbs2-0005" title="BelczakSQ , SincosIR , CamposW , BeserraJ , NeringG , AunR . Veno-active drugs for chronic venous disease: a randomized, double-blind, placebo-controlled parallel-design trial. Phlebology2014;29(7):454-60. ">Belczak 2014</a>; <a href="./references#CD003229-bbs2-0017" title="DanielssonG , JungbeckC , PetersonK , NorgrenL . A randomised controlled trial of micronised purified flavonoid fraction versus placebo in patients with chronic venous disease. European Journal of Vascular and Endovascular Surgery2002;23(1):73-6. ">Danielsson 2002</a>; <a href="./references#CD003229-bbs2-0019" title="Fundación Iberoamericana Itaca. Randomized, double-blind multicenter clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of ulcer secondaries to chronic venous disease. ClinicalTrials.gov2009. ">DOBESILATO500/2</a>; <a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a>; <a href="./references#CD003229-bbs2-0039" title="MarinelloJ , et al. Multicentric, randomised, double-blind, placebo controlled, clinical trial that assess the efficacy of calcium dobesilate in the treatment of venous hypertension in patients with chronic venous insufficiency [Ensayo clínico multicéntrico, doble ciego, aleatorizado, controlado con placebo sobre la eficacia de dobesilato de calcio en el tratamiento de la hipertensión venosa en pacientes afectos de insuficiencia venosa crónica en sus extremidades inferiores. Código: ESCLIN-004/99]. Laboratorios Dr. Esteve. MarinelloJ , VidelaS . Chronic venous insufficiency of the lower limbs: suitability of transcutaneous blood gas monitoring as an endpoint to evaluate the outcome of pharmacological treatment with calcium dobesilate. Methods and Findings in Experimental and Clinical Pharmacology2004;26(10):775-80. ">Marinello 2002</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0053" title="RabeE , AgusGB , RoztocilK . Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. International Angiology2015;34(5):428-36. ">Rabe 2015</a>; <a href="./references#CD003229-bbs2-0054" title="RabeE , BallariniS , LehrL , Doxium EDX09/01 Study Group. A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology2016;31(4):264-74. ">Rabe 2016</a>; <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>; <a href="./references#CD003229-bbs2-0065" title="VanscheidtW , JostV , WolnaP , LückerA , MullerA , TheurerC , et al. Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittel-Forschung2002;52(4):243-50. ">Vanscheidt 2002b</a>), followed by Widmer's classification (<a href="./references#CD003229-bbs2-0009" title="Casley-SmithJR . A double-blind, placebo -controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. In: Davy A and StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. London and Paris: John Libbey Eurotext Ltd, 1989. Casley-SmithJR . A double-blind, placebo-controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. Phlebologie1989;2:709-11. Casley-SmithJR . A double-blind trial of calcium dobesilate in chronic venous insufficiency. Angiology1988;39(10):853-7. ">Casley‐Smith 1988</a>; <a href="./references#CD003229-bbs2-0015" title="CloarecM , ClémentR , GritonP . A double-blind clinical trial of hydroxyethylrutosides in the treatment of the symptoms and signs of chronic venous insufficiency. Phlebology1996;11(2):76-82. ">Cloarec 1996</a>; <a href="./references#CD003229-bbs2-0031" title="KoscielnnyJ , RadtkeH , Hoffmann, JungF , MüllerA , GrütznerKI , et al. Fagorutin buckwheat herb tea in chronic venous insufficiency. Zeitschrift für Phytotherapie1996;17(3):147-59. ">Koscielnny 1996</a>; <a href="./references#CD003229-bbs2-0044" title="ParradoF , BuzziA . A study of the efficacy and tolerability of a preparation containing Ruscus aculeatus in the treatment of chronic venous insufficiency of the lower limbs. Clinical Drug Investigation1999;18(4):255-61. ">Parrado 1999</a>; <a href="./references#CD003229-bbs2-0063" title="UnkaufM , RehnD , KlingerJ , MotteS , GrobmannK . Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings. Arzneimittel-Forschung1996;46(5):478-82. ">Unkauf 1996</a>). Wert's was the only other classification used (<a href="./references#CD003229-bbs2-0029" title="KiesewetterH , KoscielnyJ , GrütznerK , MüllerA , HoffmannKH , BirkA . Buckwheat herb/troxerutin-combination for the treatment of chronic venous insufficiency. Zeitschrift für Phytotherapie1997;18(6):341-6. ">Kiesewetter 1997</a>). </p> <p>Differences in severity of disease were observed: some studies were performed with participants at early and symptomatic CVI stages (<a href="./references#CD003229-bbs2-0016" title="Cornu-ThenardA , DahanB , De ParadesB . Study of the action in venous insufficiency of the legs. Pierre Fabre Medicament Laboratoires (Novartis). Report no. DC982GEC51(2),1985. ">Cornu‐Thenard 1985</a>; <a href="./references#CD003229-bbs2-0017" title="DanielssonG , JungbeckC , PetersonK , NorgrenL . A randomised controlled trial of micronised purified flavonoid fraction versus placebo in patients with chronic venous disease. European Journal of Vascular and Endovascular Surgery2002;23(1):73-6. ">Danielsson 2002</a>; <a href="./references#CD003229-bbs2-0023" title="FrileuxC , GillyR . Activité thérapeutic de Daflon 500 mg dans l'insuffisance veineuse chronique des membres inférieurs. Journal Internationale de Medicine1994;Suppl 99:36-9. GillyR , PillionG , FrileuxC . Evaluation of a new venactive micronized flavonoid fraction (S5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology1994;9(2):67-70. ThiolletM , FrileuxC , GillyR . Evaluation of a new micronized diosmin in the treatment of chronic venous incompetence: a double-blind, placebo controlled trial. Journal of Vascular Surgery1992;15(2):447. ">Gilly 1994</a>; <a href="./references#CD003229-bbs2-0025" title="HachenHJ , LorenzP . Double-blind clinical and plethysmographic study of calcium dobesilate in patients with peripheral microvascular disorders. Angiology1982;33(7):480-8. ">Hachen 1982</a>; <a href="./references#CD003229-bbs2-0061" title="ThebautJF , ThebautP , VinF . Trial of vasculoprotective agent (plant products of the flavan class) in functional manifestations of peripheral venous insufficiency (double-blind trial in 92 cases). Gazette Medicale1985;92(12):96-100. ">Thebaut 1985</a>), and others included participants at advanced stages because of long progression of the disease or the presence of venous ulcers (<a href="./references#CD003229-bbs2-0009" title="Casley-SmithJR . A double-blind, placebo -controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. In: Davy A and StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. London and Paris: John Libbey Eurotext Ltd, 1989. Casley-SmithJR . A double-blind, placebo-controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. Phlebologie1989;2:709-11. Casley-SmithJR . A double-blind trial of calcium dobesilate in chronic venous insufficiency. Angiology1988;39(10):853-7. ">Casley‐Smith 1988</a>; <a href="./references#CD003229-bbs2-0019" title="Fundación Iberoamericana Itaca. Randomized, double-blind multicenter clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of ulcer secondaries to chronic venous disease. ClinicalTrials.gov2009. ">DOBESILATO500/2</a>; <a href="./references#CD003229-bbs2-0024" title="GuilhouJJ , DereureO , MarzinL , OuvryP , ZuccarelliF , DebureC , et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomised, controlled versus placebo trial in 107 patients. Angiology1997;48(1):77-85. ">Guilhou 1997</a>; <a href="./references#CD003229-bbs2-0036" title="LazzariniA , DanieliL . Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers [Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche]. Rassegna Internazionale di Clinica e Terapia1982;62(12):825-44. ">Lazzarini 1982</a>; <a href="./references#CD003229-bbs2-0039" title="MarinelloJ , et al. Multicentric, randomised, double-blind, placebo controlled, clinical trial that assess the efficacy of calcium dobesilate in the treatment of venous hypertension in patients with chronic venous insufficiency [Ensayo clínico multicéntrico, doble ciego, aleatorizado, controlado con placebo sobre la eficacia de dobesilato de calcio en el tratamiento de la hipertensión venosa en pacientes afectos de insuficiencia venosa crónica en sus extremidades inferiores. Código: ESCLIN-004/99]. Laboratorios Dr. Esteve. MarinelloJ , VidelaS . Chronic venous insufficiency of the lower limbs: suitability of transcutaneous blood gas monitoring as an endpoint to evaluate the outcome of pharmacological treatment with calcium dobesilate. Methods and Findings in Experimental and Clinical Pharmacology2004;26(10):775-80. ">Marinello 2002</a>; <a href="./references#CD003229-bbs2-0048" title="PlanchonB . Venous insufficiency and Daflon 500 mg [Insuffisance veineuse et Daflon 500 mg]. Artères et Veines1990;IX(4):376-80. ">Planchon 1990</a>; <a href="./references#CD003229-bbs2-0058" title="Schultz-EhrenburgU , MüllerB . Two multicentre clinical trials of two different dosages of O-(beta-hydroxyethyl)-rutosides in the treatment of leg ulcers. Phlebology1993;8 Suppl 1:29-30. ">Schultz‐Ehrenburg 1993</a>; <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>). However, most studies included participants at moderate CVI stages with oedema, skin pigmentation, varicose veins and post‐thrombotic syndromes. </p> <p>Ten studies specified that investigators used additional compression therapy (<a href="./references#CD003229-bbs2-0019" title="Fundación Iberoamericana Itaca. Randomized, double-blind multicenter clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of ulcer secondaries to chronic venous disease. ClinicalTrials.gov2009. ">DOBESILATO500/2</a>; <a href="./references#CD003229-bbs2-0024" title="GuilhouJJ , DereureO , MarzinL , OuvryP , ZuccarelliF , DebureC , et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomised, controlled versus placebo trial in 107 patients. Angiology1997;48(1):77-85. ">Guilhou 1997</a>; <a href="./references#CD003229-bbs2-0035" title="LaurentR , GillyR , FrileuxC . Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg. International Angiology1988;7(2 Suppl):39-43. ">Laurent 1988</a>; <a href="./references#CD003229-bbs2-0036" title="LazzariniA , DanieliL . Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers [Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche]. Rassegna Internazionale di Clinica e Terapia1982;62(12):825-44. ">Lazzarini 1982</a>; <a href="./references#CD003229-bbs2-0039" title="MarinelloJ , et al. Multicentric, randomised, double-blind, placebo controlled, clinical trial that assess the efficacy of calcium dobesilate in the treatment of venous hypertension in patients with chronic venous insufficiency [Ensayo clínico multicéntrico, doble ciego, aleatorizado, controlado con placebo sobre la eficacia de dobesilato de calcio en el tratamiento de la hipertensión venosa en pacientes afectos de insuficiencia venosa crónica en sus extremidades inferiores. Código: ESCLIN-004/99]. Laboratorios Dr. Esteve. MarinelloJ , VidelaS . Chronic venous insufficiency of the lower limbs: suitability of transcutaneous blood gas monitoring as an endpoint to evaluate the outcome of pharmacological treatment with calcium dobesilate. Methods and Findings in Experimental and Clinical Pharmacology2004;26(10):775-80. ">Marinello 2002</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>; <a href="./references#CD003229-bbs2-0048" title="PlanchonB . Venous insufficiency and Daflon 500 mg [Insuffisance veineuse et Daflon 500 mg]. Artères et Veines1990;IX(4):376-80. ">Planchon 1990</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0058" title="Schultz-EhrenburgU , MüllerB . Two multicentre clinical trials of two different dosages of O-(beta-hydroxyethyl)-rutosides in the treatment of leg ulcers. Phlebology1993;8 Suppl 1:29-30. ">Schultz‐Ehrenburg 1993</a>; <a href="./references#CD003229-bbs2-0069" title="ZucarelliF . Clinical efficacy and tolerability of rutin. Double blind, placebo controlled clinical trial. [Efficacité clinique et tolerance de la coumarine rutine. Étude controlée en double aveugle versus placebo]. Gazette Médicale1987;94(32):80-6. ">Zucarelli 1987</a>). </p> <p>Eleven studies used a visual analogue scale (VAS) to measure subjective variables (<a href="./references#CD003229-bbs2-0002" title="AlterkamperH . Efficacy of antivaricotic drugs can be measured objectively. Phlebologie in der Praxis1987;2(9-10):19-20. ">Alterkamper 1987</a>; <a href="./references#CD003229-bbs2-0012" title="CesaroneMR , IncandelaL , DeSanctisMT , BelcaroG , GriffinM , IppolitoE , et al. Treatment of edema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton; O-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized, dose-ranging trial. Journal of Cardiovascular Pharmacology and Therapeutics2002;7 Suppl 1:S21-4. ">Cesarone 2002</a>; <a href="./references#CD003229-bbs2-0019" title="Fundación Iberoamericana Itaca. Randomized, double-blind multicenter clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of ulcer secondaries to chronic venous disease. ClinicalTrials.gov2009. ">DOBESILATO500/2</a>; <a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0053" title="RabeE , AgusGB , RoztocilK . Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. International Angiology2015;34(5):428-36. ">Rabe 2015</a>; <a href="./references#CD003229-bbs2-0063" title="UnkaufM , RehnD , KlingerJ , MotteS , GrobmannK . Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings. Arzneimittel-Forschung1996;46(5):478-82. ">Unkauf 1996</a>; <a href="./references#CD003229-bbs2-0065" title="VanscheidtW , JostV , WolnaP , LückerA , MullerA , TheurerC , et al. Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittel-Forschung2002;52(4):243-50. ">Vanscheidt 2002b</a>; <a href="./references#CD003229-bbs2-0068" title="WidmerL , BilandL , BarrasJP . Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study. International Angiology1990;9(2):105-10. ">Widmer 1990</a>; <a href="./references#CD003229-bbs2-0069" title="ZucarelliF . Clinical efficacy and tolerability of rutin. Double blind, placebo controlled clinical trial. [Efficacité clinique et tolerance de la coumarine rutine. Étude controlée en double aveugle versus placebo]. Gazette Médicale1987;94(32):80-6. ">Zucarelli 1987</a>). Other studies used ordinal categorical scales with a scoring system from ‐3 to +1 (<a href="./references#CD003229-bbs2-0025" title="HachenHJ , LorenzP . Double-blind clinical and plethysmographic study of calcium dobesilate in patients with peripheral microvascular disorders. Angiology1982;33(7):480-8. ">Hachen 1982</a>), ‐1 to + 1 (<a href="./references#CD003229-bbs2-0009" title="Casley-SmithJR . A double-blind, placebo -controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. In: Davy A and StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. London and Paris: John Libbey Eurotext Ltd, 1989. Casley-SmithJR . A double-blind, placebo-controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. Phlebologie1989;2:709-11. Casley-SmithJR . A double-blind trial of calcium dobesilate in chronic venous insufficiency. Angiology1988;39(10):853-7. ">Casley‐Smith 1988</a>), 0 to 1 (<a href="./references#CD003229-bbs2-0026" title="IhmeN , KiesewetterH , JungF , HoffmannKH , BirkA , MüllerA , et al. Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomized, double-blind, placebo-controlled clinical trial. European Journal of Clinical Pharmacology1996;50(6):443-7. ">Ihme 1996</a>), 0 to 2 (<a href="./references#CD003229-bbs2-0007" title="BilandL , BlättlerP , ScheiblerP , StuderS , WidmerK . Zur therapie sogenannt venosër beinsbeschwerden. Vasa1982;11(1):53-8. ">Biland 1982</a>; <a href="./references#CD003229-bbs2-0026" title="IhmeN , KiesewetterH , JungF , HoffmannKH , BirkA , MüllerA , et al. Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomized, double-blind, placebo-controlled clinical trial. European Journal of Clinical Pharmacology1996;50(6):443-7. ">Ihme 1996</a>; <a href="./references#CD003229-bbs2-0029" title="KiesewetterH , KoscielnyJ , GrütznerK , MüllerA , HoffmannKH , BirkA . Buckwheat herb/troxerutin-combination for the treatment of chronic venous insufficiency. Zeitschrift für Phytotherapie1997;18(6):341-6. ">Kiesewetter 1997</a>), 0 to 3 (<a href="./references#CD003229-bbs2-0001" title="Allegra C Pollari G, CriscuoloA , BonifacioM , TabassiD . Centella asiatica extract in venous disorders of the lower limbs. Comparative clinico-instrumental studies with a placebo. Clinica Terapeutica1981;99(5):507-13. ">Allegra 1981</a>; <a href="./references#CD003229-bbs2-0003" title="ArcangeliP . Pycnogenol in chronic venous insufficiency. Fitoterapia2000;71(3):236-44. ">Arcangeli 2000</a>; <a href="./references#CD003229-bbs2-0015" title="CloarecM , ClémentR , GritonP . A double-blind clinical trial of hydroxyethylrutosides in the treatment of the symptoms and signs of chronic venous insufficiency. Phlebology1996;11(2):76-82. ">Cloarec 1996</a>; <a href="./references#CD003229-bbs2-0016" title="Cornu-ThenardA , DahanB , De ParadesB . Study of the action in venous insufficiency of the legs. Pierre Fabre Medicament Laboratoires (Novartis). Report no. DC982GEC51(2),1985. ">Cornu‐Thenard 1985</a>; <a href="./references#CD003229-bbs2-0017" title="DanielssonG , JungbeckC , PetersonK , NorgrenL . A randomised controlled trial of micronised purified flavonoid fraction versus placebo in patients with chronic venous disease. European Journal of Vascular and Endovascular Surgery2002;23(1):73-6. ">Danielsson 2002</a>; <a href="./references#CD003229-bbs2-0018" title="DiebschlagW , NockerW , LehmacherW , RehnD . A clinical comparison of two doses of O-(beta-hydroxyethyl) rutosides (oxerutins) in patients with chronic venous insufficiency. Journal of Pharmaceutical Medicine1994;4(1):7-14. ">Diebschlag 1994</a>; <a href="./references#CD003229-bbs2-0020" title="DominguezC , BrautighamI , GonzálezE , GonzálezJA , NazcoJ , ValienteR , et al. Therapeutic effects of hidrosmin on chronic venous insufficiency of the lower limbs. Current Medical Research and Opinion1992;12(10):623-30. ">Dominguez 1992</a>; <a href="./references#CD003229-bbs2-0023" title="FrileuxC , GillyR . Activité thérapeutic de Daflon 500 mg dans l'insuffisance veineuse chronique des membres inférieurs. Journal Internationale de Medicine1994;Suppl 99:36-9. GillyR , PillionG , FrileuxC . Evaluation of a new venactive micronized flavonoid fraction (S5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology1994;9(2):67-70. ThiolletM , FrileuxC , GillyR . Evaluation of a new micronized diosmin in the treatment of chronic venous incompetence: a double-blind, placebo controlled trial. Journal of Vascular Surgery1992;15(2):447. ">Gilly 1994</a>; <a href="./references#CD003229-bbs2-0028" title="JongsteAB , JonkerJJC , HuismanMV , CateJW , AzarAJ . A double-blind trial on the short-term efficacy of HR in patients with the post-thrombotic syndrome. Phlebology1990;5(Suppl 1):21-2. JongsteAB , JonkerJJC , HuismanMV , den CateJW , AzarAJ . A double-blind three center clinical trial on the short-term efficacy of O-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome. Thrombosis and Haemostasis1989;62(3):826-9. ">Jongste 1989</a>; <a href="./references#CD003229-bbs2-0034" title="LanguillatN . Trial of Cyclo 3 Fort in venous insufficiency of the lower limbs: Xenon 133 functional investigation of venous circulatory velocity. Pierre Fabre Medicament Laboratories (Novartis). No. Report DC982GEC130(2),1988. ">Languillat 1988</a>; <a href="./references#CD003229-bbs2-0035" title="LaurentR , GillyR , FrileuxC . Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg. International Angiology1988;7(2 Suppl):39-43. ">Laurent 1988</a>; <a href="./references#CD003229-bbs2-0036" title="LazzariniA , DanieliL . Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers [Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche]. Rassegna Internazionale di Clinica e Terapia1982;62(12):825-44. ">Lazzarini 1982</a>; <a href="./references#CD003229-bbs2-0044" title="ParradoF , BuzziA . A study of the efficacy and tolerability of a preparation containing Ruscus aculeatus in the treatment of chronic venous insufficiency of the lower limbs. Clinical Drug Investigation1999;18(4):255-61. ">Parrado 1999</a>; <a href="./references#CD003229-bbs2-0048" title="PlanchonB . Venous insufficiency and Daflon 500 mg [Insuffisance veineuse et Daflon 500 mg]. Artères et Veines1990;IX(4):376-80. ">Planchon 1990</a>; <a href="./references#CD003229-bbs2-0049" title="PointelJP , BoccalonH , CloarecM , Le DevehatC , JoubertM . Titrated extract of Centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology1987;38(1 Pt 1):46-50. PointelJP . Titrated extract of centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology1986;37(5):420-1. ">Pointel 1986</a>; <a href="./references#CD003229-bbs2-0051" title="PulvertaftTB . General practice treatment of symptoms of venous insufficiency with oxerutins. Results of a 660 patient multicentre study in the UK. Vasa1983;12(4):373-6. PulvertaftTB . Paroven in the treatment of chronic venous insufficiency. Practitioner1979;223(1338):838-41. ">Pulvertaft 1983</a>; <a href="./references#CD003229-bbs2-0060" title="SerraldeCF , AcevesAQ . Clinical trial of the O-(β-hydroxy-ethyl-rutosides) in patients with chronic venous insufficiency [Ensayo clínico de o-(beta-hidroxietil-rutósidos) en pacientes con insuficiencia venosa crónica]. Revista Médica del Hospital General de México1990;53(2):102-6. ">Serralde 1990</a>; <a href="./references#CD003229-bbs2-0061" title="ThebautJF , ThebautP , VinF . Trial of vasculoprotective agent (plant products of the flavan class) in functional manifestations of peripheral venous insufficiency (double-blind trial in 92 cases). Gazette Medicale1985;92(12):96-100. ">Thebaut 1985</a>; <a href="./references#CD003229-bbs2-0062" title="TsouderosY . Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency. Our experience with Daflon 500 mg. International Angiology1989;8(4):53-9. TsouderosY . Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg. Zeitschrift fur Kardiologie1991;80 Suppl 7:95-101. ">Tsouderos 1989</a>; <a href="./references#CD003229-bbs2-0067" title="WelchW , MoriauM , vanGyselJP . A double-blind, placebo controlled trial of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Novartis1985. ">Welch 1985</a>), 0 to 4 (<a href="./references#CD003229-bbs2-0004" title="BalmerA , LimoniC . Clinical, placebo-controlled double-blind study of venoruton in the treatment of chronic venous insufficiency. Importance of the selection of patients. Vasa1980;9(1):76-82. BlumeJ . Therapy of venous oedemas [Tratamento do edema de origem venosa]. Revista Brasileira de Medicina1994;51(3):283-8. ">Balmer 1980</a>; <a href="./references#CD003229-bbs2-0013" title="ChassignolleJF , AmielM , LanfranchiG , BarbeR . Activite therapeutique de daflon 500 mg dans l'insuffisance veineuse fonctionnelle. Journal International de Medicine1994;Suppl 99:32-5. ">Chassignolle 1994</a>; <a href="./references#CD003229-bbs2-0021" title="FermosoJ , LegidoAG , Del PinoJ , ValienteR . Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Current Therapeutic Research, Clinical and Experimental1992;52(1):124-34. ">Fermoso 1992</a>; <a href="./references#CD003229-bbs2-0022" title="Flota-CerveraF ,  Flota-RuizC ,  TreviñoC ,  BerberA . Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology2008;59(3):352-6. FlotaLF . Prospective, randomised, double-blind, placebo controlled, clinical trial that assesses the efficacy of calcium dobesilate in the limphoedema by varicose disease [Estudio clínico prospectivo aleatorizado, doble ciego, con control placebo, para evaluar la eficacia en la resolución del edema de origen lifático, del dobesilato de calcio en pacientes con enfermedad varicosa]. Knoll de Mexico S.A. Laboratorios Dr. Esteve. No de proyec. Knoll-mex-02-99, 003/MEX, 99. ">Flota‐Cervera 2008</a>), 0 to 5 (<a href="./references#CD003229-bbs2-0041" title="NCT01848210. Efficacy and safety of coumarin and troxerutin in the symptomatic treatment of chronic venous insufficiency. clinicaltrials.gov/ct2/show/NCT01848210 (first posted 7 May 2013). ">NCT01848210</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>), 0 to 7 (<a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a>) or 0 to 9 (<a href="./references#CD003229-bbs2-0020" title="DominguezC , BrautighamI , GonzálezE , GonzálezJA , NazcoJ , ValienteR , et al. Therapeutic effects of hidrosmin on chronic venous insufficiency of the lower limbs. Current Medical Research and Opinion1992;12(10):623-30. ">Dominguez 1992</a>). Likewise, some of these scales were used to evaluate signs or objective variables such as oedema or trophic disorders. Methods used to measure oedema included metric tape to measure ankle or calf circumference and plethysmographic values (used in most studies) to determine leg volume. </p> </section> <section id="CD003229-sec-0042"> <h4 class="title">Excluded studies</h4> <p>For this update, we identified two new studies that were excluded (<a href="./references#CD003229-bbs2-0113" title="EudraCT2009-014681-25. Pharmacodynamic and clinical assessment of DC 982 GE (2,4 or 6 capsules per day) in patients with chronic venous disorders: randomised, placebo-controlled, dose effect, double blind, parallel group study. clinicaltrialsregister.eu/ctr-search/search?query=2009-014681-25 (first posted 21 October 2009). ">EudraCT2009‐014681‐25</a>; <a href="./references#CD003229-bbs2-0125" title="ISRCTN54360155. A 3 month clinical trial of herbal medicine combination intended for topical application in patients with leg symptoms complaints due to chronic venous insufficiency: a double-blind randomized controlled trial. www.isrctn.com/ISRCTN54360155 (first posted 5 January 2015). ">ISRCTN54360155</a>). Four previously excluded studies were also identified by the search (<a href="./references#CD003229-bbs2-0005" title="BelczakSQ , SincosIR , CamposW , BeserraJ , NeringG , AunR . Veno-active drugs for chronic venous disease: a randomized, double-blind, placebo-controlled parallel-design trial. Phlebology2014;29(7):454-60. ">Belczak 2014</a>; <a href="./references#CD003229-bbs2-0029" title="KiesewetterH , KoscielnyJ , GrütznerK , MüllerA , HoffmannKH , BirkA . Buckwheat herb/troxerutin-combination for the treatment of chronic venous insufficiency. Zeitschrift für Phytotherapie1997;18(6):341-6. ">Kiesewetter 1997</a>; <a href="./references#CD003229-bbs2-0050" title="PrerovskyI , RoztocilK , HlavovaA , KoleilatZ , RazgovaL , OlivaI . The effects of hydroxyethylrutosides after acute and chronic oral administration in patients with venous diseases. A double blind study. Angiologica1972;9(3-6):408-14. ">Prerovsky 1972</a>; <a href="./references#CD003229-bbs2-0176" title="NCT01532882. Efficacy and safety of Diosmin 600mg versus placebo on painful symptomatology in patients with chronic venous disease of lower limbs (EDEN). clinicaltrials.gov/show/NCT01532882 (first posted 15 Febraury 2012). ">NCT01532882</a>), making a total of 104 studies excluded for a variety of reasons (see <a href="./references#CD003229-sec-0114" title="">Characteristics of excluded studies</a> for details). We summarise the exclusion details below. </p> <p> <ul id="CD003229-list-0014"> <li> <p>We excluded 58 studies because the intervention used by researchers was not included in this Cochrane Review (<a href="./references#CD003229-bbs2-0070" title="AkbulutB . Calcium dobesilate and oxerutin: effectiveness of combination therapy. Phlebology2010;25:66-71. ">Akbulut 2010</a>; <a href="./references#CD003229-bbs2-0073" title="BacciPA , AllegraC , BottaG , ManciniS . The role of a multifunctional plant complex in phlebolymphology: randomized, placebo-controlled double-blind clinical study. Amercian College of Phlebology. Abstracts from the 17th Annual Congress, August 27 - 31, 2003 — San Diego, California. ">Bacci 2003</a>; <a href="./references#CD003229-bbs2-0074" title="BastideG , BecadeP , GoulleyY . Double blind study of Dihydroergotamine Sandoz in venous pathology of lower limbs. Angeiologie1976;28(5):249-54. ">Bastide 1976</a>; <a href="./references#CD003229-bbs2-0075" title="BatchvarovaV . Effet Clinique du Troxevit sur l'Insuffisance Veineuse Chronique. Vol. 2. London &amp; Paris: John Libby Eurotext Ltd, 1989. ">Batchvarova 1989a</a>; <a href="./references#CD003229-bbs2-0076" title="BeharA , NathanP , LavieuvilleM , AllaertFA . Effect of veinotonyl 75 on the capillary permeability test using technetium albumin in cyclic orthostatic edemas. Phlébologie1993;46(4):721-31. ">Behar 1993</a>; <a href="./references#CD003229-bbs2-0080" title="BelloAA , MeyerK , GarciaAT , ReinagaVV . Calcium dobesilate combined with a heparinoid in the topical treatment of chronic venous insufficiency: a double-blind study. Acta Therapeutica1990;16(1):79-87. ">Bello 1990</a>; <a href="./references#CD003229-bbs2-0081" title="BentoC , BrandãoDDC , SmithP . A multicentric, IV phase, multidisciplinary, prospective, randomized, double blinded, comparative study to evaluate the castanha-da-índia, rutina, smilax japicanga and polygonum punctatum combination efficacy and tolerability in the treatment of patients suffering from symptomatic venous insufficiency comparing to placebo treatment. Revista Brasileira de Medicina2006;63(8):422-6. ">Bento 2006</a>; <a href="./references#CD003229-bbs2-0082" title="BersonI . About a new medicamentous treatment of the varicose syndrome. Schweiz Rundschau Med (PRAXIS)1978;67:981-3. ">Berson 1978</a>; <a href="./references#CD003229-bbs2-0084" title="BohmC . Venodiuretics: a new combination of diuretic and edema protective drugs. Medizinische Welt1989;40(30-31):887-8. ">Bohm 1989</a>; <a href="./references#CD003229-bbs2-0086" title="BolligerAA . Results of a double blind trial of percutaneously administered rutoside. Angiologica1972;9:397-400. ">Bolliger 1972</a>; <a href="./references#CD003229-bbs2-0088" title="BosseK , DrieschnerP , KloseL . Comparative studies concerning the effectiveness of therapeutic agents in chronic venous insufficiency. Phlebologie und Proktologie1985;14:111-4. ">Bosse 1985</a>; <a href="./references#CD003229-bbs2-0089" title="BramiC , MorereMCNK , MegretG , ElbazC . Double-blind controlled trial against placebo of dihydroergocryptine mesilate plus caffeine in chronic venous insufficiency. Angeiologie1983;35(8):281-3. ">Brami 1983</a>; <a href="./references#CD003229-bbs2-0090" title="CarstensC , HampelH . Treatment of oedemata in chronic venous insufficiency by means of an additional therapy with DIU Venostatin. Die Medizinische Welt1985;36:867-70. ">Carstens 1985</a>; <a href="./references#CD003229-bbs2-0091" title="CataldiA , GasbarroV , ViaggiR , SoveriniR , GrestaE , MascoliF . Effectiveness of the association of alphatocopherol, rutin, melilotus and centella asiatica in the treatment of patients affected by chronic venous insufficiency [Efficacia clinica di un'associazine di alfatocoferoli, rutina, meliloto e centella asiatica nel trattamento di pazienti con insufficienza venosa cronica]. Minerva Cardioangiologica2001;49(2):159-63. ">Cataldi 2001</a>; <a href="./references#CD003229-bbs2-0096" title="CesaroneMR , IncandelaL , BelcaroG , SanctisMT , RicciA , GriffinM . Two-week topical treatment with Essaven gel in patients with diabetic microangiopathy: a placebo-controlled, randomized study. Angiology2001;52 Suppl 3:S43-8. ">Cesarone 2001b</a>; <a href="./references#CD003229-bbs2-0101" title="ChiummarielloS , De GadoF , MonarcaC , RuggieroM , CarlesimoB , ScuderiN , et al. [Multicentric study on a topical compound with lymph-draining action in the treatment of the phlebostatic ulcer of the inferior limbs]. Il Giornale di chirurgia2009;30(11-12):497-501. ">Chiummariello 2009</a>; <a href="./references#CD003229-bbs2-0103" title="CospiteM , MilioG . Heparan sulfate vs diosmin: effects on microcirculation in chronic venous insufficiency of the lower extremities. Advances in Therapy1996;13(3):178-190. ">Cospite 1996</a>; <a href="./references#CD003229-bbs2-0107" title="deParadesB , DemarezJP , CauquilJ . Comparative analysis of the therapeutic effects of Cyclo 3 Fort and Diosmin 450 mg in combination with hesperidin 50 mg in venous insufficiency of the legs. Vie Medicale1990;6:226-32. ">de Parades 1990</a>; <a href="./references#CD003229-bbs2-0105" title="DelacroixP . Double-blind trial of endotelon (TM) in chronic venous insufficiency. La Revue de Medecine1981;22(27-28):1793-802. ">Delacroix 1981</a>; <a href="./references#CD003229-bbs2-0106" title="DelecluseM , DucrosJJ , EgalG , HamelH , JunkR , LerouxA , et al. [Clinical study of Diovenor 300 mg versus a mixture of flavonoides in 90 % of diosmine in the treatment of symptoms of chronic venous insufficiency in young active females]. Essai Clinique Pragmatique de Diovenor 300 mg Versus Melange de Flavonoides a 90 % de Diosmine Dans le Traitement des Manifestations d'Insuffisance Veineuse Chronique Chez la Femme Active Jeune1991;10(7):498-503. ">Delecluse 1991</a>; <a href="./references#CD003229-bbs2-0110" title="DustmannHO , GodoliasG , SeibelK . Foot volume with chronic venous insufficiency while standing: effect of a new treatment. Therapiewoche1984;34(36):5077-86. ">Dustmann 1984</a>; <a href="./references#CD003229-bbs2-0111" title="ErdlenF . Clinical efficacy of venostasin. A double blind trial. Medizinische Welt1989;40(36):994-6. ">Erdlen 1989</a>; <a href="./references#CD003229-bbs2-0112" title="ErlerM . Horse chestnut seed extract in the therapy of the peripheral venous edema - Clinical therapies in comparison. Medizinische Welt1991;42(7):593-6. ">Erler 1991</a>; <a href="./references#CD003229-bbs2-0113" title="EudraCT2009-014681-25. Pharmacodynamic and clinical assessment of DC 982 GE (2,4 or 6 capsules per day) in patients with chronic venous disorders: randomised, placebo-controlled, dose effect, double blind, parallel group study. clinicaltrialsregister.eu/ctr-search/search?query=2009-014681-25 (first posted 21 October 2009). ">EudraCT2009‐014681‐25</a>; <a href="./references#CD003229-bbs2-0119" title="HenrietJP . [Functional venous insufficiency: clinical study comparing once a day DIOVENOR 600 mg (600 mg of diosmine d'hemisyntheses) versus two doses per day of a mixture of 500 mg of flavonoides (900 mg of diosmine)]. Phlebologie1995;48(2):285-90. ">Henriet 1995</a>; <a href="./references#CD003229-bbs2-0120" title="HorvathW , TomschiF . [The postthrombotic state and the effect of dihydroergotamine]. Das Postthrombotische Zustandsbild und Seine Beeinflussung Durch Dihyrdroergotamin1985;14(1):84-9. ">Horvath 1985</a>; <a href="./references#CD003229-bbs2-0127" title="JanssensD , MichielsC , GuillaumeG , CuisinierB , LouagieY , RemacleJ . Increase in circulating endothelial cells in patients with primary chronic venous insufficiency: protective effect of Ginkor Fort in a randomized double-blind, placebo-controlled clinical trial. Journal of Cardiovascular Pharmacology1999;33(1):7-11. ">Janssens 1999a</a>; <a href="./references#CD003229-bbs2-0129" title="KiesewetterH , KoscielnyJ , KalusU , VixJM , PeilH , PetriniO , et al. Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I-II). A randomized, double-blind, placebo-controlled trial. Arzneimittel-Forschung2000;50(2):109-17. ">Kiesewetter 2000</a>; <a href="./references#CD003229-bbs2-0130" title="KoltringerP , LangstegerW , KlimaG , ReiseckerF , EberO . Hemorheologic effects of ginkgo biloba extract EGb 761. Dose- dependent effect of EGb 761 on microcirculation and viscoelasticity of blood. [German]. Fortschritte der Medizin1993;111(10):170-2. ">Koltringer 1993</a>; <a href="./references#CD003229-bbs2-0132" title="KrähenbühlB . Chronic arterial insufficiency of lower limbs: treatment by bencyclan (fludilat). Schweizerische Rundschau fur Medizin Praxis1975;64(20):632-4. ">Krähenbühl 1975</a>; <a href="./references#CD003229-bbs2-0133" title="KrcílekA , SmejkalV . Therapeutic effects of venotonics in clinical pharmacotherapeutical evaluations by double-blind tests. Casopis Lekaru Ceskych1973;112:930-3. ">Krcílek 1973</a>; <a href="./references#CD003229-bbs2-0134" title="LanguillatN , ZucarrelliF . Etude en double aveugle contre placebo de l'activite veinotonique due veliten: evolution de la permeabilite capillare et de lat vitesse de circulation veineuse. Acta Medica Internationale Angiologie1988;5(83):3-5. ">Languillat 1988b</a>; <a href="./references#CD003229-bbs2-0138" title="MarastoniF , CrespiB , MontorsiM , De StefanoA . A clinical and instrumental assessment of the effect of dihydroergotamine in lower extremity venous insufficiency. Archivio per le Scienze Mediche1982;139(2):165-74. ">Marastoni 1982</a>; <a href="./references#CD003229-bbs2-0140" title="Monteil-SeurinJ . Lymphatic venous insufficiency: comparative study of Cyclo 3 Fort (TM) versus diosmin. Comptes Rendus de Therapeutique et de Pharmacologie Clinique1993;11(109):3-7. ">Monteil‐Seurin 1993</a>; <a href="./references#CD003229-bbs2-0141" title="MoralesCA , BarrosRM . Efficacy and safety on use of dried horse chestnut extract in the treatment of chronic venous insufficiency of the limbs [Eficácia e segurança do extracto seco da semente de castanha-da-India no tratamento da insuficiencia venosa crônica de membros inferiores]. Revista Brasileira de Medicina1993;50(11):1563-5. ">Morales 1993</a>; <a href="./references#CD003229-bbs2-0144" title="NCT02191163. Efficacy of Antlstax In improving microcirculation of the skin in the leg in patients suffering from chronic venous insufficiency. https://clinicaltrials.gov/ct2/show/NCT02191163 (accessed 9 Sepember 2015). ">NCT02191163</a>; <a href="./references#CD003229-bbs2-0145" title="NCT02191254. Efficacy and tolerability of Antlstax in male and female patients sufferlng from chronlc venous insufficiency. https://clinicaltrials.gov/ct2/show/NCT02191254 (accessed 9 September 2015). ">NCT02191254</a>; <a href="./references#CD003229-bbs2-0146" title="NCT02191280. Antistax In patients with chronlc venous insufficiency. https://clinicaltrials.gov/ct2/show/NCT02191280 (accessed 9 September 2015). ">NCT02191280</a>; <a href="./references#CD003229-bbs2-0149" title="Neumann-MangoldtVP . Treatment of venous disorders of the lower extremities with Essaven-capsules, results of a double blind trial. Fortschritte der Medizin1979;97(45):2117-20. ">Neumann‐Mangoldt 1979</a>; <a href="./references#CD003229-bbs2-0150" title="NillHJ , FischerH , NillHJ , FischerH . Comparative investigations concerning the effect of extract of horse chestnut upon the pressure-volume-diagram of patients with venous disorders. [German]. Arztliche Forschung1970;24(5):141-3. ">Nill 1970</a>; <a href="./references#CD003229-bbs2-0151" title="OttillingerB , GreeskeK . Rational therapy of chronic venous insufficiency--chances and limits of the therapeutic use of horse-chestnut seeds extract. BMC Cardiovascular Disorders2001;1(1):5. ">Ottillinger 2001</a>; <a href="./references#CD003229-bbs2-0152" title="PaciaroniE , MariniM . Topical therapy for phlebopathies. Results of a controlled clinical study. Policlinico - Sezione Medica1982;89:255-64. [ID: 8761]">Paciaroni 1982</a>; <a href="./references#CD003229-bbs2-0153" title="PartschH . Improvement of venous insufficiency with oral dehydroergotamine [Besserung der venosen insuffizienz durch orales dihydroergotamin]. Die Medizinische Welt1981;32:1668-71. ">Partsch 1981</a>; <a href="./references#CD003229-bbs2-0154" title="PaulV , LangeA . Benzarone in edema of the legs due to chronic venous insufficiency. Munchener Medizinische Wochenschrift1983;125(16):343-4. ">Paul 1983</a>; <a href="./references#CD003229-bbs2-0155" title="PauschingerP . Clinical and experimental examination of the effect of horse-chestnut extract on the transcapillary filtratrion and the intravasel volume in patients with chronic venous insufficiency [Klinisch experimentelle Untersuchungen zur Wirkung von Rosskastanien-samenextrakt auf die transkapilläre Filtration und das intravasale Volumen an Parienten mit chronisch venöser Insuffizienz]. Phlebol Proktol1987;16:57-61. ">Pauschinger 1987</a>; <a href="./references#CD003229-bbs2-0157" title="PointelJP , GotI , ZieglerOI , FontaineM , BenedettiF , DrouinP , et al. Double-blind controlled study of a combination of vitamin C, Ruscus aculeatus and Ribes nigrum anthocyanosides on capillary filtration in venous insufficiency [Essai controle en double insu d'une association vitamine C, ruscus aculeatus et anthocyanosides de ribes nigrum sur la filtration capillaire dans l'insuffisance veineuse]. Arteres et veines1987;6(5):395-7. ">Pointel 1987b</a>; <a href="./references#CD003229-bbs2-0158" title="PokrovskiiAV , SapelkinSV , GalaktionovaLA , FedorovEE . The assessment of medical therapy effectiveness of patients with lower limb chronic venous insufficiency: the results of prospective study with Ginkor Fort. [Russian]. Angiologiia i Sosudistaia Khirurgiia/Angiology and Vascular Surgery2005;11(3):47-52. ">Pokrovskii 2005</a>; <a href="./references#CD003229-bbs2-0160" title="RabeE , StuckerM , EsperesterA , SchaferE , OttillingerB . Efficacy and tolerability of a red-vine-leaf extract in patients suffering from chronic venous insufficiency - results of a double-blind placebo-controlled study. European Journal of Vascular and Endovascular Surgery2011;41(4):540-7. ">Rabe 2011b</a>; <a href="./references#CD003229-bbs2-0161" title="RiccioniC , SarcinellaR , IzzoA , PalermoG , LiguoriM . Effectiveness of Troxerutin in association with Pycnogenol in the pharmacological treatment of venous insufficiency. Minerva Cardioangiologica2004;52(1):43-8. ">Riccioni 2004</a>; <a href="./references#CD003229-bbs2-0164" title="SanctisMT , CesaroneMR , IncandelaL , BelcaroG , RicciA , GriffinM . Four-week treatment with Essaven gel in diabetic microangiopathy--a placebo-controlled, randomized study. Angiology2001;52 Suppl 3:S49-55. ">Sanctis 2001</a>; <a href="./references#CD003229-bbs2-0166" title="SteinerM . Investigation on the edema-reducing and edema-protective effect of horse chestnut seed extract. Phlebol Proktol1990;19(5):239-42. ">Steiner 1990</a>; <a href="./references#CD003229-bbs2-0167" title="SteinerM . The Extent of the Edema Protective Effect of Horse Chestnut Seed Extract. Vol. 2. Paris: John Libbey Eurotext, 1992. ">Steiner 1992</a>; <a href="./references#CD003229-bbs2-0169" title="TopalovY , MarinovH , StanchevS . Troxesamol. Clinical application of the preparation in patients with vascular insufficiency of the lower extremities. Medico Biologie Information1990;4(4):22-5. ">Topalov 1990</a>; <a href="./references#CD003229-bbs2-0170" title="TurioE , RomanelliM , BarachiniP . Clinical arid instrumental evaluation of the efficacy of a vasoactive drug containing vitamin PP, vitamin C and phyto-therapeutic extracts titrated in escin, bromelain and anthocyanosides for the treatment of varicose leg ulcers. Giornale Italiano di Dermatologia e Venereologia2000;135(1):101-5. ">Turio 2000</a>; <a href="./references#CD003229-bbs2-0125" title="ISRCTN54360155. A 3 month clinical trial of herbal medicine combination intended for topical application in patients with leg symptoms complaints due to chronic venous insufficiency: a double-blind randomized controlled trial. www.isrctn.com/ISRCTN54360155 (first posted 5 January 2015). ">ISRCTN54360155</a>; <a href="./references#CD003229-bbs2-0171" title="WeindorfN , Schultz EhrenburgU . Controlled study of increasing venous tone in primary varicose veins by oral administration of Ruscus aculeatus and trimethylhespiridinchalcone. Zeitschrift fur Hautkrankheiten1987;62:28-38. ">Weindorf 1987</a>; <a href="./references#CD003229-bbs2-0172" title="WidmerLK , GlausL , RapsE . Local treatment of leg disorders and chronic venous insufficiency. Double blind study of 55 patients. Schweizerische Rundschau fur Medizin Praxis1972;61(42):1300-4. ">Widmer 1972</a>; <a href="./references#CD003229-bbs2-0173" title="ZuccarelliF . Evaluation of the effectiveness of Ginkor Fort on the symptoms of chronic venous insufficiency. Phlébologie1996;49(1):105-10. ">Zuccarelli 1996</a>). </p> </li> <li> <p>We excluded 30 studies because researchers assessed no clinical endpoints or reported only outcomes not included in this Cochrane Review (<a href="./references#CD003229-bbs2-0071" title="AndroulakisG , PanoysisPA . Plethysmographic confirmation of the beneficial effect of calcium dobesilate in primary varicose veins. Angiology1989;40(1):1-4. ">Androulakis 1989</a>; <a href="./references#CD003229-bbs2-0072" title="AuteriA , BlardiP , FrigerioC , deLilloL , di PerriT . Pharmacodynamics of troxerutine in patients with chronic venous insufficiency: correlations with plasma drug levels. International Journal of Clinical Pharmacology Research1990;10(4):235-41. ">Auteri 1990</a>; <a href="./references#CD003229-bbs2-0078" title="BelcaroG , Rosaria CesaroneM , De SanctisMT , IncandelaL , LauroraG , FevrierB , et al. Laser doppler and transcutaneous oxymetry: modern investigations to assess drug efficacy in chronic venous insufficiency. International Journal of Microcirculation: Clinical and Experimental1995;15(Suppl 1):45-9. ">Belcaro 1995</a>; <a href="./references#CD003229-bbs2-0079" title="Belcaro G Cesarone MR, LeddaA , CacchioM , RuffiniI , RicciA , et al. O-(beta-hydroxyethyl)-rutosides systemic and local treatment in chronic venous disease and microangiopathy: an independent prospective comparative study. Angiology2008;59 (Suppl 1):7S-13S. ">Belcaro 2008</a>; <a href="./references#CD003229-bbs2-0085" title="BoisseauMR , TaccoenA , GarreauC , VergnesC , RoudautMF , Garreau-GomezB . Fibrinolysis and hemorheology in chronic venous insufficiency: a double-blind study of troxerutin efficiency. Journal of Cardiovascular Surgery1995;36(4):369-74. ">Boisseau 1995</a>; <a href="./references#CD003229-bbs2-0087" title="BortH , HahnM , KlysczT , JungerM . The influence of rutosides on increased capillary permeability in chronic venous insufficiency as measured by video capillaroscopy. In: Proceedings of the Union Internationale de Phlebologie - 12th World Congress, London, 3-8 September. 1995. ">Bort 1995</a>; <a href="./references#CD003229-bbs2-0092" title="CesaroneMR , LauroraG , RicciA , BelcaroG , PomanteP , CandianiC , et al. Acute effects of hydroxyethylrutosides on capillary filtration in normal volunteers, patients with venous hypertension and in patients with diabetic microangiopathy (a dose comparison study). Vasa1992;21(1):76-80. ">Cesarone 1992</a>; <a href="./references#CD003229-bbs2-0093" title="CesaroneMR , LauroraG , De SanctisMT , IncandelaL , GrimaldiR , MarelliC , et al. Microcirculatory activity of centella asiatica in venous insufficiency. Minerva Cardioangiologica1994;42(6):299-304. ">Cesarone 1994</a>; <a href="./references#CD003229-bbs2-0094" title="CesaroneMR , De SanctisMT , IncandelaL , BelcaroG , GriffinM , BaveraP , et al. Microvascular changes in venous hypertension due to varicose veins after standardized application of Essaven gel--a placebo-controlled, randomized study. Angiology2001;52 Suppl 3:S11-6. ">Cesarone 2001</a>; <a href="./references#CD003229-bbs2-0097" title="CesaroneMR , BelcaroG , RuloA , GriffinM , RicciA , IppolitoE , et al. Microcirculatory effects of total triterpenic fraction of Centella asiatica in chronic venous hypertension: measurement by laser Doppler, TcPO2-CO2, and leg volumetry 93. Angiology2001;52 Suppl 2:S45-8. ">Cesarone 2001c</a>; <a href="./references#CD003229-bbs2-0098" title="CesaroneMR , IncandelaL , DeSanctisMT , BelcaroG , DugallM , AcerbiG . Variations in plasma free radicals in patients with venous hypertension with HR (Paroven, Venoruton; O-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized trial. Journal of Cardiovascular Pharmacology and Therapeutics2002;7 Suppl 1:S25-8. ">Cesarone 2002b</a>; <a href="./references#CD003229-bbs2-0100" title="ChantAD . The effect of paroven (HR) of the clearance of sodium-24 from the subcutaneous tissues of the foot in patients with varicose veins. Vasa1973;2(3):288-91. ">Chant 1973</a>; <a href="./references#CD003229-bbs2-0102" title="ClemensS , BislerH , BraunR . Phlebodril: Influences on the venous regurgitation. Phlebologie und Proktologie1986;15(1):15-9. ">Clemens 1986</a>; <a href="./references#CD003229-bbs2-0109" title="Duchene MarullazP , AmielM , BarbeR . Evaluation of the clinical pharmacological activity of a phlebotonic agent. Application to the study of Daflon 500 mg. International Angiology1988;7 Suppl 2:25-32. ">Duchene 1988</a>; <a href="./references#CD003229-bbs2-0114" title='ForconiS , GuerriniM , Di PerriT . Study of the activity of a flavonoid, O-(beta-hydroxyethyl)-rutoside, at high dose levels of venous tone measured by "strain gauge" plethysmography. Vasa1977;6(3):279-84. '>Forconi 1977</a>; <a href="./references#CD003229-bbs2-0117" title="Gonzalez-FajardoJA , Rodriguez-CamareroSJ , deMarinoP , Castro VillamorMA , March GarciaJR , Carpintero MediavillaL , et al. [Photoplethysmographic evaluation of the effect of a vascular tonic drug]. Angiologia1990;42(5):167-71. ">Gonzalez‐Fajardo 1990</a>; <a href="./references#CD003229-bbs2-0121" title="IncandelaL , CesaroneMR , De SanctisMT , LauroraG , RicciA , GerentesI . Evaluation of the microcirculatory effects of veinamitol 3500 mg in chronic venous insufficiency. International Angiology1995;14 Suppl 1:98-9. ">Incandela 1995</a>; <a href="./references#CD003229-bbs2-0122" title="IncandelaL , De SanctisMT , CesaroneMR , LauroraG , BelcaroG , TaccoenA , et al. Efficacy of troxerutin in patients with chronic venous insufficiency: a double-blind, placebo-controlled study. Advances in Therapy1996;13(3):161-6. ">Incandela 1996</a>; <a href="./references#CD003229-bbs2-0126" title="JanssensD , MichielsC , GuillaumeG , CuisinierB , LouagieY , RemacleJ . Increase in circulating endothelial cells in patients with primary chronic venous insufficiency: protective effect of Ginkor Fort in a randomized double-blind, placebo-controlled clinical trial. Journal of Cardiovascular Pharmacology1999;33(1):7-11. ">Janssens 1999</a>; <a href="./references#CD003229-bbs2-0128" title="KalusU , KoscielnyJ , GrigorovA , SchaeferE , PeilH , KiesewetterH . Improvement of cutaneous microcirculation and oxygen supply in patients with chronic venous insufficiency by orally administered extract of red vine leaves AS 195: a randomised, double-blind, placebo-controlled, crossover study. Drugs in R &amp; D2004;5(2):63-71. KalusU , KoscielnyJ , GrigorovA , SchaeferE , PeilH , KiesewetterH . Improvement of cutaneous microcirculation and oxygen supply in patients with chronic venous insufficiency by oral therapy with red wine leaf extract AS 195. Vasomed2004;16(1):20-1. ">Kalus 2004</a>; <a href="./references#CD003229-bbs2-0131" title="KosteringH , BanduraB , MertenHA , WiedingJU . The behaviour of blood clotting and its inhibitors under long-term with 5,6-benzo-alpha-pyrone (coumarin). Double-blind study. Arzneimittel-Forschung1985;35(8):1303-6. ">Kostering 1985</a>; <a href="./references#CD003229-bbs2-0135" title="LanguillatN , ZuccarelliF , HaritonC . Radioisotopic comparative double-blind study of venous capillary permeability and circulation rate after treatment by Veliten (R) in venous insufficiency of inferior limbs. In: Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. 1989. ">Languillat 1989</a>; <a href="./references#CD003229-bbs2-0136" title="Le DévéhatC , VimeuxM , BandouxG . Hemoreological effects of oral troxerutin treatment versus placebo in venous insufficiency of the lower limbs. Clinical Hemorrheology1989;9(4):543-52. Le DévéhatC , VimeuxM , BondouxG , KhodabandehlouT . Hemorheological effects of oral troxerutin treatment in venous insufficiency of the lower limbs. Phlebologie1989;2:766-8. Le DevehatC , LemoineA . Effet hemorheological de la troxerutine dans l'insuffisance veineuse [Effet hemorheological de la troxerutine dans l'insuffisance veineuse]. In: NegusD , JantetG , editors(s). Phlebology 1985. Herts, UK: John Libbey and Co Ltd, 1986:850-2. ">Le Dévéhat 1989</a>; <a href="./references#CD003229-bbs2-0137" title="Le DevehatC , KhodabandehlouT , VimeuxM , KempfC . Evaluation of haemorheological and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500 mg. International Journal of Microcirculation: Clinical and Experimental1997;17(Suppl 1):27-33. ">Le Dévéhat 1997</a>; <a href="./references#CD003229-bbs2-0142" title="Naser-HijaziB , GallenkemperG , RieckemannB , VanscheidtW . In contrast to its derivatives, coumarin does not influence prothrombin time: results from a randomised placebo-controlled study. Phlebologie2004;33(1):17-22. Schmeck-LindenauHJ , Naser-HijaziB , BeckerEW , Henneicke vonHH , SchnitkerJ . Safety aspects of a coumarin-troxerutin combination regarding liver function in a double-blind placebo-controlled study. International Journal of Clinical Pharmacology and Therapeutics2003;41(5):193-9. ">Naser‐Hijazi 2004</a>; <a href="./references#CD003229-bbs2-0147" title="NeumannHAM , Van Den BroekMTJB . Double blind study of the influence of O-(beta-hydroxyethyl)-rutosides on the TcpO2 and LRR curve in patients with chronic venous insufficiency. International Angiology1988;7(4):9. ">Neumann 1988</a>; <a href="./references#CD003229-bbs2-0148" title="NeumanHAM , Van der BroekMJTB . Evaluation of O-(beta-hydroxyethyl)-rutosides in chronic venous insufficiency by means of non-invasive techniques. Phlebology1990;5 Suppl 1:13-20. ">Neumann 1990</a>; <a href="./references#CD003229-bbs2-0159" title="QuestelR , WalrantP . Randomized, placebo-controlled trial of extracts of Ruscus aculeatus and Ribes nigrum plus ascorbic acid in venous insufficiency: Observation of microcirculation by conjunctival capillarography. Gazette Medicale de France1983;90(6):508-14. ">Questel 1983</a>; <a href="./references#CD003229-bbs2-0162" title="RoztocilK , PrerovskyI , OlivaI . The effect of hydroxyethylrutosides on capillary filtration rate in the lower limb of man. European Journal of Clinical Pharmacology1977;11:435-8. ">Roztocil 1977</a>; <a href="./references#CD003229-bbs2-0165" title="SeydewitzV , BergD , StaubesandJ , WelbersP . Impact of drug treatment on the activity of lysosomal enzymes in the wall of varicose veins [Einflub einer medikamentösen therapie auf die aktivität lysosomaler enzyme in der varikös veränderten Venenwand]. Phlebologie1992;21(6):288-92. ">Seydewitz 1992</a>). </p> </li> <li> <p>We excluded 16 studies because they were not double‐blinded (<a href="./references#CD003229-bbs2-0077" title="BelcaroG , RuloA , CandianiC . Evaluation of the microcirculatory effects of Venorutin in patients with chronic venous hypertension by laser Doppler flowmetry, transcutaneous PO2 and PCO2 measurements, leg volumetry and ambulatory venous pressure measurements. Vasa1989;18:146-51. BelcaroG , RuloA , CandianiC . Evaluation of the microcirculatory effects of Venoruton in patients with chronic venous hypertension by laser-Doppler flowmetry, transcutaneous PO2 and PCO2 measurements, leg volumetry and ambulatory venous pressure measurements. Phlebology1989;4(1):23-30. ">Belcaro 1989</a>; <a href="./references#CD003229-bbs2-0083" title="BlumeJ , WüstenbergP . Chronic vein insufficiency. Treatment results with benzopyrones during and after compression therapy [Cronisch-venöse Insuffizienz (CVI). Behandlungsergebnisse mit benzopyronen und nach Kompressiontherapie]. Therapiewoche1996;46(10):540-4. BlumeJ . Therapy of venous oedema [Tratamento do edema de origem venosa. Eficácia de um tratamento medicamentoso em combinaçao com o tratamento compresivo]. Revista Brasileira de Medicina1994;51(3):283-8. ">Blume 1996</a>; <a href="./references#CD003229-bbs2-0095" title="CesaroneMR , BelcaroG , De SanctisMT , IncandelaL , CacchioM , BaveraP , et al. Effects of the total triterpenic fraction of Centella asiatica in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial. Angiology2001;52 Suppl 2:S15–8. ">Cesarone 2001a</a>; <a href="./references#CD003229-bbs2-0099" title="CesaroneMR , BelcaroG , RohdewaldP , PellegriniL , LeddaA , VinciguerraG , et al. Improvement of signs and symptoms of chronic venous insufficiency and microangiopathy with Pycnogenol: a prospective, controlled study. Phytomedicine2010;17(11):835-9. ">Cesarone 2010</a>; <a href="./references#CD003229-bbs2-0104" title="De AnnaD , MariF , IntiniS , GasbarroV , SortiniA , PozzaE , et al. Effects of therapy with aminaftone on chronic venous and lymphatic stasis [Effetti della terapia con aminaftone sulla stasi venosa e linfatica cronica]. Minerva Cardioangiologica1989;37(5):251-4. De AnnaD , RisalitiA , IntiniS , TerrosuG , PetriR , TaddeoU , et al. Aminaphtone therapy in venous lymphatic stasis of lower limbs. Phlebologie1989;2:753-5. De AnnaD , RisalitiA , IntiniS , UzzauA , TerrosuG , PetriR , et al. Aminaphtone therapy in venous and lymphatic stasis of lower limbs. In: Davy A and StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29-September 1989. Vol. 2. London and Paris: John Libbey Eurotext Ltd, 1989:753-5. ">De Anna 1989</a>; <a href="./references#CD003229-bbs2-0108" title="De SanctisMT , BelcaroG , IncandelaL , CesaroneMR , GriffinM , IppolitoE , et al. Treatment of edema and increased capillary filtration in venous hypertension with total triterpenic fraction of Centella asiatica: a clinical, prospective, placebo-controlled, randomized, dose-ranging trial. Angiology2001;52(Suppl 2):S55-9. ">De Sanctis 2001</a>; <a href="./references#CD003229-bbs2-0115" title="FrausiniG , RotatoriP , OlivaS . Controlled trial on clinical-dynamic effects of three treatments in chronic venous insufficiency. Giornale Italiano di Angiologica1985;5(2):147-51. ">Frausini 1985</a>; <a href="./references#CD003229-bbs2-0116" title="GlinskiW , ChodynickaB , RoszkiewiczJ , BogdanowskiT , Lecewicz-TorunB , KaszubaA , et al. Effectiveness of a micronized purified flavonoid fraction (MPFF) in the healing process of lower limb ulcers. An open multicentre study, controlled and randomized. Minerva Cardioangiologica2001;49(2):107-14. GlinskiW , ChodynickaB , RoszkiewiczJ , BogdanowskiT , Lecewicz TorunB , KaszubaA , et al. The beneficial augmentative effect of micronised purified flavonoid fraction (MPFF) on the healing of leg ulcers: an open, multicentre, controlled, randomised study. Phlebology1999;14(4):151-7. ">Glinski 1999</a>; <a href="./references#CD003229-bbs2-0118" title="GrangerC , LaveilleC , VilainC , JochemsenR . Correlation between haemodynamic parameters of venous tone and clinical symptoms improvement in patients with chronic venous insufficiency. A controlled randomised study of Daflon 200 mg 2 tablets per day versus placebo during two months of treatment. International Angiology1995;14 Suppl 1:343. ">Granger 1995</a>; <a href="./references#CD003229-bbs2-0123" title="IncandelaL , BelcaroG , De SanctisMT , CesaroneMR , GriffinM , IppolitoE , et al. Total triterpenic fraction of Centella asiatica in the treatment of venous hypertension: a clinical, prospective, randomized trial using a combined microcirculatory model. Angiology2001;52 Suppl 2:S61-7. ">Incandela 2001</a>; <a href="./references#CD003229-bbs2-0124" title="IncandelaL , BelcaroG , RentonS , DeSanctisT , CesaroneMR , BaveraP , et al. HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial. Journal of Cardiovascular Pharmacology and Therapeutics2002;7 Suppl 1:7-10. ">Incandela 2002</a>; <a href="./references#CD003229-bbs2-0139" title="MenyheiG , AcsadyG , HetenyiA , DubeauxD , RadoG . Chronobiology and clinical activity of daflon 500 mg in chronic venous insufficiency. Phlebology1994;9 Suppl 1:15-8. ">Menyhei 1994</a>; <a href="./references#CD003229-bbs2-0143" title="NCT01654016. Study of antiinflammatory effects of Detralex (Daflon). https://clinicaltrials.gov/ct2/show/NCT01654016 (accessed 9 September 2015). ">NCT01654016</a>; <a href="./references#CD003229-bbs2-0156" title="PetruzzellisV , TroccoliT , CandianiC , GuariscoR , LospallutiM , BelcaroG , et al. Oxerutins (Venoruton): efficacy in chronic venous insufficiency - a double-blind, randomized, controlled study. Angiology2002;53(3):257-63. ">Petruzzellis 2002</a>; <a href="./references#CD003229-bbs2-0163" title="RoztocilK , StvrtinovaV , StrejcekJ . Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency. International Angiology2003;22(1):24-31. ">Roztocil 2003</a>; <a href="./references#CD003229-bbs2-0168" title="SteruD , SteruL . Evaluation clinique d'un phlebotrope: application a l'etude du veinamitol [Evaluation clinique d'un phlebotrope: application a l'etude du veinamitol]. Arteres et Veines1988;7(4):362-4. ">Steru 1988</a>). </p> </li> </ul> </p> </section> <section id="CD003229-sec-0043"> <h4 class="title">Ongoing studies</h4> <p>For this update, we identified two new ongoing studies (<a href="./references#CD003229-bbs2-0174" title="BarattiniDF , DogaruDE . Clinical trial to assess the efficacy of μSmin® Plus. clinicaltrials.gov/ct2/show/NCT04101201 (first posted 24 September 2019). ">Barattini 2019</a>; <a href="./references#CD003229-bbs2-0177" title="NCT03833024. The MUFFIN-PTS Trial (MUFFIN-PTS). clinicaltrials.gov/ct2/show/NCT03833024 (first posted 6 February 2019). ">NCT03833024</a>). This brings the total number of ongoing studies included to four (<a href="./references#CD003229-bbs2-0174" title="BarattiniDF , DogaruDE . Clinical trial to assess the efficacy of μSmin® Plus. clinicaltrials.gov/ct2/show/NCT04101201 (first posted 24 September 2019). ">Barattini 2019</a>; <a href="./references#CD003229-bbs2-0175" title="ISRCTN18841175. Effects of micronised purified flavonoic fraction on microcirculation in women suffering from chronic venous disease. www.isrctn.com/ISRCTN18841175 (first posted 20 July 2009). ">ISRCTN18841175</a>; <a href="./references#CD003229-bbs2-0176" title="NCT01532882. Efficacy and safety of Diosmin 600mg versus placebo on painful symptomatology in patients with chronic venous disease of lower limbs (EDEN). clinicaltrials.gov/show/NCT01532882 (first posted 15 Febraury 2012). ">NCT01532882</a>; <a href="./references#CD003229-bbs2-0177" title="NCT03833024. The MUFFIN-PTS Trial (MUFFIN-PTS). clinicaltrials.gov/ct2/show/NCT03833024 (first posted 6 February 2019). ">NCT03833024</a>). Details of these can be found in the <a href="./references#CD003229-sec-0115" title="">Characteristics of ongoing studies</a> table. </p> </section> </section> <section id="CD003229-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall, only four studies (<a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>) were at low risk of bias (see <a href="./references#CD003229-sec-0113" title="">Characteristics of included studies</a>, <a href="#CD003229-fig-0003">Figure 3</a> and <a href="#CD003229-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD003229-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD003229-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003229-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD003229-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <section id="CD003229-sec-0045"> <h4 class="title">Allocation</h4> <p>Of the 69 studies included, 19 (28%) submitted details on the randomisation process and were assessed as being at low risk (see <a href="#CD003229-fig-0004">Figure 4</a> and <a href="./references#CD003229-sec-0113" title="">Characteristics of included studies</a>). The remaining studies were all judged to be at an unclear risk of bias. </p> <p>Only 12 (17%) studies provided an accurate explanation of the allocation concealment process. Two used the sealed envelope method (<a href="./references#CD003229-bbs2-0017" title="DanielssonG , JungbeckC , PetersonK , NorgrenL . A randomised controlled trial of micronised purified flavonoid fraction versus placebo in patients with chronic venous disease. European Journal of Vascular and Endovascular Surgery2002;23(1):73-6. ">Danielsson 2002</a>; <a href="./references#CD003229-bbs2-0046" title="PedersenFM , HambergO , SorensenMD , NelandK . The effect of O-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs. Ugeskrift for Laeger1992;154(38):2561-3. ">Pedersen 1992</a>), four used indistinguishable number packaging (<a href="./references#CD003229-bbs2-0007" title="BilandL , BlättlerP , ScheiblerP , StuderS , WidmerK . Zur therapie sogenannt venosër beinsbeschwerden. Vasa1982;11(1):53-8. ">Biland 1982</a>; <a href="./references#CD003229-bbs2-0043" title="PadrósW . Controlled study of the effect of calcium dobesilate on syndromes of venous insufficiency. Medicina Clínica1972;58(6):515-9. PadrosW . Double blind investigation of clinical effectiveness of calcium dobesilate in the venous insufficiency syndrome (Dutch). Ars Medici Internationaal Tijdschrift voor Praktische Therapie1977;6(8):777-84. PadrosW . Double blind study of the action of calcium dobesilate on venous insufficiency syndromes. Ars Medici Revue Internationale de Therapie Pratique1977;32(8):783-90. ">Padrós 1972</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0056" title="RoseSS . A report on the use of an hydroxyethylrutoside in symptoms due to venous back pressure and allied conditions in the lower limbs. British Journal of Clinical Practice1970;24(4):161-4. ">Rose 1970</a>), one used randomised numbered bottles provided by an external investigator (<a href="./references#CD003229-bbs2-0005" title="BelczakSQ , SincosIR , CamposW , BeserraJ , NeringG , AunR . Veno-active drugs for chronic venous disease: a randomized, double-blind, placebo-controlled parallel-design trial. Phlebology2014;29(7):454-60. ">Belczak 2014</a>), two used allocation concealment by direct phone calls (<a href="./references#CD003229-bbs2-0019" title="Fundación Iberoamericana Itaca. Randomized, double-blind multicenter clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of ulcer secondaries to chronic venous disease. ClinicalTrials.gov2009. ">DOBESILATO500/2</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>), and the remaining three studies used computerised random assignment (<a href="./references#CD003229-bbs2-0028" title="JongsteAB , JonkerJJC , HuismanMV , CateJW , AzarAJ . A double-blind trial on the short-term efficacy of HR in patients with the post-thrombotic syndrome. Phlebology1990;5(Suppl 1):21-2. JongsteAB , JonkerJJC , HuismanMV , den CateJW , AzarAJ . A double-blind three center clinical trial on the short-term efficacy of O-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome. Thrombosis and Haemostasis1989;62(3):826-9. ">Jongste 1989</a>; <a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a>; <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>). </p> </section> <section id="CD003229-sec-0046"> <h4 class="title">Blinding</h4> <p>Of the 69 studies included, 41 (59%) reported that the placebo used was identical to the active treatment; thus participants, study researchers and outcome assessors were blinded to the intervention and these were judged to have a low risk of bias. The other 28 studies did not mention whether placebo had identical characteristics to those of the active drug and so were at an unclear risk of bias (see <a href="#CD003229-fig-0004">Figure 4</a> and <a href="./references#CD003229-sec-0113" title="">Characteristics of included studies</a>). </p> </section> <section id="CD003229-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p>Of the 69 studies included, 52 (75%) reported participant withdrawals, and thus were at low risk of bias. The percentage of withdrawn participants ranged from 0% to 42.5% (see <a href="./references#CD003229-sec-0113" title="">Characteristics of included studies</a>). Only eight (12%) studies included in the efficacy analysis stated that investigators carried out an ITT analysis (<a href="./references#CD003229-bbs2-0020" title="DominguezC , BrautighamI , GonzálezE , GonzálezJA , NazcoJ , ValienteR , et al. Therapeutic effects of hidrosmin on chronic venous insufficiency of the lower limbs. Current Medical Research and Opinion1992;12(10):623-30. ">Dominguez 1992</a>; <a href="./references#CD003229-bbs2-0024" title="GuilhouJJ , DereureO , MarzinL , OuvryP , ZuccarelliF , DebureC , et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomised, controlled versus placebo trial in 107 patients. Angiology1997;48(1):77-85. ">Guilhou 1997</a>; <a href="./references#CD003229-bbs2-0026" title="IhmeN , KiesewetterH , JungF , HoffmannKH , BirkA , MüllerA , et al. Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomized, double-blind, placebo-controlled clinical trial. European Journal of Clinical Pharmacology1996;50(6):443-7. ">Ihme 1996</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0054" title="RabeE , BallariniS , LehrL , Doxium EDX09/01 Study Group. A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology2016;31(4):264-74. ">Rabe 2016</a>; <a href="./references#CD003229-bbs2-0063" title="UnkaufM , RehnD , KlingerJ , MotteS , GrobmannK . Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings. Arzneimittel-Forschung1996;46(5):478-82. ">Unkauf 1996</a>; <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>). Seven studies had high risk of bias in this domain (<a href="./references#CD003229-bbs2-0011" title="Van CauwenbergeH . Double-blind clinical trial to assess the efficacy of 0-(b-hidroxy-ethyl)-rutosides in the treatment of venous disorders [Etude en double aveugle de l'efficacité de l'0-(b-hidroxyéthyl)-rutosides dans le traitement des affections veineuses]. Mèdicine et Hygiène1978;35:4175-7. ">Cauwenberge 1978</a>; <a href="./references#CD003229-bbs2-0019" title="Fundación Iberoamericana Itaca. Randomized, double-blind multicenter clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of ulcer secondaries to chronic venous disease. ClinicalTrials.gov2009. ">DOBESILATO500/2</a>; <a href="./references#CD003229-bbs2-0038" title="MannRJ . A double-blind trial of oral O-beta-hydroxyethyl rutosides for stasis leg ulcers. British Journal of Clinical Practice1981;35:79-81. ">Mann 1981</a>; <a href="./references#CD003229-bbs2-0054" title="RabeE , BallariniS , LehrL , Doxium EDX09/01 Study Group. A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology2016;31(4):264-74. ">Rabe 2016</a>; <a href="./references#CD003229-bbs2-0056" title="RoseSS . A report on the use of an hydroxyethylrutoside in symptoms due to venous back pressure and allied conditions in the lower limbs. British Journal of Clinical Practice1970;24(4):161-4. ">Rose 1970</a>; <a href="./references#CD003229-bbs2-0059" title="SentouY . Double blind study of the activity of Cyclo 3 in man. International Angiology1984;3:106-9. ">Sentou 1984</a>; <a href="./references#CD003229-bbs2-0065" title="VanscheidtW , JostV , WolnaP , LückerA , MullerA , TheurerC , et al. Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittel-Forschung2002;52(4):243-50. ">Vanscheidt 2002b</a>): four described an important percentage of losses (42.5% <a href="./references#CD003229-bbs2-0011" title="Van CauwenbergeH . Double-blind clinical trial to assess the efficacy of 0-(b-hidroxy-ethyl)-rutosides in the treatment of venous disorders [Etude en double aveugle de l'efficacité de l'0-(b-hidroxyéthyl)-rutosides dans le traitement des affections veineuses]. Mèdicine et Hygiène1978;35:4175-7. ">Cauwenberge 1978</a>; 18% <a href="./references#CD003229-bbs2-0038" title="MannRJ . A double-blind trial of oral O-beta-hydroxyethyl rutosides for stasis leg ulcers. British Journal of Clinical Practice1981;35:79-81. ">Mann 1981</a>; 39% <a href="./references#CD003229-bbs2-0056" title="RoseSS . A report on the use of an hydroxyethylrutoside in symptoms due to venous back pressure and allied conditions in the lower limbs. British Journal of Clinical Practice1970;24(4):161-4. ">Rose 1970</a>; 34% <a href="./references#CD003229-bbs2-0065" title="VanscheidtW , JostV , WolnaP , LückerA , MullerA , TheurerC , et al. Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittel-Forschung2002;52(4):243-50. ">Vanscheidt 2002b</a>), one interrupted recruitment because financial support was interrupted (<a href="./references#CD003229-bbs2-0019" title="Fundación Iberoamericana Itaca. Randomized, double-blind multicenter clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of ulcer secondaries to chronic venous disease. ClinicalTrials.gov2009. ">DOBESILATO500/2</a>) and one did not specify the number of participants included (<a href="./references#CD003229-bbs2-0059" title="SentouY . Double blind study of the activity of Cyclo 3 in man. International Angiology1984;3:106-9. ">Sentou 1984</a>). In the <a href="./references#CD003229-bbs2-0054" title="RabeE , BallariniS , LehrL , Doxium EDX09/01 Study Group. A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology2016;31(4):264-74. ">Rabe 2016</a> study, 14.8% of the randomised participants were lost during follow‐up and major protocol violations were reported for 42.4% of the randomised participants. Ten studies were judged to be at unclear risk of bias because the reasons for dropouts (<a href="./references#CD003229-bbs2-0010" title="Van CauwenbergeH . Double-blind study of the efficacy of a soluble rutoside derivative in the treatment of venous disease. Archives of Internal Pharmacodynamics and Therapeutics1972;196(Suppl 196):122-5. ">Cauwenberge 1972</a>), or the number of dropouts, were not provided (<a href="./references#CD003229-bbs2-0016" title="Cornu-ThenardA , DahanB , De ParadesB . Study of the action in venous insufficiency of the legs. Pierre Fabre Medicament Laboratoires (Novartis). Report no. DC982GEC51(2),1985. ">Cornu‐Thenard 1985</a>; <a href="./references#CD003229-bbs2-0029" title="KiesewetterH , KoscielnyJ , GrütznerK , MüllerA , HoffmannKH , BirkA . Buckwheat herb/troxerutin-combination for the treatment of chronic venous insufficiency. Zeitschrift für Phytotherapie1997;18(6):341-6. ">Kiesewetter 1997</a>; <a href="./references#CD003229-bbs2-0030" title="KlükenN . Double-blind clinical trial to assess the therapy with drugs for venous disorders [Estudio clínico doble ciego para tratar de objetivar la terapéutica con venofármacos]. Therapiewoche1971;21:1. ">Klüken 1971</a>; <a href="./references#CD003229-bbs2-0032" title="KrinerE , BraunR , HircheH , Van LaakHH . Treatment of venous insufficiency. A double-blind trial with Phlebodril. Zeitschrift für Allgemeinmedizin1985;61(9):309-13. ">Kriner 1985</a>; <a href="./references#CD003229-bbs2-0036" title="LazzariniA , DanieliL . Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers [Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche]. Rassegna Internazionale di Clinica e Terapia1982;62(12):825-44. ">Lazzarini 1982</a>; <a href="./references#CD003229-bbs2-0042" title="NockerW , DiebschlagW , LehmacherW . Clinical trials of the dose-related effects of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Phlebology1990;5 Suppl 1:23-6. NockerW , DiebschlagW , LehmacherW . Three-month, randomized, double-blind, dose-response study with O-(beta-hydroxyethyl)-rutosides drinking solution. Vasa1989;18(3):235-8. NockerW , DiebschlagW . An investigation of dosage effects with drinking solutions of o-(beta hydroxyethyl)-rutosides. Vasa1987;16:365-9. ">Nocker 1990</a>; <a href="./references#CD003229-bbs2-0043" title="PadrósW . Controlled study of the effect of calcium dobesilate on syndromes of venous insufficiency. Medicina Clínica1972;58(6):515-9. PadrosW . Double blind investigation of clinical effectiveness of calcium dobesilate in the venous insufficiency syndrome (Dutch). Ars Medici Internationaal Tijdschrift voor Praktische Therapie1977;6(8):777-84. PadrosW . Double blind study of the action of calcium dobesilate on venous insufficiency syndromes. Ars Medici Revue Internationale de Therapie Pratique1977;32(8):783-90. ">Padrós 1972</a>; <a href="./references#CD003229-bbs2-0046" title="PedersenFM , HambergO , SorensenMD , NelandK . The effect of O-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs. Ugeskrift for Laeger1992;154(38):2561-3. ">Pedersen 1992</a>), or the standard deviation was lacking in the results (<a href="./references#CD003229-bbs2-0061" title="ThebautJF , ThebautP , VinF . Trial of vasculoprotective agent (plant products of the flavan class) in functional manifestations of peripheral venous insufficiency (double-blind trial in 92 cases). Gazette Medicale1985;92(12):96-100. ">Thebaut 1985</a>). </p> </section> <section id="CD003229-sec-0048"> <h4 class="title">Selective reporting</h4> <p>Of the 69 studies included, 57 (84%) reported all outcomes specified in the methods section and were judged as being at low risk of reporting bias. We evaluated seven studies as having high risk of selective reporting bias because we noted differences between outcomes reported in the methods and results sections (<a href="./references#CD003229-bbs2-0014" title="CloarecM , ClementR , GritonP , GuillouGB , GoldenG . A double blind three centre trial on efficacy of o-(beta-hydroxyethyl) rutosides in patients with venous insufficiency. International Angiology1994;13 Suppl 1(2):74. ">Cloarec 1994</a>; <a href="./references#CD003229-bbs2-0027" title="De JongsteAB , Ten CateJW , HuismanMV . The effectiveness of o-(b-hydroxyethyl)-rutosides (HR) in the post-thrombotic syndrome (PTS). Phlebology1986;85 Suppl 285:837-9. ">Jongste 1986</a>; <a href="./references#CD003229-bbs2-0028" title="JongsteAB , JonkerJJC , HuismanMV , CateJW , AzarAJ . A double-blind trial on the short-term efficacy of HR in patients with the post-thrombotic syndrome. Phlebology1990;5(Suppl 1):21-2. JongsteAB , JonkerJJC , HuismanMV , den CateJW , AzarAJ . A double-blind three center clinical trial on the short-term efficacy of O-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome. Thrombosis and Haemostasis1989;62(3):826-9. ">Jongste 1989</a>; <a href="./references#CD003229-bbs2-0038" title="MannRJ . A double-blind trial of oral O-beta-hydroxyethyl rutosides for stasis leg ulcers. British Journal of Clinical Practice1981;35:79-81. ">Mann 1981</a>; <a href="./references#CD003229-bbs2-0053" title="RabeE , AgusGB , RoztocilK . Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. International Angiology2015;34(5):428-36. ">Rabe 2015</a>), and because data before the cross‐over were not reported (<a href="./references#CD003229-bbs2-0043" title="PadrósW . Controlled study of the effect of calcium dobesilate on syndromes of venous insufficiency. Medicina Clínica1972;58(6):515-9. PadrosW . Double blind investigation of clinical effectiveness of calcium dobesilate in the venous insufficiency syndrome (Dutch). Ars Medici Internationaal Tijdschrift voor Praktische Therapie1977;6(8):777-84. PadrosW . Double blind study of the action of calcium dobesilate on venous insufficiency syndromes. Ars Medici Revue Internationale de Therapie Pratique1977;32(8):783-90. ">Padrós 1972</a>; <a href="./references#CD003229-bbs2-0056" title="RoseSS . A report on the use of an hydroxyethylrutoside in symptoms due to venous back pressure and allied conditions in the lower limbs. British Journal of Clinical Practice1970;24(4):161-4. ">Rose 1970</a>). One study was interrupted, and results of this study were not published (<a href="./references#CD003229-bbs2-0019" title="Fundación Iberoamericana Itaca. Randomized, double-blind multicenter clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of ulcer secondaries to chronic venous disease. ClinicalTrials.gov2009. ">DOBESILATO500/2</a>). <a href="./references#CD003229-bbs2-0036" title="LazzariniA , DanieliL . Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers [Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche]. Rassegna Internazionale di Clinica e Terapia1982;62(12):825-44. ">Lazzarini 1982</a> provided no information about adverse events. Two studies were judged to be at unclear risk of reporting bias because characteristics of participants were not provided ((<a href="./references#CD003229-bbs2-0001" title="Allegra C Pollari G, CriscuoloA , BonifacioM , TabassiD . Centella asiatica extract in venous disorders of the lower limbs. Comparative clinico-instrumental studies with a placebo. Clinica Terapeutica1981;99(5):507-13. ">Allegra 1981</a>) and outcomes were not reported in methods and neither a protocol was published (<a href="./references#CD003229-bbs2-0030" title="KlükenN . Double-blind clinical trial to assess the therapy with drugs for venous disorders [Estudio clínico doble ciego para tratar de objetivar la terapéutica con venofármacos]. Therapiewoche1971;21:1. ">Klüken 1971</a>). </p> <p><a href="#CD003229-fig-0001">Figure 1</a> shows that all studies, except one (<a href="./references#CD003229-bbs2-0009" title="Casley-SmithJR . A double-blind, placebo -controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. In: Davy A and StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. London and Paris: John Libbey Eurotext Ltd, 1989. Casley-SmithJR . A double-blind, placebo-controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. Phlebologie1989;2:709-11. Casley-SmithJR . A double-blind trial of calcium dobesilate in chronic venous insufficiency. Angiology1988;39(10):853-7. ">Casley‐Smith 1988</a>), are located symmetrically around the effect measure at the top of the pyramid, indicating highly precise results (<a href="./references#CD003229-bbs2-0010" title="Van CauwenbergeH . Double-blind study of the efficacy of a soluble rutoside derivative in the treatment of venous disease. Archives of Internal Pharmacodynamics and Therapeutics1972;196(Suppl 196):122-5. ">Cauwenberge 1972</a>; <a href="./references#CD003229-bbs2-0016" title="Cornu-ThenardA , DahanB , De ParadesB . Study of the action in venous insufficiency of the legs. Pierre Fabre Medicament Laboratoires (Novartis). Report no. DC982GEC51(2),1985. ">Cornu‐Thenard 1985</a>; <a href="./references#CD003229-bbs2-0029" title="KiesewetterH , KoscielnyJ , GrütznerK , MüllerA , HoffmannKH , BirkA . Buckwheat herb/troxerutin-combination for the treatment of chronic venous insufficiency. Zeitschrift für Phytotherapie1997;18(6):341-6. ">Kiesewetter 1997</a>; <a href="./references#CD003229-bbs2-0030" title="KlükenN . Double-blind clinical trial to assess the therapy with drugs for venous disorders [Estudio clínico doble ciego para tratar de objetivar la terapéutica con venofármacos]. Therapiewoche1971;21:1. ">Klüken 1971</a>; <a href="./references#CD003229-bbs2-0032" title="KrinerE , BraunR , HircheH , Van LaakHH . Treatment of venous insufficiency. A double-blind trial with Phlebodril. Zeitschrift für Allgemeinmedizin1985;61(9):309-13. ">Kriner 1985</a>; <a href="./references#CD003229-bbs2-0036" title="LazzariniA , DanieliL . Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers [Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche]. Rassegna Internazionale di Clinica e Terapia1982;62(12):825-44. ">Lazzarini 1982</a>; <a href="./references#CD003229-bbs2-0042" title="NockerW , DiebschlagW , LehmacherW . Clinical trials of the dose-related effects of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Phlebology1990;5 Suppl 1:23-6. NockerW , DiebschlagW , LehmacherW . Three-month, randomized, double-blind, dose-response study with O-(beta-hydroxyethyl)-rutosides drinking solution. Vasa1989;18(3):235-8. NockerW , DiebschlagW . An investigation of dosage effects with drinking solutions of o-(beta hydroxyethyl)-rutosides. Vasa1987;16:365-9. ">Nocker 1990</a>; <a href="./references#CD003229-bbs2-0043" title="PadrósW . Controlled study of the effect of calcium dobesilate on syndromes of venous insufficiency. Medicina Clínica1972;58(6):515-9. PadrosW . Double blind investigation of clinical effectiveness of calcium dobesilate in the venous insufficiency syndrome (Dutch). Ars Medici Internationaal Tijdschrift voor Praktische Therapie1977;6(8):777-84. PadrosW . Double blind study of the action of calcium dobesilate on venous insufficiency syndromes. Ars Medici Revue Internationale de Therapie Pratique1977;32(8):783-90. ">Padrós 1972</a>; <a href="./references#CD003229-bbs2-0046" title="PedersenFM , HambergO , SorensenMD , NelandK . The effect of O-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs. Ugeskrift for Laeger1992;154(38):2561-3. ">Pedersen 1992</a>; <a href="./references#CD003229-bbs2-0061" title="ThebautJF , ThebautP , VinF . Trial of vasculoprotective agent (plant products of the flavan class) in functional manifestations of peripheral venous insufficiency (double-blind trial in 92 cases). Gazette Medicale1985;92(12):96-100. ">Thebaut 1985</a>). Apart from one imprecise study favouring phlebotonics, no small or heterogeneous studies provided results favouring placebo or phlebotonics (<a href="./references#CD003229-bbs2-0009" title="Casley-SmithJR . A double-blind, placebo -controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. In: Davy A and StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. London and Paris: John Libbey Eurotext Ltd, 1989. Casley-SmithJR . A double-blind, placebo-controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. Phlebologie1989;2:709-11. Casley-SmithJR . A double-blind trial of calcium dobesilate in chronic venous insufficiency. Angiology1988;39(10):853-7. ">Casley‐Smith 1988</a>). </p> </section> <section id="CD003229-sec-0049"> <h4 class="title">Other potential sources of bias</h4> <p>No other potential sources of bias were detected.</p> </section> </section> <section id="CD003229-sec-0050"> <h3 class="title" id="CD003229-sec-0050">Effects of interventions</h3> <p>See: <a href="./full#CD003229-tbl-0001"><b>Summary of findings 1</b> Do phlebotonics improve signs and symptoms of venous insufficiency when compared with placebo?</a> </p> <p>See <a href="./full#CD003229-tbl-0001">summary of findings Table 1</a> for the main comparison. Results of all analyzed outcomes are specified in an additional <a href="#CD003229-tbl-0002">Table 1</a>. Results of outcomes analyzed by active agent (aminaftone, calcium dobesilate, <i>Centella asiatica</i>, diosmine and hidrosmine, French maritime pine bark extract, grape seed extract and rutosides) are specified in <a href="#CD003229-tbl-0003">Table 2</a>; <a href="#CD003229-tbl-0004">Table 3</a>; <a href="#CD003229-tbl-0005">Table 4</a>; <a href="#CD003229-tbl-0006">Table 5</a>; <a href="#CD003229-tbl-0007">Table 6</a>; <a href="#CD003229-tbl-0008">Table 7</a>; and <a href="#CD003229-tbl-0009">Table 8</a>, respectively. </p> <div class="table" id="CD003229-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Results of all outcomes analysed (all phlebotonics)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Variables</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dichotomous</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Continuous</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.70 (0.63 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema (mm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐4.27 (‐5.61 to ‐2.93)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema (volume)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.24 (‐0.33 to ‐0.15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulcer cured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trophic disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.87 (0.81 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.35 (‐0.54, ‐0.17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cramps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.72 (0.58 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restless legs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.81 (0.72 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Itching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heaviness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.63 (0.50 to 0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paraesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.67 (0.50 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global assessment by the participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.14 (1.02 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Note: No measures of effect are specified when I<sup>2</sup> was &gt; 75% for the subgroup </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>RR: risk ratio<br/>MD: mean difference<br/>NS: non‐significant<br/>RR: risk ratio<br/>SMD: standardized mean difference </p> </div> </div> <div class="table" id="CD003229-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Results by pharmacological group: aminaftone</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Variables</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dichotomous</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Continous</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.53 (0.28 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.17 (‐0.61 to 0.28)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulcer cured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trophic disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.43 (0.23 to 0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cramps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.56 (0.31 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Itching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.53 (0.31 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heaviness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.32 (0.17 to 0.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of live</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐10.00 (‐17.01 to ‐2.99)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Note: Only 1 study was analyzed</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>MD: mean difference<br/>NS: non‐significant<br/>RR: risk ratio<br/>SMD: standardized mean difference </p> </div> </div> <div class="table" id="CD003229-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results by pharmacological group: calcium dobesilate</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Variables</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dichotomous</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Continuous</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema (mm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema (volume)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.38 (‐0.51 to ‐0.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulcer cured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.53 (0.35 to 0.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cramps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.65 (0.50 to 0.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restless legs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.73 (0.59 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Itching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heaviness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.19 (0.08 to 0.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paraesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global assessment by the participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.52 (‐0.71 to ‐0.33)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.22 (1.0 to 1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Note: No measures of effect are specified when I<sup>2</sup> was &gt; 75% for the subgroup </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NS: non‐significant<br/>RR: risk ratio<br/>SMD: standardized mean difference </p> </div> </div> <div class="table" id="CD003229-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Results by pharmacological group: Centella asiatica </span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Variables</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dichotomous</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Continuous</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heaviness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global assessment by the participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.28 (0.14 to 0.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Note: Only 1 study was analyzed</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NS: non‐significant<br/>RR: risk ratio </p> </div> </div> <div class="table" id="CD003229-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Results by pharmacological group: diosmine, hidrosmine</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Variables</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dichotomous</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Continuous</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.63 (0.46 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema (mm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐5.98 (‐7.78 to ‐4.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulcer cured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trophic disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.87 (0.81 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.23 (‐0.41 to ‐0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cramps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.83 (0.70 to 0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.46 (‐0.78 to ‐0.14)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restless legs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Itching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heaviness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.69 (‐1.02 to ‐0.36)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.70 (0.52 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.92 (‐1.26 to ‐0.58)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paraesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global assessment by the participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.81 (‐1.14 to ‐0.47)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Note: No measures of effect are specified when I<sup>2</sup> was &gt; 75% for the subgroup </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>MD: mean difference<br/>NS: non‐significant<br/>RR: risk ratio<br/>SMD: standardized mean difference </p> </div> </div> <div class="table" id="CD003229-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Results by pharmacological group: French maritime pine bark extract</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Variables</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dichotomous</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Continuous</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.66 (0.48 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐1.39 (‐2.09 to ‐0.69)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heaviness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐1.50 (‐2.21 to ‐0.79)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐1.65 (‐2.38 to ‐0.92)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Note: Only 1 study was analyzed</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NS: non‐significant<br/>RR: risk ratio<br/>SMD: standardized mean difference </p> </div> </div> <div class="table" id="CD003229-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Results by pharmacological group: grape seed extract</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Variables</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dichotomous</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Continuous</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Note: Only 1 study was analyzed</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NS: non‐significant</p> </div> </div> <div class="table" id="CD003229-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Results by pharmacological group: rutosides</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Variables</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dichotomous</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Continuous</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.72 (0.64 to 0.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema (mm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema (volume)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.15 (‐0.16 to ‐0.03)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulcer cured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trophic disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.71 (‐1.23 to ‐0.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cramps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR ‐0.83 (‐1.50 to ‐0.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restless legs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Itching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.58 (‐1.10 to ‐0.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heaviness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.60 (0.48 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.67 (0.50 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paraesthesias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.55 (0.37 to 0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global assessment by the participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.22 (1.04 to 1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Note: No measures of effect are specified when I<sup>2</sup> was &gt; 75% </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NS: non‐significant<br/>RR: risk ratio<br/>SMD: standardized mean difference </p> </div> </div> <p>Of the 69 included studies, we excluded 13 studies from the efficacy analysis for the reasons explained under <a href="#CD003229-sec-0041">Included studies</a> (<a href="./references#CD003229-bbs2-0006" title="BerqvistD , HallböökT , LindbladB , LindhagenA . A double-blind trial of O-(beta-hydroxyethyl)-rutoside in patients with chronic venous insufficiency. Vasa1981;10(3):253-60. ">Bergqvist 1981</a>; <a href="./references#CD003229-bbs2-0014" title="CloarecM , ClementR , GritonP , GuillouGB , GoldenG . A double blind three centre trial on efficacy of o-(beta-hydroxyethyl) rutosides in patients with venous insufficiency. International Angiology1994;13 Suppl 1(2):74. ">Cloarec 1994</a>; <a href="./references#CD003229-bbs2-0027" title="De JongsteAB , Ten CateJW , HuismanMV . The effectiveness of o-(b-hydroxyethyl)-rutosides (HR) in the post-thrombotic syndrome (PTS). Phlebology1986;85 Suppl 285:837-9. ">Jongste 1986</a>; <a href="./references#CD003229-bbs2-0038" title="MannRJ . A double-blind trial of oral O-beta-hydroxyethyl rutosides for stasis leg ulcers. British Journal of Clinical Practice1981;35:79-81. ">Mann 1981</a>; <a href="./references#CD003229-bbs2-0042" title="NockerW , DiebschlagW , LehmacherW . Clinical trials of the dose-related effects of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Phlebology1990;5 Suppl 1:23-6. NockerW , DiebschlagW , LehmacherW . Three-month, randomized, double-blind, dose-response study with O-(beta-hydroxyethyl)-rutosides drinking solution. Vasa1989;18(3):235-8. NockerW , DiebschlagW . An investigation of dosage effects with drinking solutions of o-(beta hydroxyethyl)-rutosides. Vasa1987;16:365-9. ">Nocker 1990</a>; <a href="./references#CD003229-bbs2-0043" title="PadrósW . Controlled study of the effect of calcium dobesilate on syndromes of venous insufficiency. Medicina Clínica1972;58(6):515-9. PadrosW . Double blind investigation of clinical effectiveness of calcium dobesilate in the venous insufficiency syndrome (Dutch). Ars Medici Internationaal Tijdschrift voor Praktische Therapie1977;6(8):777-84. PadrosW . Double blind study of the action of calcium dobesilate on venous insufficiency syndromes. Ars Medici Revue Internationale de Therapie Pratique1977;32(8):783-90. ">Padrós 1972</a>; <a href="./references#CD003229-bbs2-0045" title="PecchiS , De FrancoV , DamianiP , GuerriniM , Di PerriT . Calcium dobesilate in the treatment of primary venous insufficiency of the lower limbs. A controlled clinical study [Il dobesilato di calcio nel trattamento del l´insufficienza venosa primitiva degli arti inferiori]. Clinica Terapeutica1990;132(6):409-17. ">Pecchi 1990</a>; <a href="./references#CD003229-bbs2-0047" title="PetrassiC , MastromarinoA , SparteraC . Pycnogenol in chronic venous insufficiency. Phytomedicine2000;7(5):383-8. ">Petrassi 2000</a>; <a href="./references#CD003229-bbs2-0050" title="PrerovskyI , RoztocilK , HlavovaA , KoleilatZ , RazgovaL , OlivaI . The effects of hydroxyethylrutosides after acute and chronic oral administration in patients with venous diseases. A double blind study. Angiologica1972;9(3-6):408-14. ">Prerovsky 1972</a>; <a href="./references#CD003229-bbs2-0055" title="RentonS , LeonM , BelcaroG , NicolaidesAN . The effect of hydroxyethylrutosides on capillary filtration in moderate venous hypertension: a double blind study. International Angiology1994;13(3):259-62. ">Renton 1994</a>; <a href="./references#CD003229-bbs2-0056" title="RoseSS . A report on the use of an hydroxyethylrutoside in symptoms due to venous back pressure and allied conditions in the lower limbs. British Journal of Clinical Practice1970;24(4):161-4. ">Rose 1970</a>; <a href="./references#CD003229-bbs2-0057" title="RudofskyG , DiehmC , GrubJ , HartmannM , Schultz-EhrenburgHU , BislerH . Ruscus saponines and the flavonoid hesperidinmethylchalcone in the treatment of chronic venous insufficiency. In: DavyA , StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. London and Paris: John Libbey Eurotext Ltd, 1989:728-30. RudofskyG , DiehmC , GrussJD , HartmanM , Schultz-EhrenburgHK , BislerH . Chronic venous insufficiency: treatment with Ruscus extract and trimethyl hesperidine chalcone. Münchener Medizinische Wochenschrift1990;132(13):205-10. ">Rudofsky 1989</a>; <a href="./references#CD003229-bbs2-0059" title="SentouY . Double blind study of the activity of Cyclo 3 in man. International Angiology1984;3:106-9. ">Sentou 1984</a>). <a href="./references#CD003229-bbs2-0005" title="BelczakSQ , SincosIR , CamposW , BeserraJ , NeringG , AunR . Veno-active drugs for chronic venous disease: a randomized, double-blind, placebo-controlled parallel-design trial. Phlebology2014;29(7):454-60. ">Belczak 2014</a> compared three different interventions with placebo. For the analysis, we included only the comparison of aminaftone with placebo because the other two interventions were combinations of different drugs (micronised diosmine and hesperidin; coumarin and troxerutin). </p> <section id="CD003229-sec-0051"> <h4 class="title">Primary outcomes</h4> <section id="CD003229-sec-0052"> <h5 class="title">Oedema in the lower limb (dichotomous variable)</h5> <p>We included 13 trials in the meta‐analysis: seven corresponding to rutosides (<a href="./references#CD003229-bbs2-0010" title="Van CauwenbergeH . Double-blind study of the efficacy of a soluble rutoside derivative in the treatment of venous disease. Archives of Internal Pharmacodynamics and Therapeutics1972;196(Suppl 196):122-5. ">Cauwenberge 1972</a>; <a href="./references#CD003229-bbs2-0011" title="Van CauwenbergeH . Double-blind clinical trial to assess the efficacy of 0-(b-hidroxy-ethyl)-rutosides in the treatment of venous disorders [Etude en double aveugle de l'efficacité de l'0-(b-hidroxyéthyl)-rutosides dans le traitement des affections veineuses]. Mèdicine et Hygiène1978;35:4175-7. ">Cauwenberge 1978</a>; <a href="./references#CD003229-bbs2-0015" title="CloarecM , ClémentR , GritonP . A double-blind clinical trial of hydroxyethylrutosides in the treatment of the symptoms and signs of chronic venous insufficiency. Phlebology1996;11(2):76-82. ">Cloarec 1996</a>; <a href="./references#CD003229-bbs2-0026" title="IhmeN , KiesewetterH , JungF , HoffmannKH , BirkA , MüllerA , et al. Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomized, double-blind, placebo-controlled clinical trial. European Journal of Clinical Pharmacology1996;50(6):443-7. ">Ihme 1996</a>; <a href="./references#CD003229-bbs2-0032" title="KrinerE , BraunR , HircheH , Van LaakHH . Treatment of venous insufficiency. A double-blind trial with Phlebodril. Zeitschrift für Allgemeinmedizin1985;61(9):309-13. ">Kriner 1985</a>; <a href="./references#CD003229-bbs2-0037" title="DiklandWJ . A clinical trial on the effect of hydroxyethylrutosides on venous refilling time as measured by light reflection rheography. Scripta Phlebologica1995;3:4-7. MacLennanWJ , WilsonJ , RattenhuberV , DiklandWJ , VanerdoncktJ , MoriauM . Hydroxyethylrutosides in elderly patients with chronic venous insufficiency. Its efficacy and tolerability. Gerontology1994;40(1):45-52. ">MacLennan 1994</a>; <a href="./references#CD003229-bbs2-0067" title="WelchW , MoriauM , vanGyselJP . A double-blind, placebo controlled trial of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Novartis1985. ">Welch 1985</a>), two to calcium dobesilate (<a href="./references#CD003229-bbs2-0009" title="Casley-SmithJR . A double-blind, placebo -controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. In: Davy A and StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. London and Paris: John Libbey Eurotext Ltd, 1989. Casley-SmithJR . A double-blind, placebo-controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. Phlebologie1989;2:709-11. Casley-SmithJR . A double-blind trial of calcium dobesilate in chronic venous insufficiency. Angiology1988;39(10):853-7. ">Casley‐Smith 1988</a>; <a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a>), two to hidrosmine and diosmine (<a href="./references#CD003229-bbs2-0021" title="FermosoJ , LegidoAG , Del PinoJ , ValienteR . Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Current Therapeutic Research, Clinical and Experimental1992;52(1):124-34. ">Fermoso 1992</a>; <a href="./references#CD003229-bbs2-0048" title="PlanchonB . Venous insufficiency and Daflon 500 mg [Insuffisance veineuse et Daflon 500 mg]. Artères et Veines1990;IX(4):376-80. ">Planchon 1990</a>), one to grape seed extract (<a href="./references#CD003229-bbs2-0061" title="ThebautJF , ThebautP , VinF . Trial of vasculoprotective agent (plant products of the flavan class) in functional manifestations of peripheral venous insufficiency (double-blind trial in 92 cases). Gazette Medicale1985;92(12):96-100. ">Thebaut 1985</a>) and one to aminaftone (<a href="./references#CD003229-bbs2-0036" title="LazzariniA , DanieliL . Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers [Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche]. Rassegna Internazionale di Clinica e Terapia1982;62(12):825-44. ">Lazzarini 1982</a>), with a total of 626 participants in the active treatment group and 619 in the placebo group. The median time to follow‐up was 49 days. Phebotonics probably reduce oedema in the lower limb compared to placebo (RR 0.70, 95% CI 0.63 to 0.78; 13 studies; 1245 participants; moderate‐certainty evidence; <a href="./references#CD003229-fig-0005" title="">Analysis 1.1</a>). The certainty of the evidence was downgraded by one step to moderate because of overall risk of bias (10 studies had an unclear risk of bias and two had a high risk of bias) (<a href="./full#CD003229-tbl-0001">summary of findings Table 1</a>). No differences between the subgroups was detected (test for subgroup differences: P = 0.74). </p> </section> <section id="CD003229-sec-0053"> <h5 class="title">Oedema in the lower limb (continuous variables)</h5> <section id="CD003229-sec-0054"> <h6 class="title">Ankle perimeter circumference</h6> <p>We included 15 studies in the meta‐analysis: seven corresponding to rutosides (<a href="./references#CD003229-bbs2-0015" title="CloarecM , ClémentR , GritonP . A double-blind clinical trial of hydroxyethylrutosides in the treatment of the symptoms and signs of chronic venous insufficiency. Phlebology1996;11(2):76-82. ">Cloarec 1996</a>; <a href="./references#CD003229-bbs2-0016" title="Cornu-ThenardA , DahanB , De ParadesB . Study of the action in venous insufficiency of the legs. Pierre Fabre Medicament Laboratoires (Novartis). Report no. DC982GEC51(2),1985. ">Cornu‐Thenard 1985</a>; <a href="./references#CD003229-bbs2-0028" title="JongsteAB , JonkerJJC , HuismanMV , CateJW , AzarAJ . A double-blind trial on the short-term efficacy of HR in patients with the post-thrombotic syndrome. Phlebology1990;5(Suppl 1):21-2. JongsteAB , JonkerJJC , HuismanMV , den CateJW , AzarAJ . A double-blind three center clinical trial on the short-term efficacy of O-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome. Thrombosis and Haemostasis1989;62(3):826-9. ">Jongste 1989</a>; <a href="./references#CD003229-bbs2-0037" title="DiklandWJ . A clinical trial on the effect of hydroxyethylrutosides on venous refilling time as measured by light reflection rheography. Scripta Phlebologica1995;3:4-7. MacLennanWJ , WilsonJ , RattenhuberV , DiklandWJ , VanerdoncktJ , MoriauM . Hydroxyethylrutosides in elderly patients with chronic venous insufficiency. Its efficacy and tolerability. Gerontology1994;40(1):45-52. ">MacLennan 1994</a>; <a href="./references#CD003229-bbs2-0044" title="ParradoF , BuzziA . A study of the efficacy and tolerability of a preparation containing Ruscus aculeatus in the treatment of chronic venous insufficiency of the lower limbs. Clinical Drug Investigation1999;18(4):255-61. ">Parrado 1999</a>; <a href="./references#CD003229-bbs2-0066" title="VinE , ChabanelA , TaccoenA , DucrosJ , GrufazJ , HutinelB , et al. Action of Veinamitol 3500 mg on clinical and hemorheological data in CVI. International Angiology1995;14(Suppl 1):99. VinF , ChabanelA , TaccoenA , DucrosJ , GruffazJ , HutinelB , et al. Action de la troxérutine sur les paramètres cliniques, pléthysmographiques et rhéologiques de l'insuffisance veineuse des membres inférieurs. Etude contrôlée contre placebo. Artères et Veines1992;XI:333-42. VinF , ChabanelA , TaccoenA , DucrosJ , GruffazJ , HutinelB , et al. Double-blind trial of the efficacy of troxerutin in chronic venous insufficiency. Phlebology1994;9(2):71-6. ">Vin 1994</a>; <a href="./references#CD003229-bbs2-0067" title="WelchW , MoriauM , vanGyselJP . A double-blind, placebo controlled trial of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Novartis1985. ">Welch 1985</a>), five to calcium dobesilate (<a href="./references#CD003229-bbs2-0022" title="Flota-CerveraF ,  Flota-RuizC ,  TreviñoC ,  BerberA . Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology2008;59(3):352-6. FlotaLF . Prospective, randomised, double-blind, placebo controlled, clinical trial that assesses the efficacy of calcium dobesilate in the limphoedema by varicose disease [Estudio clínico prospectivo aleatorizado, doble ciego, con control placebo, para evaluar la eficacia en la resolución del edema de origen lifático, del dobesilato de calcio en pacientes con enfermedad varicosa]. Knoll de Mexico S.A. Laboratorios Dr. Esteve. No de proyec. Knoll-mex-02-99, 003/MEX, 99. ">Flota‐Cervera 2008</a>; <a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0068" title="WidmerL , BilandL , BarrasJP . Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study. International Angiology1990;9(2):105-10. ">Widmer 1990</a>), and three to diosmine (<a href="./references#CD003229-bbs2-0023" title="FrileuxC , GillyR . Activité thérapeutic de Daflon 500 mg dans l'insuffisance veineuse chronique des membres inférieurs. Journal Internationale de Medicine1994;Suppl 99:36-9. GillyR , PillionG , FrileuxC . Evaluation of a new venactive micronized flavonoid fraction (S5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology1994;9(2):67-70. ThiolletM , FrileuxC , GillyR . Evaluation of a new micronized diosmin in the treatment of chronic venous incompetence: a double-blind, placebo controlled trial. Journal of Vascular Surgery1992;15(2):447. ">Gilly 1994</a>; <a href="./references#CD003229-bbs2-0048" title="PlanchonB . Venous insufficiency and Daflon 500 mg [Insuffisance veineuse et Daflon 500 mg]. Artères et Veines1990;IX(4):376-80. ">Planchon 1990</a>; <a href="./references#CD003229-bbs2-0062" title="TsouderosY . Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency. Our experience with Daflon 500 mg. International Angiology1989;8(4):53-9. TsouderosY . Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg. Zeitschrift fur Kardiologie1991;80 Suppl 7:95-101. ">Tsouderos 1989</a>), with a total of 1001 participants given active treatment and 1009 given placebo. The median time to follow‐up was 60 days. Phlebotonics probably slightly reduce ankle perimeter circumference compared to placebo (MD ‐4.27 mm; 95% CI ‐5.61 to ‐2.93; 15 studies; 2010 participants; moderate‐certainty evidence; <a href="./references#CD003229-fig-0006" title="">Analysis 1.2</a>). The certainty of the evidence was downgraded by one step to moderate because of overall risk of bias (11 studies had an unclear risk of bias and one had a high risk of bias). Differences between the subgroups was detected (test for subgroup differences: P = 0.02) due to a larger effect of diosmin‐hidrosmin. </p> </section> <section id="CD003229-sec-0055"> <h6 class="title">Volume of the leg</h6> <p>We included 11 studies in the analysis: six corresponding to rutosides (<a href="./references#CD003229-bbs2-0008" title="BurnandKG , PowellS , BishopC , StaceyM , PulvertaftT . Effect of Paroven on skin oxygenation in patients with varicose veins. Phlebologie1989;4(1):15-22. ">Burnand 1989</a>; <a href="./references#CD003229-bbs2-0018" title="DiebschlagW , NockerW , LehmacherW , RehnD . A clinical comparison of two doses of O-(beta-hydroxyethyl) rutosides (oxerutins) in patients with chronic venous insufficiency. Journal of Pharmaceutical Medicine1994;4(1):7-14. ">Diebschlag 1994</a>; <a href="./references#CD003229-bbs2-0026" title="IhmeN , KiesewetterH , JungF , HoffmannKH , BirkA , MüllerA , et al. Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomized, double-blind, placebo-controlled clinical trial. European Journal of Clinical Pharmacology1996;50(6):443-7. ">Ihme 1996</a>; <a href="./references#CD003229-bbs2-0029" title="KiesewetterH , KoscielnyJ , GrütznerK , MüllerA , HoffmannKH , BirkA . Buckwheat herb/troxerutin-combination for the treatment of chronic venous insufficiency. Zeitschrift für Phytotherapie1997;18(6):341-6. ">Kiesewetter 1997</a>; <a href="./references#CD003229-bbs2-0041" title="NCT01848210. Efficacy and safety of coumarin and troxerutin in the symptomatic treatment of chronic venous insufficiency. clinicaltrials.gov/ct2/show/NCT01848210 (first posted 7 May 2013). ">NCT01848210</a>; <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>), four to calcium dobesilate (<a href="./references#CD003229-bbs2-0009" title="Casley-SmithJR . A double-blind, placebo -controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. In: Davy A and StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. London and Paris: John Libbey Eurotext Ltd, 1989. Casley-SmithJR . A double-blind, placebo-controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. Phlebologie1989;2:709-11. Casley-SmithJR . A double-blind trial of calcium dobesilate in chronic venous insufficiency. Angiology1988;39(10):853-7. ">Casley‐Smith 1988</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>;<a href="./references#CD003229-bbs2-0054" title="RabeE , BallariniS , LehrL , Doxium EDX09/01 Study Group. A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology2016;31(4):264-74. ">Rabe 2016</a>; <a href="./references#CD003229-bbs2-0068" title="WidmerL , BilandL , BarrasJP . Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study. International Angiology1990;9(2):105-10. ">Widmer 1990</a>) and one to aminaftone (<a href="./references#CD003229-bbs2-0005" title="BelczakSQ , SincosIR , CamposW , BeserraJ , NeringG , AunR . Veno-active drugs for chronic venous disease: a randomized, double-blind, placebo-controlled parallel-design trial. Phlebology2014;29(7):454-60. ">Belczak 2014</a>), with a total of 686 participants treated with phlebotonics and 706 with placebo. Phlebotonics probably slightly reduce volume of the leg compared to placebo (SMD ‐0.24 mL; 95% CI ‐0.33 to ‐0.15; 11 studies; 2072 participants; moderate‐certainty evidence; <a href="./references#CD003229-fig-0007" title="">Analysis 1.3</a>). The certainty of the evidence was downgraded (1 level) to moderate because of overall risk of bias (seven studies had an unclear risk of bias and one had a high risk of bias). Differences between the subgroups was detected (test for subgroup differences: P = 0.04) due to a larger effect of calcium dobesilate. </p> </section> </section> <section id="CD003229-sec-0056"> <h5 class="title">QoL</h5> <p>Seven studies evaluated QoL (<a href="./references#CD003229-bbs2-0005" title="BelczakSQ , SincosIR , CamposW , BeserraJ , NeringG , AunR . Veno-active drugs for chronic venous disease: a randomized, double-blind, placebo-controlled parallel-design trial. Phlebology2014;29(7):454-60. ">Belczak 2014</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0053" title="RabeE , AgusGB , RoztocilK . Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. International Angiology2015;34(5):428-36. ">Rabe 2015</a>; <a href="./references#CD003229-bbs2-0054" title="RabeE , BallariniS , LehrL , Doxium EDX09/01 Study Group. A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology2016;31(4):264-74. ">Rabe 2016</a>; <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>; <a href="./references#CD003229-bbs2-0065" title="VanscheidtW , JostV , WolnaP , LückerA , MullerA , TheurerC , et al. Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittel-Forschung2002;52(4):243-50. ">Vanscheidt 2002b</a>). <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a> and <a href="./references#CD003229-bbs2-0065" title="VanscheidtW , JostV , WolnaP , LückerA , MullerA , TheurerC , et al. Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittel-Forschung2002;52(4):243-50. ">Vanscheidt 2002b</a> assessed QoL by using a questionnaire (EuroQol Measure of Health‐Related QoL and Freiburg Life Quality Assessment, respectively) and therefore did not provide quantifiable results. <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>, <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>, <a href="./references#CD003229-bbs2-0053" title="RabeE , AgusGB , RoztocilK . Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. International Angiology2015;34(5):428-36. ">Rabe 2015</a> and <a href="./references#CD003229-bbs2-0054" title="RabeE , BallariniS , LehrL , Doxium EDX09/01 Study Group. A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology2016;31(4):264-74. ">Rabe 2016</a> evaluated QoL via the Chronic Venous Insufficiency International Questionnaire (CIVIQ). <a href="./references#CD003229-bbs2-0005" title="BelczakSQ , SincosIR , CamposW , BeserraJ , NeringG , AunR . Veno-active drugs for chronic venous disease: a randomized, double-blind, placebo-controlled parallel-design trial. Phlebology2014;29(7):454-60. ">Belczak 2014</a> used a specific questionnaire for chronic venous disease adapted from <a href="./references#CD003229-bbs2-0185" title="CesaroneMR , BelcaroG , RohdewaldP , PellegriniL , LeddaA , VinciguerraG , et al. Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study. Clinical and Applied Thrombosis/Hemostasis2006;12(2):205-12.">Cesarone 2006</a>. Phebotonics probably make little or no difference to QoL compared with placebo (SMD ‐0.06, 95% CI ‐0.22 to 0.10; five studies; 1639 participants; moderate‐certainty evidence; <a href="./references#CD003229-fig-0008" title="">Analysis 1.4</a>). The certainty of the evidence was downgraded by one step to moderate because of overall risk of bias (one study had an unclear risk of bias and two had a high risk of bias). Differences between the subgroups was detected (test for subgroup differences: P = 0.02) due to a larger effect of aminaftone . </p> </section> </section> <section id="CD003229-sec-0057"> <h4 class="title">Secondary outcomes</h4> <section id="CD003229-sec-0058"> <h5 class="title">Assessment of CVI by objective signs: skin manifestations</h5> <section id="CD003229-sec-0059"> <h6 class="title">Ulcer healing (dichotomous variable)</h6> <p>We included six trials in the meta‐analysis: one on aminaftone (<a href="./references#CD003229-bbs2-0036" title="LazzariniA , DanieliL . Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers [Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche]. Rassegna Internazionale di Clinica e Terapia1982;62(12):825-44. ">Lazzarini 1982</a>), one on calcium dobesilate (<a href="./references#CD003229-bbs2-0019" title="Fundación Iberoamericana Itaca. Randomized, double-blind multicenter clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of ulcer secondaries to chronic venous disease. ClinicalTrials.gov2009. ">DOBESILATO500/2</a>), two on diosmine (<a href="./references#CD003229-bbs2-0021" title="FermosoJ , LegidoAG , Del PinoJ , ValienteR . Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Current Therapeutic Research, Clinical and Experimental1992;52(1):124-34. ">Fermoso 1992</a>; <a href="./references#CD003229-bbs2-0024" title="GuilhouJJ , DereureO , MarzinL , OuvryP , ZuccarelliF , DebureC , et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomised, controlled versus placebo trial in 107 patients. Angiology1997;48(1):77-85. ">Guilhou 1997</a>) and two on rutoside (<a href="./references#CD003229-bbs2-0037" title="DiklandWJ . A clinical trial on the effect of hydroxyethylrutosides on venous refilling time as measured by light reflection rheography. Scripta Phlebologica1995;3:4-7. MacLennanWJ , WilsonJ , RattenhuberV , DiklandWJ , VanerdoncktJ , MoriauM . Hydroxyethylrutosides in elderly patients with chronic venous insufficiency. Its efficacy and tolerability. Gerontology1994;40(1):45-52. ">MacLennan 1994</a>; <a href="./references#CD003229-bbs2-0058" title="Schultz-EhrenburgU , MüllerB . Two multicentre clinical trials of two different dosages of O-(beta-hydroxyethyl)-rutosides in the treatment of leg ulcers. Phlebology1993;8 Suppl 1:29-30. ">Schultz‐Ehrenburg 1993</a>), with a total of 230 participants in the active treatment group and 231 in the placebo group. Phlebotonics may make little or no difference to dichotomous variable ulcer cured compared to placebo (RR 0.94; 95% CI 0.79 to 1.13; 6 studies; 461 participants; low‐certainty evidence; <a href="./references#CD003229-fig-0009" title="">Analysis 1.5</a>). The certainty of the evidence was downgraded by two levels to low because of overall risk of bias (four studies had an unclear risk of bias and two had a high risk of bias) and imprecision (low number of total events) (<a href="./full#CD003229-tbl-0001">summary of findings Table 1</a>). No differences between the subgroups was detected (test for subgroup differences: P = 0.21). </p> </section> <section id="CD003229-sec-0060"> <h6 class="title">Trophic disorders (dichotomous variable)</h6> <p>We included six studies in the meta‐analysis: four on hidrosmine and diosmine (<a href="./references#CD003229-bbs2-0021" title="FermosoJ , LegidoAG , Del PinoJ , ValienteR . Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Current Therapeutic Research, Clinical and Experimental1992;52(1):124-34. ">Fermoso 1992</a>; <a href="./references#CD003229-bbs2-0023" title="FrileuxC , GillyR . Activité thérapeutic de Daflon 500 mg dans l'insuffisance veineuse chronique des membres inférieurs. Journal Internationale de Medicine1994;Suppl 99:36-9. GillyR , PillionG , FrileuxC . Evaluation of a new venactive micronized flavonoid fraction (S5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology1994;9(2):67-70. ThiolletM , FrileuxC , GillyR . Evaluation of a new micronized diosmin in the treatment of chronic venous incompetence: a double-blind, placebo controlled trial. Journal of Vascular Surgery1992;15(2):447. ">Gilly 1994</a>; <a href="./references#CD003229-bbs2-0035" title="LaurentR , GillyR , FrileuxC . Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg. International Angiology1988;7(2 Suppl):39-43. ">Laurent 1988</a>; <a href="./references#CD003229-bbs2-0048" title="PlanchonB . Venous insufficiency and Daflon 500 mg [Insuffisance veineuse et Daflon 500 mg]. Artères et Veines1990;IX(4):376-80. ">Planchon 1990</a>), one on aminaftone (<a href="./references#CD003229-bbs2-0036" title="LazzariniA , DanieliL . Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers [Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche]. Rassegna Internazionale di Clinica e Terapia1982;62(12):825-44. ">Lazzarini 1982</a>) and one on rutosides (<a href="./references#CD003229-bbs2-0037" title="DiklandWJ . A clinical trial on the effect of hydroxyethylrutosides on venous refilling time as measured by light reflection rheography. Scripta Phlebologica1995;3:4-7. MacLennanWJ , WilsonJ , RattenhuberV , DiklandWJ , VanerdoncktJ , MoriauM . Hydroxyethylrutosides in elderly patients with chronic venous insufficiency. Its efficacy and tolerability. Gerontology1994;40(1):45-52. ">MacLennan 1994</a>), with a total of 355 participants in the phlebotonics group and 350 in the placebo group. Phlebotonics probably slightly improve trophic disorders compared to placebo (RR 0.87, 95% CI 0.81 to 0.95; 6 studies; 705 participants; moderate‐certainty evidence; <a href="./references#CD003229-fig-0010" title="">Analysis 1.6</a>). The certainty of the evidence was downgraded by one level to moderate because of overall risk of bias (five studies had an unclear risk of bias and one had a high risk of bias). No differences between the subgroups was detected (test for subgroup differences: P = 0.80). </p> </section> <section id="CD003229-sec-0061"> <h6 class="title">Telangiectasia, reticular veins and varicose veins (dichotomous variable)</h6> <p>Included studies did not report data on improvement in skin signs such as telangiectasia, reticular veins and varicose veins. Only <a href="./references#CD003229-bbs2-0021" title="FermosoJ , LegidoAG , Del PinoJ , ValienteR . Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Current Therapeutic Research, Clinical and Experimental1992;52(1):124-34. ">Fermoso 1992</a> reported results regarding varicose veins. Before treatment, 3/16 (18.8%) participants presented varicose veins in the hidrosmine group and 2/12 participants in the placebo group (16.7%). After treatment, one participant from the hidrosmine group was cured of varicose veins, and no participants from the placebo group were cured. </p> </section> </section> <section id="CD003229-sec-0062"> <h5 class="title">Assessment of CVI by subjective symptoms</h5> <section id="CD003229-sec-0063"> <h6 class="title">Pain in the lower legs (dichotomous variable)</h6> <p>A total of 21 studies reported on this outcome as a dichotomous variable: 10 on rutosides (<a href="./references#CD003229-bbs2-0004" title="BalmerA , LimoniC . Clinical, placebo-controlled double-blind study of venoruton in the treatment of chronic venous insufficiency. Importance of the selection of patients. Vasa1980;9(1):76-82. BlumeJ . Therapy of venous oedemas [Tratamento do edema de origem venosa]. Revista Brasileira de Medicina1994;51(3):283-8. ">Balmer 1980</a>; <a href="./references#CD003229-bbs2-0010" title="Van CauwenbergeH . Double-blind study of the efficacy of a soluble rutoside derivative in the treatment of venous disease. Archives of Internal Pharmacodynamics and Therapeutics1972;196(Suppl 196):122-5. ">Cauwenberge 1972</a>; <a href="./references#CD003229-bbs2-0011" title="Van CauwenbergeH . Double-blind clinical trial to assess the efficacy of 0-(b-hidroxy-ethyl)-rutosides in the treatment of venous disorders [Etude en double aveugle de l'efficacité de l'0-(b-hidroxyéthyl)-rutosides dans le traitement des affections veineuses]. Mèdicine et Hygiène1978;35:4175-7. ">Cauwenberge 1978</a>; <a href="./references#CD003229-bbs2-0028" title="JongsteAB , JonkerJJC , HuismanMV , CateJW , AzarAJ . A double-blind trial on the short-term efficacy of HR in patients with the post-thrombotic syndrome. Phlebology1990;5(Suppl 1):21-2. JongsteAB , JonkerJJC , HuismanMV , den CateJW , AzarAJ . A double-blind three center clinical trial on the short-term efficacy of O-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome. Thrombosis and Haemostasis1989;62(3):826-9. ">Jongste 1989</a>; <a href="./references#CD003229-bbs2-0030" title="KlükenN . Double-blind clinical trial to assess the therapy with drugs for venous disorders [Estudio clínico doble ciego para tratar de objetivar la terapéutica con venofármacos]. Therapiewoche1971;21:1. ">Klüken 1971</a>; <a href="./references#CD003229-bbs2-0034" title="LanguillatN . Trial of Cyclo 3 Fort in venous insufficiency of the lower limbs: Xenon 133 functional investigation of venous circulatory velocity. Pierre Fabre Medicament Laboratories (Novartis). No. Report DC982GEC130(2),1988. ">Languillat 1988</a>; <a href="./references#CD003229-bbs2-0046" title="PedersenFM , HambergO , SorensenMD , NelandK . The effect of O-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs. Ugeskrift for Laeger1992;154(38):2561-3. ">Pedersen 1992</a>; <a href="./references#CD003229-bbs2-0051" title="PulvertaftTB . General practice treatment of symptoms of venous insufficiency with oxerutins. Results of a 660 patient multicentre study in the UK. Vasa1983;12(4):373-6. PulvertaftTB . Paroven in the treatment of chronic venous insufficiency. Practitioner1979;223(1338):838-41. ">Pulvertaft 1983</a>; <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>; <a href="./references#CD003229-bbs2-0067" title="WelchW , MoriauM , vanGyselJP . A double-blind, placebo controlled trial of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Novartis1985. ">Welch 1985</a>), five on calcium dobesilate (<a href="./references#CD003229-bbs2-0009" title="Casley-SmithJR . A double-blind, placebo -controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. In: Davy A and StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. London and Paris: John Libbey Eurotext Ltd, 1989. Casley-SmithJR . A double-blind, placebo-controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. Phlebologie1989;2:709-11. Casley-SmithJR . A double-blind trial of calcium dobesilate in chronic venous insufficiency. Angiology1988;39(10):853-7. ">Casley‐Smith 1988</a>; <a href="./references#CD003229-bbs2-0022" title="Flota-CerveraF ,  Flota-RuizC ,  TreviñoC ,  BerberA . Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology2008;59(3):352-6. FlotaLF . Prospective, randomised, double-blind, placebo controlled, clinical trial that assesses the efficacy of calcium dobesilate in the limphoedema by varicose disease [Estudio clínico prospectivo aleatorizado, doble ciego, con control placebo, para evaluar la eficacia en la resolución del edema de origen lifático, del dobesilato de calcio en pacientes con enfermedad varicosa]. Knoll de Mexico S.A. Laboratorios Dr. Esteve. No de proyec. Knoll-mex-02-99, 003/MEX, 99. ">Flota‐Cervera 2008</a>; <a href="./references#CD003229-bbs2-0025" title="HachenHJ , LorenzP . Double-blind clinical and plethysmographic study of calcium dobesilate in patients with peripheral microvascular disorders. Angiology1982;33(7):480-8. ">Hachen 1982</a>; <a href="./references#CD003229-bbs2-0054" title="RabeE , BallariniS , LehrL , Doxium EDX09/01 Study Group. A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology2016;31(4):264-74. ">Rabe 2016</a>; <a href="./references#CD003229-bbs2-0068" title="WidmerL , BilandL , BarrasJP . Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study. International Angiology1990;9(2):105-10. ">Widmer 1990</a>), four on diosmine and hidrosmine (<a href="./references#CD003229-bbs2-0007" title="BilandL , BlättlerP , ScheiblerP , StuderS , WidmerK . Zur therapie sogenannt venosër beinsbeschwerden. Vasa1982;11(1):53-8. ">Biland 1982</a>; <a href="./references#CD003229-bbs2-0020" title="DominguezC , BrautighamI , GonzálezE , GonzálezJA , NazcoJ , ValienteR , et al. Therapeutic effects of hidrosmin on chronic venous insufficiency of the lower limbs. Current Medical Research and Opinion1992;12(10):623-30. ">Dominguez 1992</a>; <a href="./references#CD003229-bbs2-0021" title="FermosoJ , LegidoAG , Del PinoJ , ValienteR . Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Current Therapeutic Research, Clinical and Experimental1992;52(1):124-34. ">Fermoso 1992</a>; <a href="./references#CD003229-bbs2-0048" title="PlanchonB . Venous insufficiency and Daflon 500 mg [Insuffisance veineuse et Daflon 500 mg]. Artères et Veines1990;IX(4):376-80. ">Planchon 1990</a>), one on aminaftone (<a href="./references#CD003229-bbs2-0036" title="LazzariniA , DanieliL . Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers [Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche]. Rassegna Internazionale di Clinica e Terapia1982;62(12):825-44. ">Lazzarini 1982</a>), and one on French maritime pine bark extract (<a href="./references#CD003229-bbs2-0003" title="ArcangeliP . Pycnogenol in chronic venous insufficiency. Fitoterapia2000;71(3):236-44. ">Arcangeli 2000</a>), with a total of 1468 participants treated with phlebotonics and 1130 with placebo (<a href="./references#CD003229-fig-0011" title="">Analysis 1.7</a>). The analysis showed heterogeneity (I<sup>2</sup> = 77%); therefore, we did not pool the data. </p> </section> <section id="CD003229-sec-0064"> <h6 class="title">Pain in the lower legs (continuous variable)</h6> <p>We included 12 studies in the meta‐analysis: five on calcium dobesilate (<a href="./references#CD003229-bbs2-0019" title="Fundación Iberoamericana Itaca. Randomized, double-blind multicenter clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of ulcer secondaries to chronic venous disease. ClinicalTrials.gov2009. ">DOBESILATO500/2</a>; <a href="./references#CD003229-bbs2-0039" title="MarinelloJ , et al. Multicentric, randomised, double-blind, placebo controlled, clinical trial that assess the efficacy of calcium dobesilate in the treatment of venous hypertension in patients with chronic venous insufficiency [Ensayo clínico multicéntrico, doble ciego, aleatorizado, controlado con placebo sobre la eficacia de dobesilato de calcio en el tratamiento de la hipertensión venosa en pacientes afectos de insuficiencia venosa crónica en sus extremidades inferiores. Código: ESCLIN-004/99]. Laboratorios Dr. Esteve. MarinelloJ , VidelaS . Chronic venous insufficiency of the lower limbs: suitability of transcutaneous blood gas monitoring as an endpoint to evaluate the outcome of pharmacological treatment with calcium dobesilate. Methods and Findings in Experimental and Clinical Pharmacology2004;26(10):775-80. ">Marinello 2002</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0054" title="RabeE , BallariniS , LehrL , Doxium EDX09/01 Study Group. A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology2016;31(4):264-74. ">Rabe 2016</a>), three on rutosides (<a href="./references#CD003229-bbs2-0015" title="CloarecM , ClémentR , GritonP . A double-blind clinical trial of hydroxyethylrutosides in the treatment of the symptoms and signs of chronic venous insufficiency. Phlebology1996;11(2):76-82. ">Cloarec 1996</a>; <a href="./references#CD003229-bbs2-0016" title="Cornu-ThenardA , DahanB , De ParadesB . Study of the action in venous insufficiency of the legs. Pierre Fabre Medicament Laboratoires (Novartis). Report no. DC982GEC51(2),1985. ">Cornu‐Thenard 1985</a>; <a href="./references#CD003229-bbs2-0044" title="ParradoF , BuzziA . A study of the efficacy and tolerability of a preparation containing Ruscus aculeatus in the treatment of chronic venous insufficiency of the lower limbs. Clinical Drug Investigation1999;18(4):255-61. ">Parrado 1999</a>), three on diosmine (<a href="./references#CD003229-bbs2-0023" title="FrileuxC , GillyR . Activité thérapeutic de Daflon 500 mg dans l'insuffisance veineuse chronique des membres inférieurs. Journal Internationale de Medicine1994;Suppl 99:36-9. GillyR , PillionG , FrileuxC . Evaluation of a new venactive micronized flavonoid fraction (S5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology1994;9(2):67-70. ThiolletM , FrileuxC , GillyR . Evaluation of a new micronized diosmin in the treatment of chronic venous incompetence: a double-blind, placebo controlled trial. Journal of Vascular Surgery1992;15(2):447. ">Gilly 1994</a>; <a href="./references#CD003229-bbs2-0048" title="PlanchonB . Venous insufficiency and Daflon 500 mg [Insuffisance veineuse et Daflon 500 mg]. Artères et Veines1990;IX(4):376-80. ">Planchon 1990</a>; <a href="./references#CD003229-bbs2-0053" title="RabeE , AgusGB , RoztocilK . Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. International Angiology2015;34(5):428-36. ">Rabe 2015</a>) and one on French maritime pine bark extract (<a href="./references#CD003229-bbs2-0003" title="ArcangeliP . Pycnogenol in chronic venous insufficiency. Fitoterapia2000;71(3):236-44. ">Arcangeli 2000</a>), with a total of 1110 participants assigned to phlebotonics and 1122 to placebo (<a href="./references#CD003229-fig-0012" title="">Analysis 1.8</a>). Phlebotonics may reduce pain (measured as a continuous variable) in the lower legs compared to placebo (SMD ‐0.35, 95% CI ‐0.54 to ‐0.17; 12 studies; 2232 participants; low‐certainty evidence). The certainty of the evidence was downgraded by two levels to low because of overall risk of bias (seven studies had an unclear risk of bias and three had a high risk of bias) and imprecision. We used a random‐effects model as heterogeneity was detected (I<sup>2</sup> = 75%). Differences between the subgroups was detected (test for subgroup differences: P = 0.002) due to differences in results between the subgroup of French maritime pine bark extract compared to the other subgroups. </p> </section> <section id="CD003229-sec-0065"> <h6 class="title">Cramps in the lower legs (dichotomous variable)</h6> <p>We included 14 studies in the meta‐analysis: eight on rutosides (<a href="./references#CD003229-bbs2-0004" title="BalmerA , LimoniC . Clinical, placebo-controlled double-blind study of venoruton in the treatment of chronic venous insufficiency. Importance of the selection of patients. Vasa1980;9(1):76-82. BlumeJ . Therapy of venous oedemas [Tratamento do edema de origem venosa]. Revista Brasileira de Medicina1994;51(3):283-8. ">Balmer 1980</a>; <a href="./references#CD003229-bbs2-0011" title="Van CauwenbergeH . Double-blind clinical trial to assess the efficacy of 0-(b-hidroxy-ethyl)-rutosides in the treatment of venous disorders [Etude en double aveugle de l'efficacité de l'0-(b-hidroxyéthyl)-rutosides dans le traitement des affections veineuses]. Mèdicine et Hygiène1978;35:4175-7. ">Cauwenberge 1978</a>; <a href="./references#CD003229-bbs2-0028" title="JongsteAB , JonkerJJC , HuismanMV , CateJW , AzarAJ . A double-blind trial on the short-term efficacy of HR in patients with the post-thrombotic syndrome. Phlebology1990;5(Suppl 1):21-2. JongsteAB , JonkerJJC , HuismanMV , den CateJW , AzarAJ . A double-blind three center clinical trial on the short-term efficacy of O-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome. Thrombosis and Haemostasis1989;62(3):826-9. ">Jongste 1989</a>; <a href="./references#CD003229-bbs2-0034" title="LanguillatN . Trial of Cyclo 3 Fort in venous insufficiency of the lower limbs: Xenon 133 functional investigation of venous circulatory velocity. Pierre Fabre Medicament Laboratories (Novartis). No. Report DC982GEC130(2),1988. ">Languillat 1988</a>; <a href="./references#CD003229-bbs2-0046" title="PedersenFM , HambergO , SorensenMD , NelandK . The effect of O-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs. Ugeskrift for Laeger1992;154(38):2561-3. ">Pedersen 1992</a>; <a href="./references#CD003229-bbs2-0051" title="PulvertaftTB . General practice treatment of symptoms of venous insufficiency with oxerutins. Results of a 660 patient multicentre study in the UK. Vasa1983;12(4):373-6. PulvertaftTB . Paroven in the treatment of chronic venous insufficiency. Practitioner1979;223(1338):838-41. ">Pulvertaft 1983</a>; <a href="./references#CD003229-bbs2-0066" title="VinE , ChabanelA , TaccoenA , DucrosJ , GrufazJ , HutinelB , et al. Action of Veinamitol 3500 mg on clinical and hemorheological data in CVI. International Angiology1995;14(Suppl 1):99. VinF , ChabanelA , TaccoenA , DucrosJ , GruffazJ , HutinelB , et al. Action de la troxérutine sur les paramètres cliniques, pléthysmographiques et rhéologiques de l'insuffisance veineuse des membres inférieurs. Etude contrôlée contre placebo. Artères et Veines1992;XI:333-42. VinF , ChabanelA , TaccoenA , DucrosJ , GruffazJ , HutinelB , et al. Double-blind trial of the efficacy of troxerutin in chronic venous insufficiency. Phlebology1994;9(2):71-6. ">Vin 1994</a>; <a href="./references#CD003229-bbs2-0067" title="WelchW , MoriauM , vanGyselJP . A double-blind, placebo controlled trial of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Novartis1985. ">Welch 1985</a>), three on diosmine and hidrosmine (<a href="./references#CD003229-bbs2-0007" title="BilandL , BlättlerP , ScheiblerP , StuderS , WidmerK . Zur therapie sogenannt venosër beinsbeschwerden. Vasa1982;11(1):53-8. ">Biland 1982</a>; <a href="./references#CD003229-bbs2-0021" title="FermosoJ , LegidoAG , Del PinoJ , ValienteR . Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Current Therapeutic Research, Clinical and Experimental1992;52(1):124-34. ">Fermoso 1992</a>; <a href="./references#CD003229-bbs2-0048" title="PlanchonB . Venous insufficiency and Daflon 500 mg [Insuffisance veineuse et Daflon 500 mg]. Artères et Veines1990;IX(4):376-80. ">Planchon 1990</a>), two on calcium dobesilate (<a href="./references#CD003229-bbs2-0009" title="Casley-SmithJR . A double-blind, placebo -controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. In: Davy A and StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. London and Paris: John Libbey Eurotext Ltd, 1989. Casley-SmithJR . A double-blind, placebo-controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. Phlebologie1989;2:709-11. Casley-SmithJR . A double-blind trial of calcium dobesilate in chronic venous insufficiency. Angiology1988;39(10):853-7. ">Casley‐Smith 1988</a>; <a href="./references#CD003229-bbs2-0068" title="WidmerL , BilandL , BarrasJP . Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study. International Angiology1990;9(2):105-10. ">Widmer 1990</a>) and one on aminaftone (<a href="./references#CD003229-bbs2-0036" title="LazzariniA , DanieliL . Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers [Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche]. Rassegna Internazionale di Clinica e Terapia1982;62(12):825-44. ">Lazzarini 1982</a>), with a total of 1072 participants treated with phlebotonics and 721 with placebo. Phlebotonics probably reduce cramps (measured as a dichotomous variable) compared to placebo (RR 0.72, 95% CI 0.58 to 0.89; 14 studies; 1793 participants; moderate‐certainty evidence; <a href="./references#CD003229-fig-0013" title="">Analysis 1.9</a>) The certainty of the evidence was downgraded by one level to moderate because of overall risk of bias (11 studies had an unclear risk of bias and three had a high risk of bias). We used a random‐effects model as heterogeneity was detected (I<sup>2</sup> = 73%). No differences between the subgroups was detected (test for subgroup differences: P = 0.28). </p> </section> <section id="CD003229-sec-0066"> <h6 class="title">Cramps in the lower legs (continuous variable)</h6> <p>We included four studies in the meta‐analysis: two on rutosides (<a href="./references#CD003229-bbs2-0015" title="CloarecM , ClémentR , GritonP . A double-blind clinical trial of hydroxyethylrutosides in the treatment of the symptoms and signs of chronic venous insufficiency. Phlebology1996;11(2):76-82. ">Cloarec 1996</a>; <a href="./references#CD003229-bbs2-0044" title="ParradoF , BuzziA . A study of the efficacy and tolerability of a preparation containing Ruscus aculeatus in the treatment of chronic venous insufficiency of the lower limbs. Clinical Drug Investigation1999;18(4):255-61. ">Parrado 1999</a>), one on calcium dobesilate (<a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>), and one on diosmine (<a href="./references#CD003229-bbs2-0023" title="FrileuxC , GillyR . Activité thérapeutic de Daflon 500 mg dans l'insuffisance veineuse chronique des membres inférieurs. Journal Internationale de Medicine1994;Suppl 99:36-9. GillyR , PillionG , FrileuxC . Evaluation of a new venactive micronized flavonoid fraction (S5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology1994;9(2):67-70. ThiolletM , FrileuxC , GillyR . Evaluation of a new micronized diosmin in the treatment of chronic venous incompetence: a double-blind, placebo controlled trial. Journal of Vascular Surgery1992;15(2):447. ">Gilly 1994</a>), with 363 participants treated with phlebotonics and 366 with placebo (<a href="./references#CD003229-fig-0014" title="">Analysis 1.10</a>). The analysis showed heterogeneity (I<sup>2</sup> = 86%); therefore, we did not pool the data. </p> </section> <section id="CD003229-sec-0067"> <h6 class="title">Restless legs (dichotomous variable)</h6> <p>We included seven studies in the meta‐analysis: four on rutosides (<a href="./references#CD003229-bbs2-0004" title="BalmerA , LimoniC . Clinical, placebo-controlled double-blind study of venoruton in the treatment of chronic venous insufficiency. Importance of the selection of patients. Vasa1980;9(1):76-82. BlumeJ . Therapy of venous oedemas [Tratamento do edema de origem venosa]. Revista Brasileira de Medicina1994;51(3):283-8. ">Balmer 1980</a>; <a href="./references#CD003229-bbs2-0011" title="Van CauwenbergeH . Double-blind clinical trial to assess the efficacy of 0-(b-hidroxy-ethyl)-rutosides in the treatment of venous disorders [Etude en double aveugle de l'efficacité de l'0-(b-hidroxyéthyl)-rutosides dans le traitement des affections veineuses]. Mèdicine et Hygiène1978;35:4175-7. ">Cauwenberge 1978</a>; <a href="./references#CD003229-bbs2-0028" title="JongsteAB , JonkerJJC , HuismanMV , CateJW , AzarAJ . A double-blind trial on the short-term efficacy of HR in patients with the post-thrombotic syndrome. Phlebology1990;5(Suppl 1):21-2. JongsteAB , JonkerJJC , HuismanMV , den CateJW , AzarAJ . A double-blind three center clinical trial on the short-term efficacy of O-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome. Thrombosis and Haemostasis1989;62(3):826-9. ">Jongste 1989</a>; <a href="./references#CD003229-bbs2-0046" title="PedersenFM , HambergO , SorensenMD , NelandK . The effect of O-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs. Ugeskrift for Laeger1992;154(38):2561-3. ">Pedersen 1992</a>), two on calcium dobesilate (<a href="./references#CD003229-bbs2-0009" title="Casley-SmithJR . A double-blind, placebo -controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. In: Davy A and StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. London and Paris: John Libbey Eurotext Ltd, 1989. Casley-SmithJR . A double-blind, placebo-controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. Phlebologie1989;2:709-11. Casley-SmithJR . A double-blind trial of calcium dobesilate in chronic venous insufficiency. Angiology1988;39(10):853-7. ">Casley‐Smith 1988</a>; <a href="./references#CD003229-bbs2-0068" title="WidmerL , BilandL , BarrasJP . Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study. International Angiology1990;9(2):105-10. ">Widmer 1990</a>), and one on diosmine (<a href="./references#CD003229-bbs2-0007" title="BilandL , BlättlerP , ScheiblerP , StuderS , WidmerK . Zur therapie sogenannt venosër beinsbeschwerden. Vasa1982;11(1):53-8. ">Biland 1982</a>). A total of 329 participants were treated with phlebotonics and 323 with placebo (<a href="./references#CD003229-fig-0015" title="">Analysis 1.11</a>). Phebotonics probably slightly reduce restless legs (measured as a dichotomous variable) compared to placebo (RR 0.81, 95% CI 0.72 to 0.91; 7 studies; 652 participants; moderate‐certainty evidence). The certainty of the evidence was downgraded by one level to moderate because of overall risk of bias (five studies had an unclear risk of bias and two had a high risk of bias). No differences between the subgroups was detected (test for subgroup differences: P = 0.41). </p> </section> <section id="CD003229-sec-0068"> <h6 class="title">Itching in the lower legs (dichotomous variable)</h6> <p>We included four studies in the analysis: two on rutoside (<a href="./references#CD003229-bbs2-0046" title="PedersenFM , HambergO , SorensenMD , NelandK . The effect of O-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs. Ugeskrift for Laeger1992;154(38):2561-3. ">Pedersen 1992</a>; <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>), one on hidrosmine (<a href="./references#CD003229-bbs2-0021" title="FermosoJ , LegidoAG , Del PinoJ , ValienteR . Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Current Therapeutic Research, Clinical and Experimental1992;52(1):124-34. ">Fermoso 1992</a>), and one on aminaftone (<a href="./references#CD003229-bbs2-0036" title="LazzariniA , DanieliL . Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers [Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche]. Rassegna Internazionale di Clinica e Terapia1982;62(12):825-44. ">Lazzarini 1982</a>). A total of 206 participants were included in the active treatment group and 199 in the placebo group (<a href="./references#CD003229-fig-0016" title="">Analysis 1.12</a>). The analysis showed heterogeneity (I<sup>2</sup> = 92%); therefore, we did not pool the data. </p> </section> <section id="CD003229-sec-0069"> <h6 class="title">Itching in the lower legs (continuous variable)</h6> <p>We included two studies in the analysis: one on calcium dobesilate (<a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>), and one on rutosides (<a href="./references#CD003229-bbs2-0044" title="ParradoF , BuzziA . A study of the efficacy and tolerability of a preparation containing Ruscus aculeatus in the treatment of chronic venous insufficiency of the lower limbs. Clinical Drug Investigation1999;18(4):255-61. ">Parrado 1999</a>). A total of 234 participants were treated with phlebotonics and 242 with placebo (<a href="./references#CD003229-fig-0017" title="">Analysis 1.13</a>). The analysis showed heterogeneity (I<sup>2</sup> = 82%), and we did not pool the data. </p> </section> <section id="CD003229-sec-0070"> <h6 class="title">Feeling of heaviness in the lower legs (dichotomous variable)</h6> <p>We included 19 studies in the analysis: nine on rutosides (<a href="./references#CD003229-bbs2-0010" title="Van CauwenbergeH . Double-blind study of the efficacy of a soluble rutoside derivative in the treatment of venous disease. Archives of Internal Pharmacodynamics and Therapeutics1972;196(Suppl 196):122-5. ">Cauwenberge 1972</a>; <a href="./references#CD003229-bbs2-0011" title="Van CauwenbergeH . Double-blind clinical trial to assess the efficacy of 0-(b-hidroxy-ethyl)-rutosides in the treatment of venous disorders [Etude en double aveugle de l'efficacité de l'0-(b-hidroxyéthyl)-rutosides dans le traitement des affections veineuses]. Mèdicine et Hygiène1978;35:4175-7. ">Cauwenberge 1978</a>; <a href="./references#CD003229-bbs2-0028" title="JongsteAB , JonkerJJC , HuismanMV , CateJW , AzarAJ . A double-blind trial on the short-term efficacy of HR in patients with the post-thrombotic syndrome. Phlebology1990;5(Suppl 1):21-2. JongsteAB , JonkerJJC , HuismanMV , den CateJW , AzarAJ . A double-blind three center clinical trial on the short-term efficacy of O-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome. Thrombosis and Haemostasis1989;62(3):826-9. ">Jongste 1989</a>; <a href="./references#CD003229-bbs2-0034" title="LanguillatN . Trial of Cyclo 3 Fort in venous insufficiency of the lower limbs: Xenon 133 functional investigation of venous circulatory velocity. Pierre Fabre Medicament Laboratories (Novartis). No. Report DC982GEC130(2),1988. ">Languillat 1988</a>; <a href="./references#CD003229-bbs2-0046" title="PedersenFM , HambergO , SorensenMD , NelandK . The effect of O-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs. Ugeskrift for Laeger1992;154(38):2561-3. ">Pedersen 1992</a>; <a href="./references#CD003229-bbs2-0051" title="PulvertaftTB . General practice treatment of symptoms of venous insufficiency with oxerutins. Results of a 660 patient multicentre study in the UK. Vasa1983;12(4):373-6. PulvertaftTB . Paroven in the treatment of chronic venous insufficiency. Practitioner1979;223(1338):838-41. ">Pulvertaft 1983</a>; <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>; <a href="./references#CD003229-bbs2-0066" title="VinE , ChabanelA , TaccoenA , DucrosJ , GrufazJ , HutinelB , et al. Action of Veinamitol 3500 mg on clinical and hemorheological data in CVI. International Angiology1995;14(Suppl 1):99. VinF , ChabanelA , TaccoenA , DucrosJ , GruffazJ , HutinelB , et al. Action de la troxérutine sur les paramètres cliniques, pléthysmographiques et rhéologiques de l'insuffisance veineuse des membres inférieurs. Etude contrôlée contre placebo. Artères et Veines1992;XI:333-42. VinF , ChabanelA , TaccoenA , DucrosJ , GruffazJ , HutinelB , et al. Double-blind trial of the efficacy of troxerutin in chronic venous insufficiency. Phlebology1994;9(2):71-6. ">Vin 1994</a>; <a href="./references#CD003229-bbs2-0067" title="WelchW , MoriauM , vanGyselJP . A double-blind, placebo controlled trial of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Novartis1985. ">Welch 1985</a>), four on diosmine and hidrosmine (<a href="./references#CD003229-bbs2-0020" title="DominguezC , BrautighamI , GonzálezE , GonzálezJA , NazcoJ , ValienteR , et al. Therapeutic effects of hidrosmin on chronic venous insufficiency of the lower limbs. Current Medical Research and Opinion1992;12(10):623-30. ">Dominguez 1992</a>; <a href="./references#CD003229-bbs2-0021" title="FermosoJ , LegidoAG , Del PinoJ , ValienteR . Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Current Therapeutic Research, Clinical and Experimental1992;52(1):124-34. ">Fermoso 1992</a>; <a href="./references#CD003229-bbs2-0048" title="PlanchonB . Venous insufficiency and Daflon 500 mg [Insuffisance veineuse et Daflon 500 mg]. Artères et Veines1990;IX(4):376-80. ">Planchon 1990</a>; <a href="./references#CD003229-bbs2-0062" title="TsouderosY . Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency. Our experience with Daflon 500 mg. International Angiology1989;8(4):53-9. TsouderosY . Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg. Zeitschrift fur Kardiologie1991;80 Suppl 7:95-101. ">Tsouderos 1989</a>), three on calcium dobesilate (<a href="./references#CD003229-bbs2-0009" title="Casley-SmithJR . A double-blind, placebo -controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. In: Davy A and StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. London and Paris: John Libbey Eurotext Ltd, 1989. Casley-SmithJR . A double-blind, placebo-controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. Phlebologie1989;2:709-11. Casley-SmithJR . A double-blind trial of calcium dobesilate in chronic venous insufficiency. Angiology1988;39(10):853-7. ">Casley‐Smith 1988</a>; <a href="./references#CD003229-bbs2-0025" title="HachenHJ , LorenzP . Double-blind clinical and plethysmographic study of calcium dobesilate in patients with peripheral microvascular disorders. Angiology1982;33(7):480-8. ">Hachen 1982</a>; <a href="./references#CD003229-bbs2-0068" title="WidmerL , BilandL , BarrasJP . Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study. International Angiology1990;9(2):105-10. ">Widmer 1990</a>), one on aminaftone (<a href="./references#CD003229-bbs2-0036" title="LazzariniA , DanieliL . Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers [Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche]. Rassegna Internazionale di Clinica e Terapia1982;62(12):825-44. ">Lazzarini 1982</a>), one on <i>Centella asiatica</i> (<a href="./references#CD003229-bbs2-0049" title="PointelJP , BoccalonH , CloarecM , Le DevehatC , JoubertM . Titrated extract of Centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology1987;38(1 Pt 1):46-50. PointelJP . Titrated extract of centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology1986;37(5):420-1. ">Pointel 1986</a>), and one on French maritime pine bark extract (<a href="./references#CD003229-bbs2-0003" title="ArcangeliP . Pycnogenol in chronic venous insufficiency. Fitoterapia2000;71(3):236-44. ">Arcangeli 2000</a>). A total of 1257 participants were included in the active treatment group and 909 in the placebo group (<a href="./references#CD003229-fig-0018" title="">Analysis 1.14</a>). The analysis showed heterogeneity (I<sup>2</sup> = 80%), and we did not pool the data. </p> </section> <section id="CD003229-sec-0071"> <h6 class="title">Feeling of heaviness in the lower legs (continuous variable)</h6> <p>We included 10 studies in the analysis: six on rutosides (<a href="./references#CD003229-bbs2-0002" title="AlterkamperH . Efficacy of antivaricotic drugs can be measured objectively. Phlebologie in der Praxis1987;2(9-10):19-20. ">Alterkamper 1987</a>; <a href="./references#CD003229-bbs2-0015" title="CloarecM , ClémentR , GritonP . A double-blind clinical trial of hydroxyethylrutosides in the treatment of the symptoms and signs of chronic venous insufficiency. Phlebology1996;11(2):76-82. ">Cloarec 1996</a>; <a href="./references#CD003229-bbs2-0016" title="Cornu-ThenardA , DahanB , De ParadesB . Study of the action in venous insufficiency of the legs. Pierre Fabre Medicament Laboratoires (Novartis). Report no. DC982GEC51(2),1985. ">Cornu‐Thenard 1985</a>; <a href="./references#CD003229-bbs2-0018" title="DiebschlagW , NockerW , LehmacherW , RehnD . A clinical comparison of two doses of O-(beta-hydroxyethyl) rutosides (oxerutins) in patients with chronic venous insufficiency. Journal of Pharmaceutical Medicine1994;4(1):7-14. ">Diebschlag 1994</a>; <a href="./references#CD003229-bbs2-0044" title="ParradoF , BuzziA . A study of the efficacy and tolerability of a preparation containing Ruscus aculeatus in the treatment of chronic venous insufficiency of the lower limbs. Clinical Drug Investigation1999;18(4):255-61. ">Parrado 1999</a>; <a href="./references#CD003229-bbs2-0063" title="UnkaufM , RehnD , KlingerJ , MotteS , GrobmannK . Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings. Arzneimittel-Forschung1996;46(5):478-82. ">Unkauf 1996</a>), two on calcium dobesilate (<a href="./references#CD003229-bbs2-0039" title="MarinelloJ , et al. Multicentric, randomised, double-blind, placebo controlled, clinical trial that assess the efficacy of calcium dobesilate in the treatment of venous hypertension in patients with chronic venous insufficiency [Ensayo clínico multicéntrico, doble ciego, aleatorizado, controlado con placebo sobre la eficacia de dobesilato de calcio en el tratamiento de la hipertensión venosa en pacientes afectos de insuficiencia venosa crónica en sus extremidades inferiores. Código: ESCLIN-004/99]. Laboratorios Dr. Esteve. MarinelloJ , VidelaS . Chronic venous insufficiency of the lower limbs: suitability of transcutaneous blood gas monitoring as an endpoint to evaluate the outcome of pharmacological treatment with calcium dobesilate. Methods and Findings in Experimental and Clinical Pharmacology2004;26(10):775-80. ">Marinello 2002</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>), one on diosmine (<a href="./references#CD003229-bbs2-0023" title="FrileuxC , GillyR . Activité thérapeutic de Daflon 500 mg dans l'insuffisance veineuse chronique des membres inférieurs. Journal Internationale de Medicine1994;Suppl 99:36-9. GillyR , PillionG , FrileuxC . Evaluation of a new venactive micronized flavonoid fraction (S5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology1994;9(2):67-70. ThiolletM , FrileuxC , GillyR . Evaluation of a new micronized diosmin in the treatment of chronic venous incompetence: a double-blind, placebo controlled trial. Journal of Vascular Surgery1992;15(2):447. ">Gilly 1994</a>), and one on French maritime pine bark extract (<a href="./references#CD003229-bbs2-0003" title="ArcangeliP . Pycnogenol in chronic venous insufficiency. Fitoterapia2000;71(3):236-44. ">Arcangeli 2000</a>). A total of 557 participants were included in the active treatment group and 557 in the placebo group (<a href="./references#CD003229-fig-0019" title="">Analysis 1.15</a>). The analysis showed heterogeneity (I<sup>2</sup> = 91%); therefore, we did not pool the data. </p> </section> <section id="CD003229-sec-0072"> <h6 class="title">Swelling in the lower legs (dichotomous variable)</h6> <p>We included 14 studies in the analysis: nine on rutosides (<a href="./references#CD003229-bbs2-0004" title="BalmerA , LimoniC . Clinical, placebo-controlled double-blind study of venoruton in the treatment of chronic venous insufficiency. Importance of the selection of patients. Vasa1980;9(1):76-82. BlumeJ . Therapy of venous oedemas [Tratamento do edema de origem venosa]. Revista Brasileira de Medicina1994;51(3):283-8. ">Balmer 1980</a>; <a href="./references#CD003229-bbs2-0011" title="Van CauwenbergeH . Double-blind clinical trial to assess the efficacy of 0-(b-hidroxy-ethyl)-rutosides in the treatment of venous disorders [Etude en double aveugle de l'efficacité de l'0-(b-hidroxyéthyl)-rutosides dans le traitement des affections veineuses]. Mèdicine et Hygiène1978;35:4175-7. ">Cauwenberge 1978</a>; <a href="./references#CD003229-bbs2-0028" title="JongsteAB , JonkerJJC , HuismanMV , CateJW , AzarAJ . A double-blind trial on the short-term efficacy of HR in patients with the post-thrombotic syndrome. Phlebology1990;5(Suppl 1):21-2. JongsteAB , JonkerJJC , HuismanMV , den CateJW , AzarAJ . A double-blind three center clinical trial on the short-term efficacy of O-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome. Thrombosis and Haemostasis1989;62(3):826-9. ">Jongste 1989</a>; <a href="./references#CD003229-bbs2-0032" title="KrinerE , BraunR , HircheH , Van LaakHH . Treatment of venous insufficiency. A double-blind trial with Phlebodril. Zeitschrift für Allgemeinmedizin1985;61(9):309-13. ">Kriner 1985</a>; <a href="./references#CD003229-bbs2-0034" title="LanguillatN . Trial of Cyclo 3 Fort in venous insufficiency of the lower limbs: Xenon 133 functional investigation of venous circulatory velocity. Pierre Fabre Medicament Laboratories (Novartis). No. Report DC982GEC130(2),1988. ">Languillat 1988</a>; <a href="./references#CD003229-bbs2-0046" title="PedersenFM , HambergO , SorensenMD , NelandK . The effect of O-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs. Ugeskrift for Laeger1992;154(38):2561-3. ">Pedersen 1992</a>; <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>; <a href="./references#CD003229-bbs2-0066" title="VinE , ChabanelA , TaccoenA , DucrosJ , GrufazJ , HutinelB , et al. Action of Veinamitol 3500 mg on clinical and hemorheological data in CVI. International Angiology1995;14(Suppl 1):99. VinF , ChabanelA , TaccoenA , DucrosJ , GruffazJ , HutinelB , et al. Action de la troxérutine sur les paramètres cliniques, pléthysmographiques et rhéologiques de l'insuffisance veineuse des membres inférieurs. Etude contrôlée contre placebo. Artères et Veines1992;XI:333-42. VinF , ChabanelA , TaccoenA , DucrosJ , GruffazJ , HutinelB , et al. Double-blind trial of the efficacy of troxerutin in chronic venous insufficiency. Phlebology1994;9(2):71-6. ">Vin 1994</a>; <a href="./references#CD003229-bbs2-0067" title="WelchW , MoriauM , vanGyselJP . A double-blind, placebo controlled trial of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Novartis1985. ">Welch 1985</a>), two on calcium dobesilate (<a href="./references#CD003229-bbs2-0009" title="Casley-SmithJR . A double-blind, placebo -controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. In: Davy A and StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. London and Paris: John Libbey Eurotext Ltd, 1989. Casley-SmithJR . A double-blind, placebo-controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. Phlebologie1989;2:709-11. Casley-SmithJR . A double-blind trial of calcium dobesilate in chronic venous insufficiency. Angiology1988;39(10):853-7. ">Casley‐Smith 1988</a>; <a href="./references#CD003229-bbs2-0025" title="HachenHJ , LorenzP . Double-blind clinical and plethysmographic study of calcium dobesilate in patients with peripheral microvascular disorders. Angiology1982;33(7):480-8. ">Hachen 1982</a>), two on diosmine and hidrosmine (<a href="./references#CD003229-bbs2-0007" title="BilandL , BlättlerP , ScheiblerP , StuderS , WidmerK . Zur therapie sogenannt venosër beinsbeschwerden. Vasa1982;11(1):53-8. ">Biland 1982</a>; <a href="./references#CD003229-bbs2-0021" title="FermosoJ , LegidoAG , Del PinoJ , ValienteR . Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Current Therapeutic Research, Clinical and Experimental1992;52(1):124-34. ">Fermoso 1992</a>), and one on French maritime pine bark extract (<a href="./references#CD003229-bbs2-0003" title="ArcangeliP . Pycnogenol in chronic venous insufficiency. Fitoterapia2000;71(3):236-44. ">Arcangeli 2000</a>), with 544 participants included in the active treatment group and 528 in the placebo group. Phebotonics probably reduce swelling in the lower leg (measured as a dichotomous variable) compared to placebo (RR 0.63, 95% CI 0.50 to 0.80; 14 studies; 1072 participants; moderate‐certainty evidence; <a href="./references#CD003229-fig-0020" title="">Analysis 1.16</a>). The certainty of the evidence was downgraded by one level to moderate because of overall risk of bias (11 studies had an unclear risk of bias and two had a high risk of bias). We used a random‐effects model as heterogeneity was detected (I<sup>2</sup> = 69%). Differences between the subgroups was detected (test for subgroup differences: P = 0.007) due to a larger effect of calcium dobesilate. </p> </section> <section id="CD003229-sec-0073"> <h6 class="title">Swelling in the lower legs (continuous variable)</h6> <p>We included six studies in the analysis: three on rutosides (<a href="./references#CD003229-bbs2-0015" title="CloarecM , ClémentR , GritonP . A double-blind clinical trial of hydroxyethylrutosides in the treatment of the symptoms and signs of chronic venous insufficiency. Phlebology1996;11(2):76-82. ">Cloarec 1996</a>; <a href="./references#CD003229-bbs2-0018" title="DiebschlagW , NockerW , LehmacherW , RehnD . A clinical comparison of two doses of O-(beta-hydroxyethyl) rutosides (oxerutins) in patients with chronic venous insufficiency. Journal of Pharmaceutical Medicine1994;4(1):7-14. ">Diebschlag 1994</a>; <a href="./references#CD003229-bbs2-0063" title="UnkaufM , RehnD , KlingerJ , MotteS , GrobmannK . Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings. Arzneimittel-Forschung1996;46(5):478-82. ">Unkauf 1996</a>), one on diosmine (<a href="./references#CD003229-bbs2-0023" title="FrileuxC , GillyR . Activité thérapeutic de Daflon 500 mg dans l'insuffisance veineuse chronique des membres inférieurs. Journal Internationale de Medicine1994;Suppl 99:36-9. GillyR , PillionG , FrileuxC . Evaluation of a new venactive micronized flavonoid fraction (S5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology1994;9(2):67-70. ThiolletM , FrileuxC , GillyR . Evaluation of a new micronized diosmin in the treatment of chronic venous incompetence: a double-blind, placebo controlled trial. Journal of Vascular Surgery1992;15(2):447. ">Gilly 1994</a>), one on calcium dobesilate (<a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>), and one on French maritime pine bark extract (<a href="./references#CD003229-bbs2-0003" title="ArcangeliP . Pycnogenol in chronic venous insufficiency. Fitoterapia2000;71(3):236-44. ">Arcangeli 2000</a>), with 436 participants assigned to active treatment and 435 to placebo (<a href="./references#CD003229-fig-0021" title="">Analysis 1.17</a>). The analysis showed heterogeneity (I<sup>2</sup> = 95%), and we did not pool the data. </p> </section> <section id="CD003229-sec-0074"> <h6 class="title">Paraesthesia in the lower legs (dichotomous variable)</h6> <p>We included nine studies in the analysis: four on rutosides (<a href="./references#CD003229-bbs2-0004" title="BalmerA , LimoniC . Clinical, placebo-controlled double-blind study of venoruton in the treatment of chronic venous insufficiency. Importance of the selection of patients. Vasa1980;9(1):76-82. BlumeJ . Therapy of venous oedemas [Tratamento do edema de origem venosa]. Revista Brasileira de Medicina1994;51(3):283-8. ">Balmer 1980</a>; <a href="./references#CD003229-bbs2-0011" title="Van CauwenbergeH . Double-blind clinical trial to assess the efficacy of 0-(b-hidroxy-ethyl)-rutosides in the treatment of venous disorders [Etude en double aveugle de l'efficacité de l'0-(b-hidroxyéthyl)-rutosides dans le traitement des affections veineuses]. Mèdicine et Hygiène1978;35:4175-7. ">Cauwenberge 1978</a>; <a href="./references#CD003229-bbs2-0051" title="PulvertaftTB . General practice treatment of symptoms of venous insufficiency with oxerutins. Results of a 660 patient multicentre study in the UK. Vasa1983;12(4):373-6. PulvertaftTB . Paroven in the treatment of chronic venous insufficiency. Practitioner1979;223(1338):838-41. ">Pulvertaft 1983</a>; <a href="./references#CD003229-bbs2-0067" title="WelchW , MoriauM , vanGyselJP . A double-blind, placebo controlled trial of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Novartis1985. ">Welch 1985</a>), three on calcium dobesilate (<a href="./references#CD003229-bbs2-0009" title="Casley-SmithJR . A double-blind, placebo -controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. In: Davy A and StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. London and Paris: John Libbey Eurotext Ltd, 1989. Casley-SmithJR . A double-blind, placebo-controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. Phlebologie1989;2:709-11. Casley-SmithJR . A double-blind trial of calcium dobesilate in chronic venous insufficiency. Angiology1988;39(10):853-7. ">Casley‐Smith 1988</a>; <a href="./references#CD003229-bbs2-0025" title="HachenHJ , LorenzP . Double-blind clinical and plethysmographic study of calcium dobesilate in patients with peripheral microvascular disorders. Angiology1982;33(7):480-8. ">Hachen 1982</a>; <a href="./references#CD003229-bbs2-0068" title="WidmerL , BilandL , BarrasJP . Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study. International Angiology1990;9(2):105-10. ">Widmer 1990</a>) and two on diosmine and hidrosmine (<a href="./references#CD003229-bbs2-0021" title="FermosoJ , LegidoAG , Del PinoJ , ValienteR . Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Current Therapeutic Research, Clinical and Experimental1992;52(1):124-34. ">Fermoso 1992</a>; <a href="./references#CD003229-bbs2-0048" title="PlanchonB . Venous insufficiency and Daflon 500 mg [Insuffisance veineuse et Daflon 500 mg]. Artères et Veines1990;IX(4):376-80. ">Planchon 1990</a>), with 896 participants assigned to active treatment and 560 to placebo (<a href="./references#CD003229-fig-0022" title="">Analysis 1.18</a>). Phlebotonics probably reduce paraesthesia in the lower legs (measured as a dichotomous variable) compared to placebo (RR 0.67, 95% CI 0.50 to 0.88; 9 studies; 1456 participants; moderate‐certainty evidence). The certainty of the evidence was downgraded by one level) to moderate because of overall risk of bias (eight studies had an unclear risk of bias and one had a high risk of bias). We used a random‐effects model as heterogeneity was detected (I<sup>2</sup> = 72%). No differences between the subgroups was detected (test for subgroup differences: P = 0.32). </p> </section> <section id="CD003229-sec-0075"> <h6 class="title">Paraesthesia in the lower legs (continuous variable)</h6> <p>We included two studies in the analysis: one on diosmine (<a href="./references#CD003229-bbs2-0023" title="FrileuxC , GillyR . Activité thérapeutic de Daflon 500 mg dans l'insuffisance veineuse chronique des membres inférieurs. Journal Internationale de Medicine1994;Suppl 99:36-9. GillyR , PillionG , FrileuxC . Evaluation of a new venactive micronized flavonoid fraction (S5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology1994;9(2):67-70. ThiolletM , FrileuxC , GillyR . Evaluation of a new micronized diosmin in the treatment of chronic venous incompetence: a double-blind, placebo controlled trial. Journal of Vascular Surgery1992;15(2):447. ">Gilly 1994</a>), and one on rutoside (<a href="./references#CD003229-bbs2-0016" title="Cornu-ThenardA , DahanB , De ParadesB . Study of the action in venous insufficiency of the legs. Pierre Fabre Medicament Laboratoires (Novartis). Report no. DC982GEC51(2),1985. ">Cornu‐Thenard 1985</a>), with 97 participants assigned to active treatment and 91 to placebo (<a href="./references#CD003229-fig-0023" title="">Analysis 1.19</a>). It is uncertain whether phlebotonics reduce continuous variable paraesthesia because the certainty of this evidence is very low (SMD ‐0.15, 95% CI ‐0.44 to 0.13; 2 studies; 188 participants). The certainty of the evidence was downgraded by three levels to very low because of risk of bias (one level) and the sample size was small with a high imprecision in the results (two levels). No differences between the subgroups was detected (test for subgroup differences: P = 0.59). </p> </section> <section id="CD003229-sec-0076"> <h6 class="title">Participant satisfaction (dichotomous variable)</h6> <p>We included 16 studies in the analysis: eight on rutosides (<a href="./references#CD003229-bbs2-0008" title="BurnandKG , PowellS , BishopC , StaceyM , PulvertaftT . Effect of Paroven on skin oxygenation in patients with varicose veins. Phlebologie1989;4(1):15-22. ">Burnand 1989</a>; <a href="./references#CD003229-bbs2-0015" title="CloarecM , ClémentR , GritonP . A double-blind clinical trial of hydroxyethylrutosides in the treatment of the symptoms and signs of chronic venous insufficiency. Phlebology1996;11(2):76-82. ">Cloarec 1996</a>; <a href="./references#CD003229-bbs2-0028" title="JongsteAB , JonkerJJC , HuismanMV , CateJW , AzarAJ . A double-blind trial on the short-term efficacy of HR in patients with the post-thrombotic syndrome. Phlebology1990;5(Suppl 1):21-2. JongsteAB , JonkerJJC , HuismanMV , den CateJW , AzarAJ . A double-blind three center clinical trial on the short-term efficacy of O-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome. Thrombosis and Haemostasis1989;62(3):826-9. ">Jongste 1989</a>; <a href="./references#CD003229-bbs2-0034" title="LanguillatN . Trial of Cyclo 3 Fort in venous insufficiency of the lower limbs: Xenon 133 functional investigation of venous circulatory velocity. Pierre Fabre Medicament Laboratories (Novartis). No. Report DC982GEC130(2),1988. ">Languillat 1988</a>; <a href="./references#CD003229-bbs2-0044" title="ParradoF , BuzziA . A study of the efficacy and tolerability of a preparation containing Ruscus aculeatus in the treatment of chronic venous insufficiency of the lower limbs. Clinical Drug Investigation1999;18(4):255-61. ">Parrado 1999</a>; <a href="./references#CD003229-bbs2-0046" title="PedersenFM , HambergO , SorensenMD , NelandK . The effect of O-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs. Ugeskrift for Laeger1992;154(38):2561-3. ">Pedersen 1992</a>; <a href="./references#CD003229-bbs2-0051" title="PulvertaftTB . General practice treatment of symptoms of venous insufficiency with oxerutins. Results of a 660 patient multicentre study in the UK. Vasa1983;12(4):373-6. PulvertaftTB . Paroven in the treatment of chronic venous insufficiency. Practitioner1979;223(1338):838-41. ">Pulvertaft 1983</a>; <a href="./references#CD003229-bbs2-0067" title="WelchW , MoriauM , vanGyselJP . A double-blind, placebo controlled trial of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Novartis1985. ">Welch 1985</a>), three on calcium dobesilate (<a href="./references#CD003229-bbs2-0009" title="Casley-SmithJR . A double-blind, placebo -controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. In: Davy A and StemmerR , editors(s). Proceedings of the Union Internationale de Phlebologie - 10th World Congress, Strasbourg, 25-29 September. London and Paris: John Libbey Eurotext Ltd, 1989. Casley-SmithJR . A double-blind, placebo-controlled, matched-pair trial of the mode of action of 'Doxium' in the treatment of chronic venous insufficiency. Phlebologie1989;2:709-11. Casley-SmithJR . A double-blind trial of calcium dobesilate in chronic venous insufficiency. Angiology1988;39(10):853-7. ">Casley‐Smith 1988</a>; <a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>), four on diosmine (<a href="./references#CD003229-bbs2-0007" title="BilandL , BlättlerP , ScheiblerP , StuderS , WidmerK . Zur therapie sogenannt venosër beinsbeschwerden. Vasa1982;11(1):53-8. ">Biland 1982</a>; <a href="./references#CD003229-bbs2-0013" title="ChassignolleJF , AmielM , LanfranchiG , BarbeR . Activite therapeutique de daflon 500 mg dans l'insuffisance veineuse fonctionnelle. Journal International de Medicine1994;Suppl 99:32-5. ">Chassignolle 1994</a>; <a href="./references#CD003229-bbs2-0017" title="DanielssonG , JungbeckC , PetersonK , NorgrenL . A randomised controlled trial of micronised purified flavonoid fraction versus placebo in patients with chronic venous disease. European Journal of Vascular and Endovascular Surgery2002;23(1):73-6. ">Danielsson 2002</a>; <a href="./references#CD003229-bbs2-0035" title="LaurentR , GillyR , FrileuxC . Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg. International Angiology1988;7(2 Suppl):39-43. ">Laurent 1988</a>), and one on <i>Centella asiatica</i> (<a href="./references#CD003229-bbs2-0001" title="Allegra C Pollari G, CriscuoloA , BonifacioM , TabassiD . Centella asiatica extract in venous disorders of the lower limbs. Comparative clinico-instrumental studies with a placebo. Clinica Terapeutica1981;99(5):507-13. ">Allegra 1981</a>), with a total of 1265 participants treated with phlebotonics and 939 with placebo (<a href="./references#CD003229-fig-0024" title="">Analysis 1.20</a>). The analysis showed heterogeneity (I<sup>2</sup> = 86%), and we did not pool the data. </p> </section> <section id="CD003229-sec-0077"> <h6 class="title">Participant satisfaction (continuous variable)</h6> <p>We included seven studies in the analysis: four on rutosides (<a href="./references#CD003229-bbs2-0012" title="CesaroneMR , IncandelaL , DeSanctisMT , BelcaroG , GriffinM , IppolitoE , et al. Treatment of edema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton; O-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized, dose-ranging trial. Journal of Cardiovascular Pharmacology and Therapeutics2002;7 Suppl 1:S21-4. ">Cesarone 2002</a>; <a href="./references#CD003229-bbs2-0015" title="CloarecM , ClémentR , GritonP . A double-blind clinical trial of hydroxyethylrutosides in the treatment of the symptoms and signs of chronic venous insufficiency. Phlebology1996;11(2):76-82. ">Cloarec 1996</a>; <a href="./references#CD003229-bbs2-0026" title="IhmeN , KiesewetterH , JungF , HoffmannKH , BirkA , MüllerA , et al. Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomized, double-blind, placebo-controlled clinical trial. European Journal of Clinical Pharmacology1996;50(6):443-7. ">Ihme 1996</a>; <a href="./references#CD003229-bbs2-0029" title="KiesewetterH , KoscielnyJ , GrütznerK , MüllerA , HoffmannKH , BirkA . Buckwheat herb/troxerutin-combination for the treatment of chronic venous insufficiency. Zeitschrift für Phytotherapie1997;18(6):341-6. ">Kiesewetter 1997</a>), two on calcium dobesilate (<a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0068" title="WidmerL , BilandL , BarrasJP . Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study. International Angiology1990;9(2):105-10. ">Widmer 1990</a>), and one on diosmine (<a href="./references#CD003229-bbs2-0023" title="FrileuxC , GillyR . Activité thérapeutic de Daflon 500 mg dans l'insuffisance veineuse chronique des membres inférieurs. Journal Internationale de Medicine1994;Suppl 99:36-9. GillyR , PillionG , FrileuxC . Evaluation of a new venactive micronized flavonoid fraction (S5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology1994;9(2):67-70. ThiolletM , FrileuxC , GillyR . Evaluation of a new micronized diosmin in the treatment of chronic venous incompetence: a double-blind, placebo controlled trial. Journal of Vascular Surgery1992;15(2):447. ">Gilly 1994</a>), with 440 participants treated with phlebotonics and 441 with placebo (<a href="./references#CD003229-fig-0025" title="">Analysis 1.21</a>). The analysis showed heterogeneity (I<sup>2</sup> = 85%), and we did not pool the data. </p> </section> </section> <section id="CD003229-sec-0078"> <h5 class="title">Adverse events</h5> <p>Thirty‐seven studies reported on adverse events. These included 17 trials considering rutosides (<a href="./references#CD003229-bbs2-0002" title="AlterkamperH . Efficacy of antivaricotic drugs can be measured objectively. Phlebologie in der Praxis1987;2(9-10):19-20. ">Alterkamper 1987</a>; <a href="./references#CD003229-bbs2-0004" title="BalmerA , LimoniC . Clinical, placebo-controlled double-blind study of venoruton in the treatment of chronic venous insufficiency. Importance of the selection of patients. Vasa1980;9(1):76-82. BlumeJ . Therapy of venous oedemas [Tratamento do edema de origem venosa]. Revista Brasileira de Medicina1994;51(3):283-8. ">Balmer 1980</a>; <a href="./references#CD003229-bbs2-0018" title="DiebschlagW , NockerW , LehmacherW , RehnD . A clinical comparison of two doses of O-(beta-hydroxyethyl) rutosides (oxerutins) in patients with chronic venous insufficiency. Journal of Pharmaceutical Medicine1994;4(1):7-14. ">Diebschlag 1994</a>; <a href="./references#CD003229-bbs2-0028" title="JongsteAB , JonkerJJC , HuismanMV , CateJW , AzarAJ . A double-blind trial on the short-term efficacy of HR in patients with the post-thrombotic syndrome. Phlebology1990;5(Suppl 1):21-2. JongsteAB , JonkerJJC , HuismanMV , den CateJW , AzarAJ . A double-blind three center clinical trial on the short-term efficacy of O-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome. Thrombosis and Haemostasis1989;62(3):826-9. ">Jongste 1989</a>; <a href="./references#CD003229-bbs2-0031" title="KoscielnnyJ , RadtkeH , Hoffmann, JungF , MüllerA , GrütznerKI , et al. Fagorutin buckwheat herb tea in chronic venous insufficiency. Zeitschrift für Phytotherapie1996;17(3):147-59. ">Koscielnny 1996</a>; <a href="./references#CD003229-bbs2-0032" title="KrinerE , BraunR , HircheH , Van LaakHH . Treatment of venous insufficiency. A double-blind trial with Phlebodril. Zeitschrift für Allgemeinmedizin1985;61(9):309-13. ">Kriner 1985</a>; <a href="./references#CD003229-bbs2-0034" title="LanguillatN . Trial of Cyclo 3 Fort in venous insufficiency of the lower limbs: Xenon 133 functional investigation of venous circulatory velocity. Pierre Fabre Medicament Laboratories (Novartis). No. Report DC982GEC130(2),1988. ">Languillat 1988</a>; <a href="./references#CD003229-bbs2-0037" title="DiklandWJ . A clinical trial on the effect of hydroxyethylrutosides on venous refilling time as measured by light reflection rheography. Scripta Phlebologica1995;3:4-7. MacLennanWJ , WilsonJ , RattenhuberV , DiklandWJ , VanerdoncktJ , MoriauM . Hydroxyethylrutosides in elderly patients with chronic venous insufficiency. Its efficacy and tolerability. Gerontology1994;40(1):45-52. ">MacLennan 1994</a>; <a href="./references#CD003229-bbs2-0041" title="NCT01848210. Efficacy and safety of coumarin and troxerutin in the symptomatic treatment of chronic venous insufficiency. clinicaltrials.gov/ct2/show/NCT01848210 (first posted 7 May 2013). ">NCT01848210</a>; <a href="./references#CD003229-bbs2-0044" title="ParradoF , BuzziA . A study of the efficacy and tolerability of a preparation containing Ruscus aculeatus in the treatment of chronic venous insufficiency of the lower limbs. Clinical Drug Investigation1999;18(4):255-61. ">Parrado 1999</a>; <a href="./references#CD003229-bbs2-0060" title="SerraldeCF , AcevesAQ . Clinical trial of the O-(β-hydroxy-ethyl-rutosides) in patients with chronic venous insufficiency [Ensayo clínico de o-(beta-hidroxietil-rutósidos) en pacientes con insuficiencia venosa crónica]. Revista Médica del Hospital General de México1990;53(2):102-6. ">Serralde 1990</a>; <a href="./references#CD003229-bbs2-0063" title="UnkaufM , RehnD , KlingerJ , MotteS , GrobmannK . Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings. Arzneimittel-Forschung1996;46(5):478-82. ">Unkauf 1996</a>; <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>; <a href="./references#CD003229-bbs2-0065" title="VanscheidtW , JostV , WolnaP , LückerA , MullerA , TheurerC , et al. Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittel-Forschung2002;52(4):243-50. ">Vanscheidt 2002b</a>; <a href="./references#CD003229-bbs2-0066" title="VinE , ChabanelA , TaccoenA , DucrosJ , GrufazJ , HutinelB , et al. Action of Veinamitol 3500 mg on clinical and hemorheological data in CVI. International Angiology1995;14(Suppl 1):99. VinF , ChabanelA , TaccoenA , DucrosJ , GruffazJ , HutinelB , et al. Action de la troxérutine sur les paramètres cliniques, pléthysmographiques et rhéologiques de l'insuffisance veineuse des membres inférieurs. Etude contrôlée contre placebo. Artères et Veines1992;XI:333-42. VinF , ChabanelA , TaccoenA , DucrosJ , GruffazJ , HutinelB , et al. Double-blind trial of the efficacy of troxerutin in chronic venous insufficiency. Phlebology1994;9(2):71-6. ">Vin 1994</a>; <a href="./references#CD003229-bbs2-0067" title="WelchW , MoriauM , vanGyselJP . A double-blind, placebo controlled trial of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Novartis1985. ">Welch 1985</a>; <a href="./references#CD003229-bbs2-0069" title="ZucarelliF . Clinical efficacy and tolerability of rutin. Double blind, placebo controlled clinical trial. [Efficacité clinique et tolerance de la coumarine rutine. Étude controlée en double aveugle versus placebo]. Gazette Médicale1987;94(32):80-6. ">Zucarelli 1987</a>), nine on hidrosmine‐diosmine (<a href="./references#CD003229-bbs2-0007" title="BilandL , BlättlerP , ScheiblerP , StuderS , WidmerK . Zur therapie sogenannt venosër beinsbeschwerden. Vasa1982;11(1):53-8. ">Biland 1982</a>; <a href="./references#CD003229-bbs2-0017" title="DanielssonG , JungbeckC , PetersonK , NorgrenL . A randomised controlled trial of micronised purified flavonoid fraction versus placebo in patients with chronic venous disease. European Journal of Vascular and Endovascular Surgery2002;23(1):73-6. ">Danielsson 2002</a>; <a href="./references#CD003229-bbs2-0020" title="DominguezC , BrautighamI , GonzálezE , GonzálezJA , NazcoJ , ValienteR , et al. Therapeutic effects of hidrosmin on chronic venous insufficiency of the lower limbs. Current Medical Research and Opinion1992;12(10):623-30. ">Dominguez 1992</a>; <a href="./references#CD003229-bbs2-0021" title="FermosoJ , LegidoAG , Del PinoJ , ValienteR . Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Current Therapeutic Research, Clinical and Experimental1992;52(1):124-34. ">Fermoso 1992</a>; <a href="./references#CD003229-bbs2-0023" title="FrileuxC , GillyR . Activité thérapeutic de Daflon 500 mg dans l'insuffisance veineuse chronique des membres inférieurs. Journal Internationale de Medicine1994;Suppl 99:36-9. GillyR , PillionG , FrileuxC . Evaluation of a new venactive micronized flavonoid fraction (S5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology1994;9(2):67-70. ThiolletM , FrileuxC , GillyR . Evaluation of a new micronized diosmin in the treatment of chronic venous incompetence: a double-blind, placebo controlled trial. Journal of Vascular Surgery1992;15(2):447. ">Gilly 1994</a>; <a href="./references#CD003229-bbs2-0024" title="GuilhouJJ , DereureO , MarzinL , OuvryP , ZuccarelliF , DebureC , et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomised, controlled versus placebo trial in 107 patients. Angiology1997;48(1):77-85. ">Guilhou 1997</a>; <a href="./references#CD003229-bbs2-0035" title="LaurentR , GillyR , FrileuxC . Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg. International Angiology1988;7(2 Suppl):39-43. ">Laurent 1988</a>; <a href="./references#CD003229-bbs2-0048" title="PlanchonB . Venous insufficiency and Daflon 500 mg [Insuffisance veineuse et Daflon 500 mg]. Artères et Veines1990;IX(4):376-80. ">Planchon 1990</a>; <a href="./references#CD003229-bbs2-0053" title="RabeE , AgusGB , RoztocilK . Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. International Angiology2015;34(5):428-36. ">Rabe 2015</a>), eight on calcium dobesilate (<a href="./references#CD003229-bbs2-0022" title="Flota-CerveraF ,  Flota-RuizC ,  TreviñoC ,  BerberA . Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology2008;59(3):352-6. FlotaLF . Prospective, randomised, double-blind, placebo controlled, clinical trial that assesses the efficacy of calcium dobesilate in the limphoedema by varicose disease [Estudio clínico prospectivo aleatorizado, doble ciego, con control placebo, para evaluar la eficacia en la resolución del edema de origen lifático, del dobesilato de calcio en pacientes con enfermedad varicosa]. Knoll de Mexico S.A. Laboratorios Dr. Esteve. No de proyec. Knoll-mex-02-99, 003/MEX, 99. ">Flota‐Cervera 2008</a>; <a href="./references#CD003229-bbs2-0025" title="HachenHJ , LorenzP . Double-blind clinical and plethysmographic study of calcium dobesilate in patients with peripheral microvascular disorders. Angiology1982;33(7):480-8. ">Hachen 1982</a>; <a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a>; <a href="./references#CD003229-bbs2-0039" title="MarinelloJ , et al. Multicentric, randomised, double-blind, placebo controlled, clinical trial that assess the efficacy of calcium dobesilate in the treatment of venous hypertension in patients with chronic venous insufficiency [Ensayo clínico multicéntrico, doble ciego, aleatorizado, controlado con placebo sobre la eficacia de dobesilato de calcio en el tratamiento de la hipertensión venosa en pacientes afectos de insuficiencia venosa crónica en sus extremidades inferiores. Código: ESCLIN-004/99]. Laboratorios Dr. Esteve. MarinelloJ , VidelaS . Chronic venous insufficiency of the lower limbs: suitability of transcutaneous blood gas monitoring as an endpoint to evaluate the outcome of pharmacological treatment with calcium dobesilate. Methods and Findings in Experimental and Clinical Pharmacology2004;26(10):775-80. ">Marinello 2002</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0054" title="RabeE , BallariniS , LehrL , Doxium EDX09/01 Study Group. A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology2016;31(4):264-74. ">Rabe 2016</a>; <a href="./references#CD003229-bbs2-0068" title="WidmerL , BilandL , BarrasJP . Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study. International Angiology1990;9(2):105-10. ">Widmer 1990</a>), one on aminaftone (<a href="./references#CD003229-bbs2-0005" title="BelczakSQ , SincosIR , CamposW , BeserraJ , NeringG , AunR . Veno-active drugs for chronic venous disease: a randomized, double-blind, placebo-controlled parallel-design trial. Phlebology2014;29(7):454-60. ">Belczak 2014</a>), one on grape seed extract (<a href="./references#CD003229-bbs2-0061" title="ThebautJF , ThebautP , VinF . Trial of vasculoprotective agent (plant products of the flavan class) in functional manifestations of peripheral venous insufficiency (double-blind trial in 92 cases). Gazette Medicale1985;92(12):96-100. ">Thebaut 1985</a>), and one on <i>Centella asiatica</i> (<a href="./references#CD003229-bbs2-0049" title="PointelJP , BoccalonH , CloarecM , Le DevehatC , JoubertM . Titrated extract of Centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology1987;38(1 Pt 1):46-50. PointelJP . Titrated extract of centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology1986;37(5):420-1. ">Pointel 1986</a>). </p> <p>We included in the meta‐analysis a total of 2944 participants treated with phlebotonics and 2845 with placebo. Phlebotonics probably increase adverse events slightly, compared to placebo (RR 1.14, 95% CI 1.02 to 1.27; 37 studies; 5789 participants; moderate‐certainty evidence; <a href="./references#CD003229-fig-0026" title="">Analysis 1.22</a>). The certainty of the evidence was downgraded by one level to moderate because of overall risk of bias (28 RCTs had unclear risk of bias and four RCTs had high risk of bias) (<a href="./full#CD003229-tbl-0001">summary of findings Table 1</a>). No differences between the subgroups was detected (test for subgroup differences: P = 0.36). </p> </section> <section id="CD003229-sec-0079"> <h5 class="title">Adverse events analyzed by active agent</h5> <section id="CD003229-sec-0080"> <h6 class="title">Aminaftone</h6> <p>Only one trial reported adverse events (<a href="./references#CD003229-bbs2-0005" title="BelczakSQ , SincosIR , CamposW , BeserraJ , NeringG , AunR . Veno-active drugs for chronic venous disease: a randomized, double-blind, placebo-controlled parallel-design trial. Phlebology2014;29(7):454-60. ">Belczak 2014</a>). One participant presented with headache in the group given Aminaftone, and two in the placebo group dropped out as the result of subjective worsening of leg pain. It is uncertain whether aminaftone reduces adverse events because the certainty of this evidence is very low (RR 0.60, 95% CI 0.06 to 6.32; 79 participants; <a href="./references#CD003229-fig-0026" title="">Analysis 1.22</a>). The certainty of the evidence was downgraded by three levels to very low because <a href="./references#CD003229-bbs2-0005" title="BelczakSQ , SincosIR , CamposW , BeserraJ , NeringG , AunR . Veno-active drugs for chronic venous disease: a randomized, double-blind, placebo-controlled parallel-design trial. Phlebology2014;29(7):454-60. ">Belczak 2014</a> had unclear risk of bias (one level) and the sample size was very small with a high imprecision in the results (two levels). </p> </section> <section id="CD003229-sec-0081"> <h6 class="title">Calcium dobesilate</h6> <p>In total, eight trials evaluated adverse events with calcium dobesilate use (<a href="./references#CD003229-bbs2-0022" title="Flota-CerveraF ,  Flota-RuizC ,  TreviñoC ,  BerberA . Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology2008;59(3):352-6. FlotaLF . Prospective, randomised, double-blind, placebo controlled, clinical trial that assesses the efficacy of calcium dobesilate in the limphoedema by varicose disease [Estudio clínico prospectivo aleatorizado, doble ciego, con control placebo, para evaluar la eficacia en la resolución del edema de origen lifático, del dobesilato de calcio en pacientes con enfermedad varicosa]. Knoll de Mexico S.A. Laboratorios Dr. Esteve. No de proyec. Knoll-mex-02-99, 003/MEX, 99. ">Flota‐Cervera 2008</a>; <a href="./references#CD003229-bbs2-0025" title="HachenHJ , LorenzP . Double-blind clinical and plethysmographic study of calcium dobesilate in patients with peripheral microvascular disorders. Angiology1982;33(7):480-8. ">Hachen 1982</a>; <a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a>; <a href="./references#CD003229-bbs2-0039" title="MarinelloJ , et al. Multicentric, randomised, double-blind, placebo controlled, clinical trial that assess the efficacy of calcium dobesilate in the treatment of venous hypertension in patients with chronic venous insufficiency [Ensayo clínico multicéntrico, doble ciego, aleatorizado, controlado con placebo sobre la eficacia de dobesilato de calcio en el tratamiento de la hipertensión venosa en pacientes afectos de insuficiencia venosa crónica en sus extremidades inferiores. Código: ESCLIN-004/99]. Laboratorios Dr. Esteve. MarinelloJ , VidelaS . Chronic venous insufficiency of the lower limbs: suitability of transcutaneous blood gas monitoring as an endpoint to evaluate the outcome of pharmacological treatment with calcium dobesilate. Methods and Findings in Experimental and Clinical Pharmacology2004;26(10):775-80. ">Marinello 2002</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0054" title="RabeE , BallariniS , LehrL , Doxium EDX09/01 Study Group. A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology2016;31(4):264-74. ">Rabe 2016</a>; <a href="./references#CD003229-bbs2-0068" title="WidmerL , BilandL , BarrasJP . Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study. International Angiology1990;9(2):105-10. ">Widmer 1990</a>). Nineteen per cent of participants in the calcium dobesilate group (179/932) experienced an adverse event and 15% (133/892) in the placebo group. Calcium dobesilate may make little or no difference to adverse events compared with placebo (RR 1.22, 95% CI 1.00 to 1.49; 8 studies 1824 participants; low‐certainty evidence). The certainty of the evidence was downgraded by 2 levels to low because of overall risk of bias (four RCTs had unclear risk of bias and one RCT had high risk of bias). The most common adverse event was a gastrointestinal event (epigastric discomfort, vomiting). No agranulocytosis or white blood cell disorders were identified. Twenty‐five participants were withdrawn from the calcium dobesilate group and 17 from the placebo group as the result of adverse events. </p> </section> <section id="CD003229-sec-0082"> <h6 class="title"><i>Centella asiatica</i> </h6> <p>One study reported information on adverse events with <i>Centalla asiatica</i> (<a href="./references#CD003229-bbs2-0049" title="PointelJP , BoccalonH , CloarecM , Le DevehatC , JoubertM . Titrated extract of Centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology1987;38(1 Pt 1):46-50. PointelJP . Titrated extract of centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology1986;37(5):420-1. ">Pointel 1986</a>). Thirty‐one per cent of participants in the <i>Centella asiatica</i> group (19/61) suffered from adverse events and 27.3% (9/33) in the placebo group. It is uncertain whether <i>Centella asiatica</i> reduces adverse events because the certainty of this evidence is very‐low (RR 1.14, 95% CI 0.58 to 2.23; 94 participants). The certainty of the evidence was downgraded by three levels to very low because <a href="./references#CD003229-bbs2-0049" title="PointelJP , BoccalonH , CloarecM , Le DevehatC , JoubertM . Titrated extract of Centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology1987;38(1 Pt 1):46-50. PointelJP . Titrated extract of centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology1986;37(5):420-1. ">Pointel 1986</a> had unclear risk of bias (one level) and the sample size was very small with a high imprecision in the results (two levels). Two participants who took <i>Centella asiatica</i> 120 mg withdrew ‐ one because of gastralgia (gastric colic) and the other because of neurological absence (absence of nerve activity). One participant taking placebo discontinued the study because of cyanosis of the extremities (bluish discolouration caused by lack of oxygen in the blood). </p> </section> <section id="CD003229-sec-0083"> <h6 class="title">Diosmine and hidrosmine</h6> <p>Nine studies reported the number of participants who experienced adverse events (<a href="./references#CD003229-bbs2-0007" title="BilandL , BlättlerP , ScheiblerP , StuderS , WidmerK . Zur therapie sogenannt venosër beinsbeschwerden. Vasa1982;11(1):53-8. ">Biland 1982</a>; <a href="./references#CD003229-bbs2-0017" title="DanielssonG , JungbeckC , PetersonK , NorgrenL . A randomised controlled trial of micronised purified flavonoid fraction versus placebo in patients with chronic venous disease. European Journal of Vascular and Endovascular Surgery2002;23(1):73-6. ">Danielsson 2002</a>; <a href="./references#CD003229-bbs2-0020" title="DominguezC , BrautighamI , GonzálezE , GonzálezJA , NazcoJ , ValienteR , et al. Therapeutic effects of hidrosmin on chronic venous insufficiency of the lower limbs. Current Medical Research and Opinion1992;12(10):623-30. ">Dominguez 1992</a>; <a href="./references#CD003229-bbs2-0021" title="FermosoJ , LegidoAG , Del PinoJ , ValienteR . Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Current Therapeutic Research, Clinical and Experimental1992;52(1):124-34. ">Fermoso 1992</a>; <a href="./references#CD003229-bbs2-0023" title="FrileuxC , GillyR . Activité thérapeutic de Daflon 500 mg dans l'insuffisance veineuse chronique des membres inférieurs. Journal Internationale de Medicine1994;Suppl 99:36-9. GillyR , PillionG , FrileuxC . Evaluation of a new venactive micronized flavonoid fraction (S5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology1994;9(2):67-70. ThiolletM , FrileuxC , GillyR . Evaluation of a new micronized diosmin in the treatment of chronic venous incompetence: a double-blind, placebo controlled trial. Journal of Vascular Surgery1992;15(2):447. ">Gilly 1994</a>; <a href="./references#CD003229-bbs2-0024" title="GuilhouJJ , DereureO , MarzinL , OuvryP , ZuccarelliF , DebureC , et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomised, controlled versus placebo trial in 107 patients. Angiology1997;48(1):77-85. ">Guilhou 1997</a>; <a href="./references#CD003229-bbs2-0035" title="LaurentR , GillyR , FrileuxC . Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg. International Angiology1988;7(2 Suppl):39-43. ">Laurent 1988</a>; <a href="./references#CD003229-bbs2-0048" title="PlanchonB . Venous insufficiency and Daflon 500 mg [Insuffisance veineuse et Daflon 500 mg]. Artères et Veines1990;IX(4):376-80. ">Planchon 1990</a>; <a href="./references#CD003229-bbs2-0053" title="RabeE , AgusGB , RoztocilK . Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. International Angiology2015;34(5):428-36. ">Rabe 2015</a>). Ninety‐nine adverse events occurred in the hidrosmine and diosmine group (99/720) and 106 (106/709) in the placebo group. Diosmine and hidrosmine may make little or no difference to adverse events compared with placebo (RR 0.93, 95% CI 0.72 to 1.19; 9 studies; 1429 participants; low‐certainty evidence). The certainty of the evidence was downgraded by two levels to low because of overall risk of bias (eight RCTs had unclear risk of bias and one RCT had high risk of bias). </p> <p>Gastrointestinal disorders were the most reported adverse events (heartburn and nausea): 14 cases were reported in the hidrosmine and diosmine group and 11 in the placebo group. </p> <p>Thirteen participants withdrew from the hidrosmine group and 12 from the placebo group as the result of adverse events. </p> </section> <section id="CD003229-sec-0084"> <h6 class="title">Grape seed extract</h6> <p>One study reported information regarding adverse events (<a href="./references#CD003229-bbs2-0061" title="ThebautJF , ThebautP , VinF . Trial of vasculoprotective agent (plant products of the flavan class) in functional manifestations of peripheral venous insufficiency (double-blind trial in 92 cases). Gazette Medicale1985;92(12):96-100. ">Thebaut 1985</a>). Eleven per cent of participants (4/35) receiving active treatment reported adverse effects (three withdrew): two participants had gastralgia, one participant had a headache and one had an allergic reaction. Twenty per cent of participants in the placebo group (8/40) experienced adverse effects (one withdrew); these included constipation, gastralgia, tiredness, dry mouth and discomfort. It is uncertain whether grape seed extract reduces adverse events because of the certainty of this evidence is very low (RR 0.57, 95% CI 0.19 to 1.74; 75 participants). The certainty of the evidence was downgraded by three levels to very low because of <a href="./references#CD003229-bbs2-0061" title="ThebautJF , ThebautP , VinF . Trial of vasculoprotective agent (plant products of the flavan class) in functional manifestations of peripheral venous insufficiency (double-blind trial in 92 cases). Gazette Medicale1985;92(12):96-100. ">Thebaut 1985</a> had unclear risk of bias (one level) and the sample size was very small with a high imprecision in the results (two levels). </p> </section> <section id="CD003229-sec-0085"> <h6 class="title">Rutoside</h6> <p>Sixteen trials reported information regarding the number of participants who experienced adverse events (<a href="./references#CD003229-bbs2-0002" title="AlterkamperH . Efficacy of antivaricotic drugs can be measured objectively. Phlebologie in der Praxis1987;2(9-10):19-20. ">Alterkamper 1987</a>; <a href="./references#CD003229-bbs2-0004" title="BalmerA , LimoniC . Clinical, placebo-controlled double-blind study of venoruton in the treatment of chronic venous insufficiency. Importance of the selection of patients. Vasa1980;9(1):76-82. BlumeJ . Therapy of venous oedemas [Tratamento do edema de origem venosa]. Revista Brasileira de Medicina1994;51(3):283-8. ">Balmer 1980</a>; <a href="./references#CD003229-bbs2-0018" title="DiebschlagW , NockerW , LehmacherW , RehnD . A clinical comparison of two doses of O-(beta-hydroxyethyl) rutosides (oxerutins) in patients with chronic venous insufficiency. Journal of Pharmaceutical Medicine1994;4(1):7-14. ">Diebschlag 1994</a>; <a href="./references#CD003229-bbs2-0028" title="JongsteAB , JonkerJJC , HuismanMV , CateJW , AzarAJ . A double-blind trial on the short-term efficacy of HR in patients with the post-thrombotic syndrome. Phlebology1990;5(Suppl 1):21-2. JongsteAB , JonkerJJC , HuismanMV , den CateJW , AzarAJ . A double-blind three center clinical trial on the short-term efficacy of O-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome. Thrombosis and Haemostasis1989;62(3):826-9. ">Jongste 1989</a>; <a href="./references#CD003229-bbs2-0031" title="KoscielnnyJ , RadtkeH , Hoffmann, JungF , MüllerA , GrütznerKI , et al. Fagorutin buckwheat herb tea in chronic venous insufficiency. Zeitschrift für Phytotherapie1996;17(3):147-59. ">Koscielnny 1996</a>; <a href="./references#CD003229-bbs2-0032" title="KrinerE , BraunR , HircheH , Van LaakHH . Treatment of venous insufficiency. A double-blind trial with Phlebodril. Zeitschrift für Allgemeinmedizin1985;61(9):309-13. ">Kriner 1985</a>; <a href="./references#CD003229-bbs2-0034" title="LanguillatN . Trial of Cyclo 3 Fort in venous insufficiency of the lower limbs: Xenon 133 functional investigation of venous circulatory velocity. Pierre Fabre Medicament Laboratories (Novartis). No. Report DC982GEC130(2),1988. ">Languillat 1988</a>; <a href="./references#CD003229-bbs2-0037" title="DiklandWJ . A clinical trial on the effect of hydroxyethylrutosides on venous refilling time as measured by light reflection rheography. Scripta Phlebologica1995;3:4-7. MacLennanWJ , WilsonJ , RattenhuberV , DiklandWJ , VanerdoncktJ , MoriauM . Hydroxyethylrutosides in elderly patients with chronic venous insufficiency. Its efficacy and tolerability. Gerontology1994;40(1):45-52. ">MacLennan 1994</a>; <a href="./references#CD003229-bbs2-0044" title="ParradoF , BuzziA . A study of the efficacy and tolerability of a preparation containing Ruscus aculeatus in the treatment of chronic venous insufficiency of the lower limbs. Clinical Drug Investigation1999;18(4):255-61. ">Parrado 1999</a>; <a href="./references#CD003229-bbs2-0060" title="SerraldeCF , AcevesAQ . Clinical trial of the O-(β-hydroxy-ethyl-rutosides) in patients with chronic venous insufficiency [Ensayo clínico de o-(beta-hidroxietil-rutósidos) en pacientes con insuficiencia venosa crónica]. Revista Médica del Hospital General de México1990;53(2):102-6. ">Serralde 1990</a>; <a href="./references#CD003229-bbs2-0063" title="UnkaufM , RehnD , KlingerJ , MotteS , GrobmannK . Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings. Arzneimittel-Forschung1996;46(5):478-82. ">Unkauf 1996</a>; <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>; <a href="./references#CD003229-bbs2-0065" title="VanscheidtW , JostV , WolnaP , LückerA , MullerA , TheurerC , et al. Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittel-Forschung2002;52(4):243-50. ">Vanscheidt 2002b</a>; <a href="./references#CD003229-bbs2-0066" title="VinE , ChabanelA , TaccoenA , DucrosJ , GrufazJ , HutinelB , et al. Action of Veinamitol 3500 mg on clinical and hemorheological data in CVI. International Angiology1995;14(Suppl 1):99. VinF , ChabanelA , TaccoenA , DucrosJ , GruffazJ , HutinelB , et al. Action de la troxérutine sur les paramètres cliniques, pléthysmographiques et rhéologiques de l'insuffisance veineuse des membres inférieurs. Etude contrôlée contre placebo. Artères et Veines1992;XI:333-42. VinF , ChabanelA , TaccoenA , DucrosJ , GruffazJ , HutinelB , et al. Double-blind trial of the efficacy of troxerutin in chronic venous insufficiency. Phlebology1994;9(2):71-6. ">Vin 1994</a>; <a href="./references#CD003229-bbs2-0067" title="WelchW , MoriauM , vanGyselJP . A double-blind, placebo controlled trial of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Novartis1985. ">Welch 1985</a>; <a href="./references#CD003229-bbs2-0069" title="ZucarelliF . Clinical efficacy and tolerability of rutin. Double blind, placebo controlled clinical trial. [Efficacité clinique et tolerance de la coumarine rutine. Étude controlée en double aveugle versus placebo]. Gazette Médicale1987;94(32):80-6. ">Zucarelli 1987</a>).Twenty per cent of participants (233/1160) in the rutoside group suffered from adverse events and 16% (181/1128) in the placebo group. Rutosids may slightly increase adverse events compared to placebo (RR 1.41, 95% CI 1.08 to 1.83; 16 studies; 2288 participants; low‐certainty evidence). The certainty of the evidence was downgraded by two levels to low because of the overall risk of bias (13 RCTs had unclear risk of bias and two had high risk of bias). The most common adverse events were gastrointestinal in nature (constipation, dry mouth, epigastric discomfort, vomiting): 127 in the rutoside group and 81 in the placebo group, followed by headache (23 in the rutoside group, 21 in the placebo group) and tiredness (17 in the rutoside group, nine in the placebo group). </p> <p>Thirteen participants withdrew from the rutoside group and 22 from the placebo group as the result of adverse events. </p> </section> </section> </section> <section id="CD003229-sec-0086"> <h4 class="title">Sensitivity analysis</h4> <section id="CD003229-sec-0087"> <h5 class="title">Exclusion of studies using compression measures (elastic stockings)</h5> <p>We carried out sensitivity analysis by re‐analysing the data excluding studies that allowed the use of elastic stockings (<a href="./references#CD003229-bbs2-0004" title="BalmerA , LimoniC . Clinical, placebo-controlled double-blind study of venoruton in the treatment of chronic venous insufficiency. Importance of the selection of patients. Vasa1980;9(1):76-82. BlumeJ . Therapy of venous oedemas [Tratamento do edema de origem venosa]. Revista Brasileira de Medicina1994;51(3):283-8. ">Balmer 1980</a>; <a href="./references#CD003229-bbs2-0019" title="Fundación Iberoamericana Itaca. Randomized, double-blind multicenter clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of ulcer secondaries to chronic venous disease. ClinicalTrials.gov2009. ">DOBESILATO500/2</a>; <a href="./references#CD003229-bbs2-0024" title="GuilhouJJ , DereureO , MarzinL , OuvryP , ZuccarelliF , DebureC , et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomised, controlled versus placebo trial in 107 patients. Angiology1997;48(1):77-85. ">Guilhou 1997</a>; <a href="./references#CD003229-bbs2-0035" title="LaurentR , GillyR , FrileuxC . Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg. International Angiology1988;7(2 Suppl):39-43. ">Laurent 1988</a>; <a href="./references#CD003229-bbs2-0037" title="DiklandWJ . A clinical trial on the effect of hydroxyethylrutosides on venous refilling time as measured by light reflection rheography. Scripta Phlebologica1995;3:4-7. MacLennanWJ , WilsonJ , RattenhuberV , DiklandWJ , VanerdoncktJ , MoriauM . Hydroxyethylrutosides in elderly patients with chronic venous insufficiency. Its efficacy and tolerability. Gerontology1994;40(1):45-52. ">MacLennan 1994</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0058" title="Schultz-EhrenburgU , MüllerB . Two multicentre clinical trials of two different dosages of O-(beta-hydroxyethyl)-rutosides in the treatment of leg ulcers. Phlebology1993;8 Suppl 1:29-30. ">Schultz‐Ehrenburg 1993</a>; <a href="./references#CD003229-bbs2-0069" title="ZucarelliF . Clinical efficacy and tolerability of rutin. Double blind, placebo controlled clinical trial. [Efficacité clinique et tolerance de la coumarine rutine. Étude controlée en double aveugle versus placebo]. Gazette Médicale1987;94(32):80-6. ">Zucarelli 1987</a>). We found that generally, results did not change, except for the following variables. </p> <p> <ul id="CD003229-list-0015"> <li> <p>Phlebotonics may reduce dichotomous variable pain (RR 0.70, 95% CI 0.60 to 0.82; 18 studies; 1818 participants, low‐certainty evidence; <a href="./references#CD003229-fig-0033" title="">Analysis 2.7</a>). The certainty of evidence was downgraded by two levels to low because of overall risk of bias (18 studies had unclear risk of bias and five had high risk of bias). No differences between the subgroups was detected (test for subgroup differences: P = 0.12). In the overall analysis, the results were very heterogeneous, so we did not pool them. </p> </li> <li> <p>Phlebotonics may reduce dichotomous variable participant satisfaction (RR 0.69, 95% CI 0.53 to 0.90; 12 studies; 1193 participants; low‐certainty evidence; <a href="./references#CD003229-fig-0046" title="">Analysis 2.20</a>). The certainty of evidence was downgraded by two levels to low because of overall risk of bias (10 studies had unclear risk of bias and one had high risk of bias). No differences between the subgroups was detected (test for subgroup differences: P = 0.33). In the overall analysis, the results were very heterogeneous, so we did not pool them. </p> </li> </ul> </p> </section> <section id="CD003229-sec-0088"> <h5 class="title">Exclusion of unpublished data</h5> <p>Only one study, which focused on rutosides, was not published (<a href="./references#CD003229-bbs2-0067" title="WelchW , MoriauM , vanGyselJP . A double-blind, placebo controlled trial of o-(beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Novartis1985. ">Welch 1985</a>). When we re‐analysed the data while excluding this study, we found results very similar to those of the main analysis for all outcomes. </p> </section> <section id="CD003229-sec-0089"> <h5 class="title">Exclusion of studies at high or unclear risk of bias</h5> <p>In judging quality levels based on the aforementioned criteria, we identified only four studies with low risk of bias (<a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>). Consequently, limited sensitivity analyses for the included variables were possible. </p> <p>Results changed only for the following variables:</p> <p> <ul id="CD003229-list-0016"> <li> <p>For the dichotomous variable of oedema, only one study on calcium dobesilate was included with a low risk of bias (<a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a>). Phlebotonics may make little or no difference in the dichotomous variable oedema compared to placebo (RR 0.99, 95% CI 0.63 to 1.55; 1 study; 260 participants; low‐certainty evidence; <a href="./references#CD003229-fig-0071" title="">Analysis 4.1</a>). The certainty of the evidence was downgraded by two levels to low because <a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a> had a small sample size and imprecision. </p> </li> <li> <p>For the continuous variable of oedema (measure of ankle circumference in mm), three studies on calcium dobesilate were included with a low risk of bias (<a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>). Based on their results, phlebotonics probably make little or no difference in the continuous variable oedema (measure of ankle circumference in mm) compared to placebo (MD ‐2.34 mm, 95% CI ‐8.79 to 4.11; 3 studies; 867 participants; moderate‐certainty evidence; <a href="./references#CD003229-fig-0072" title="">Analysis 4.2</a>). The certainty of the evidence was downgraded by one level for imprecision. </p> </li> <li> <p>For the dichotomous variable of itching, only one study on rutoside had a low risk of bias (<a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>). Phlebotonics probably reduce dichotomous variable itching, compared with placebo (RR 0.44, 95% CI 0.32 to 0.62; 231 participants; moderate‐certainty evidence; <a href="./references#CD003229-fig-0077" title="">Analysis 4.7</a>). The certainty of the evidence was downgraded by one level for imprecision. </p> </li> <li> <p>For the continuous variable of itching, one study on calcium dobesilate was at low risk of bias (<a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>). Phlebotonics probably make little or no difference to the continuous variable itching (MD 4.60 cm, 95% CI ‐5.66 to 14.86; 416 participants; moderate‐certainty evidence; <a href="./references#CD003229-fig-0078" title="">Analysis 4.8</a>). The certainty of the evidence was downgraded by one level by imprecision. </p> </li> <li> <p>For the dichotomous variable of heaviness, one study on rutoside was at low risk of bias (<a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>). Phlebotonics probably reduce the dichotomous variable heaviness compared to placebo (RR 0.62, 95% CI 0.47 to 0.82; 231 participants; moderate‐certainty evidence; <a href="./references#CD003229-fig-0079" title="">Analysis 4.9</a>). The certainty of the evidence was downgraded by one level by imprecision. </p> </li> <li> <p>For the continuous variable of heaviness, one study on calcium dobesilate was at low risk of bias (<a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>). Phlebotonics probably make little or no difference on the continuous variable heaviness compared with placebo (MD ‐2.40 cm, 95% CI ‐7.89 to 3.09; 417 participants; moderate‐certainty evidence; <a href="./references#CD003229-fig-0080" title="">Analysis 4.10</a>). The certainty of the evidence was downgraded by one level for imprecision. </p> </li> <li> <p>For the continuous variable of swelling, one study on calcium dobesilate was at low risk of bias (<a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>). Phlebotonics probably make little or no difference on the continuous variable swelling, compared to placebo (MD ‐1.30 cm, 95% CI ‐6.72 to 4.12; 417 participants; moderate‐certainty evidence; <a href="./references#CD003229-fig-0082" title="">Analysis 4.12</a>). The certainty of the evidence was downgraded by one level for imprecision. </p> </li> <li> <p>For the dichotomous variable of participant satisfaction, two studies on calcium dobesilate were at low risk of bias (<a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>). Phlebotonics probably make little or no difference on the dichotomous variable participant satisfaction compared to placebo (RR 1.04, 95% CI 0.81 to 1.32; 2 studies; 476 participants; moderate‐certainty evidence; <a href="./references#CD003229-fig-0083" title="">Analysis 4.13</a>). The certainty of the evidence was downgraded by one level for imprecision. </p> </li> <li> <p>For the continuous variable of participant satisfaction, one study on calcium dobesilate had a low risk of bias (<a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>). Phlebotonics probably improve the continuous variable participant satisfaction (MD ‐5.64, 95% CI ‐8.85 to ‐2.43; 223 participants; moderate‐ certainty evidence; <a href="./references#CD003229-fig-0084" title="">Analysis 4.14</a>). The certainty of the evidence was downgraded by one level for imprecision. </p> </li> <li> <p>For the dichotomous variable of adverse events, four studies were at low risk of bias (<a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>). Phlebotonics probably make little or no difference on the dichotomous variable adverse events compared to placebo (RR 1.59, 95% CI 0.97 to 2.63; four studies; 1257 participants; moderate‐certainty evidence; <a href="./references#CD003229-fig-0085" title="">Analysis 4.15</a>). The certainty of the evidence was downgraded by one level for imprecision (low number of events). No differences between the subgroups was detected (test for subgroup differences: P = 0.70) </p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003229-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003229-sec-0090"></div> <section id="CD003229-sec-0091"> <h3 class="title" id="CD003229-sec-0091">Summary of main results</h3> <p>We evaluated the efficacy and safety of phlebotonics in the treatment of CVI. Only analyses of studies using oral phlebotonics were possible because no identified study of topical phlebotonics met the inclusion criteria of this Cochrane Review. This Cochrane Review included 69 RCTs, and analyzed data from 56 trials involving 7690 participants. Studies included in the review generally provided objective measurement of ankle and calf oedema reduction, as well as a subjective assessment of other signs and symptoms of CVI. </p> <p>According to the ITT analysis, there was moderate‐certainty evidence of a probable beneficial effect on the dichotomous variable oedema. Analyses with continuous variables also showed a probable beneficial effect of phlebotonics on oedema (moderate‐certainty evidence). </p> <p>However, there was moderate‐certainty evidence of little or no difference in QoL with phlebotonic use compared to placebo; and little or no difference to dichotomous variable ulcer healing (low‐certainty evidence). </p> <p>Phlebotonic use probably slightly improves trophic disorders compared to placebo (moderate‐certainty evidence). Data on telangiectasia, reticular veins and varicose veins were very limited. Heterogeneity prevented meta‐analysis on dichotomous variable pain but showed phlebotonic use may reduce pain (continuous variable) compared to placebo (low‐certainty evidence). Similarly, a possible benefit was seen in cramps (moderate‐certainty evidence), restless legs (moderate‐certainty evidence); swelling in lower legs (moderate‐certainty evidence); and paraesthesia (dichotomous variable) in the lower legs (moderate‐certainty evidence). However, based on very low‐certainty evidence, it is uncertain whether phlebotonics reduce continuous variable paraesthesia. </p> <p>Heterogeneity prevented meta‐analysis on the outcomes of itching and feeling of heaviness in the lower legs. </p> <p>There was moderate‐certainty evidence that the incidence of adverse events was probably slightly increased in the phlebotonics group compared to placebo group. Gastrointestinal disorders were the most frequently reported adverse events among studies that provided this information (rutosides, calcium dobesilate, diosmine‐hidrosmine). Our review did not report agranulocytosis associated with calcium dobesilate, although this adverse effect was described in a previous case‐control study that detected potential risk of agranulocytosis, with an incidence rate of 1.21 cases per 10,000 patient‐years of treatment (<a href="./references#CD003229-bbs2-0195" title="IbañezL , BallarínE , VidalX , LaporteJR . Agranulocytosis associated with calcium dobesilate. Clinical course and risk estimation with the case-control and the case-population approaches. European Journal of Clinical Pharmacology2000;56(9-10):763-7.">Ibañez 2000</a>; <a href="./references#CD003229-bbs2-0196" title="IbáñezL , VidalX , BallarínE , LaporteJR . Population-based drug-induced agranulocytosis. Archives of Internal Medicine2005;165(8):869-74.">Ibáñez 2005</a>). This could be explained by the small number of participants in the included RCTs and the short period of participant follow‐up provided. </p> <p>The results by type of active drug showed that It is uncertain whether aminaftone reduces dichotomous variables oedema, pain, cramps, itching and heaviness (very low‐certainty evidence). There was low‐certainty evidence that aminaftone may slightly improve the continuous variables oedema (volume) and QoL, and may make little or no difference to adverse events. </p> <p>Calcium dobesilate may reduce continuous volume of the leg and may slightly improve continuous variable participant satisfaction (low‐certainty evidence); it may reduce dichotomous variable swelling and may slightly reduce the dichotomous variables pain, cramps and restless legs. Meanwhile, based on moderate‐certainty evidence, calcium dobesilate probably makes little or no difference on QoL and dichotomous variables assessment by the participant and adverse events. Furthermore, calcium dobesilate may make little or no differences on the continuous variables ankle perimeter circumference, pain and heaviness; and for the dichotomous variables heaviness and paraesthesia (low‐certainty evidence). Calcium dobesilate does not have an important effect on the continuous variables swelling, cramps and itching (high‐certainty evidence). We do not know if calcium dobesilate improves dichotomous variable oedema and ulcer healing as the certainty of the evidence is very low. </p> <p>Based on very low‐certainty evidence, it is uncertain whether <i>Centella asiatica</i> compared to placebo reduces dichotomous variable heaviness (<a href="./references#CD003229-bbs2-0049" title="PointelJP , BoccalonH , CloarecM , Le DevehatC , JoubertM . Titrated extract of Centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology1987;38(1 Pt 1):46-50. PointelJP . Titrated extract of centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology1986;37(5):420-1. ">Pointel 1986</a>), improves the dichotomous variable participant satisfaction (<a href="./references#CD003229-bbs2-0001" title="Allegra C Pollari G, CriscuoloA , BonifacioM , TabassiD . Centella asiatica extract in venous disorders of the lower limbs. Comparative clinico-instrumental studies with a placebo. Clinica Terapeutica1981;99(5):507-13. ">Allegra 1981</a>) or increases adverse events (<a href="./references#CD003229-bbs2-0049" title="PointelJP , BoccalonH , CloarecM , Le DevehatC , JoubertM . Titrated extract of Centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology1987;38(1 Pt 1):46-50. PointelJP . Titrated extract of centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology1986;37(5):420-1. ">Pointel 1986</a>). </p> <p>Diosmine and hidrosmine, based on a moderate‐certainty evidence, probably slightly reduces ankle perimeter, trophic disorders and cramps; and, probably make little or no differences in dichotomous variable pain, QoL, dichotomous variable participant satisfaction and adverse events, Additionally, based on low‐certainty evidence, they may slightly reduce oedema, cramps, heaviness, swelling and dichotomous variable participant satisfaction. Furthermore, diosmine and hidrosmine, based on low‐certainty evidence, may make little or no difference in paraesthesia, ulcer healing, continuous variable pain and dichotomous variable heaviness. We do not know if these drugs improve itching because the certainty of the evidence is very low. </p> <p>Based on very low‐certainty evidence, it is uncertain whether French maritime pine bark extract reduces pain, heaviness and swelling. For grape seed extract it is also uncertain if it reduces the dichotomous variable oedema (very low‐certainty evidence). </p> <p>Rutosides were included in the greatest number of clinical trials. Based on moderate‐certainty evidence, rutosides probably improve oedema, volume of the leg and continuous variable pain; and they probably make little or no difference in ankle perimeter and ulcer healing. Based on low‐certainty evidence, rutosides may slightly reduce heaviness, participant satisfaction, continuous variables cramps and itching, dichotomous variables pain, and paraesthesia. Furthermore, rutosides may make little or no difference in continuous variables swelling and paraesthesia and dichotomous variables trophic disorders, cramps, restless and itching. Rutosides may slightly increase adverse events (low‐certainty evidence). </p> <p>No evidence was found regarding the efficacy of disodium flavodate, naftazone, chromocarbe or topical phlebotonics. </p> <p>Sensitivity analyses did not alter the results of this review. Whether elastic stockings were used did not influence pooled results, supporting the view that an appropriate randomisation method results in a homogeneous distribution of the groups under comparison. </p> </section> <section id="CD003229-sec-0092"> <h3 class="title" id="CD003229-sec-0092">Overall completeness and applicability of evidence</h3> <p>Several limitations were identified in the included studies. Only one of five studies specified standard diagnostic criteria for CVI, and different studies applied different criteria. Only eleven studies used the currently accepted CEAP classification (<a href="./references#CD003229-bbs2-0207" title="PorterJM , MonetaGL . Reporting standards in venous disease: an update. International Consensus Committee on Chronic Venous Disease. Journal of Vascular Surgery1995;21(4):635-45.">Porter 1995</a>) (<a href="./references#CD003229-bbs2-0005" title="BelczakSQ , SincosIR , CamposW , BeserraJ , NeringG , AunR . Veno-active drugs for chronic venous disease: a randomized, double-blind, placebo-controlled parallel-design trial. Phlebology2014;29(7):454-60. ">Belczak 2014</a>; <a href="./references#CD003229-bbs2-0017" title="DanielssonG , JungbeckC , PetersonK , NorgrenL . A randomised controlled trial of micronised purified flavonoid fraction versus placebo in patients with chronic venous disease. European Journal of Vascular and Endovascular Surgery2002;23(1):73-6. ">Danielsson 2002</a>; <a href="./references#CD003229-bbs2-0019" title="Fundación Iberoamericana Itaca. Randomized, double-blind multicenter clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of ulcer secondaries to chronic venous disease. ClinicalTrials.gov2009. ">DOBESILATO500/2</a>; <a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a>; <a href="./references#CD003229-bbs2-0039" title="MarinelloJ , et al. Multicentric, randomised, double-blind, placebo controlled, clinical trial that assess the efficacy of calcium dobesilate in the treatment of venous hypertension in patients with chronic venous insufficiency [Ensayo clínico multicéntrico, doble ciego, aleatorizado, controlado con placebo sobre la eficacia de dobesilato de calcio en el tratamiento de la hipertensión venosa en pacientes afectos de insuficiencia venosa crónica en sus extremidades inferiores. Código: ESCLIN-004/99]. Laboratorios Dr. Esteve. MarinelloJ , VidelaS . Chronic venous insufficiency of the lower limbs: suitability of transcutaneous blood gas monitoring as an endpoint to evaluate the outcome of pharmacological treatment with calcium dobesilate. Methods and Findings in Experimental and Clinical Pharmacology2004;26(10):775-80. ">Marinello 2002</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0053" title="RabeE , AgusGB , RoztocilK . Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. International Angiology2015;34(5):428-36. ">Rabe 2015</a>; <a href="./references#CD003229-bbs2-0054" title="RabeE , BallariniS , LehrL , Doxium EDX09/01 Study Group. A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology2016;31(4):264-74. ">Rabe 2016</a>; <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>; <a href="./references#CD003229-bbs2-0065" title="VanscheidtW , JostV , WolnaP , LückerA , MullerA , TheurerC , et al. Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittel-Forschung2002;52(4):243-50. ">Vanscheidt 2002b</a>). Therefore, homogeneity in diagnostic criteria is limited, and potential misclassification bias cannot be ruled out. Furthermore, we were unable to perform subgroup analysis by CVI stage because the severity of CVI was variable. </p> <p>In most RCTs, the way in which participants were included is heterogeneous, and this may have led to differences in response to treatment. In addition, too few participants were included in the studies with the limitations of imprecision in the results and lack of statistical power to detect a difference between phlebotonics and placebo, when an effect could have occurred (beta error, or type II error). Different instruments were used to measure signs and symptoms, and sometimes results were inconclusive. Only seven RCTs assessed the variable QoL using a standardized questionnaire (<a href="./references#CD003229-bbs2-0005" title="BelczakSQ , SincosIR , CamposW , BeserraJ , NeringG , AunR . Veno-active drugs for chronic venous disease: a randomized, double-blind, placebo-controlled parallel-design trial. Phlebology2014;29(7):454-60. ">Belczak 2014</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0053" title="RabeE , AgusGB , RoztocilK . Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. International Angiology2015;34(5):428-36. ">Rabe 2015</a>; <a href="./references#CD003229-bbs2-0054" title="RabeE , BallariniS , LehrL , Doxium EDX09/01 Study Group. A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology2016;31(4):264-74. ">Rabe 2016</a>;<a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>; <a href="./references#CD003229-bbs2-0065" title="VanscheidtW , JostV , WolnaP , LückerA , MullerA , TheurerC , et al. Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittel-Forschung2002;52(4):243-50. ">Vanscheidt 2002b</a>), but two studies did not provide quantifiable information (<a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>; <a href="./references#CD003229-bbs2-0065" title="VanscheidtW , JostV , WolnaP , LückerA , MullerA , TheurerC , et al. Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittel-Forschung2002;52(4):243-50. ">Vanscheidt 2002b</a>). Although some studies favoured phlebotonics, the clinical relevance of these findings remains questionable. </p> <p>Although infrequent, important signs such as venous ulcers have been poorly evaluated. Only six studies included participants with venous ulcers and when pooled, showed none that yielded a difference in ulcer healing (<a href="./references#CD003229-bbs2-0019" title="Fundación Iberoamericana Itaca. Randomized, double-blind multicenter clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of ulcer secondaries to chronic venous disease. ClinicalTrials.gov2009. ">DOBESILATO500/2</a>; <a href="./references#CD003229-bbs2-0021" title="FermosoJ , LegidoAG , Del PinoJ , ValienteR . Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Current Therapeutic Research, Clinical and Experimental1992;52(1):124-34. ">Fermoso 1992</a>; <a href="./references#CD003229-bbs2-0024" title="GuilhouJJ , DereureO , MarzinL , OuvryP , ZuccarelliF , DebureC , et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomised, controlled versus placebo trial in 107 patients. Angiology1997;48(1):77-85. ">Guilhou 1997</a>; <a href="./references#CD003229-bbs2-0036" title="LazzariniA , DanieliL . Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers [Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche]. Rassegna Internazionale di Clinica e Terapia1982;62(12):825-44. ">Lazzarini 1982</a>; <a href="./references#CD003229-bbs2-0037" title="DiklandWJ . A clinical trial on the effect of hydroxyethylrutosides on venous refilling time as measured by light reflection rheography. Scripta Phlebologica1995;3:4-7. MacLennanWJ , WilsonJ , RattenhuberV , DiklandWJ , VanerdoncktJ , MoriauM . Hydroxyethylrutosides in elderly patients with chronic venous insufficiency. Its efficacy and tolerability. Gerontology1994;40(1):45-52. ">MacLennan 1994</a>; <a href="./references#CD003229-bbs2-0058" title="Schultz-EhrenburgU , MüllerB . Two multicentre clinical trials of two different dosages of O-(beta-hydroxyethyl)-rutosides in the treatment of leg ulcers. Phlebology1993;8 Suppl 1:29-30. ">Schultz‐Ehrenburg 1993</a>). </p> <p>Only two studies addressing trophic disorders defined this term (<a href="./references#CD003229-bbs2-0037" title="DiklandWJ . A clinical trial on the effect of hydroxyethylrutosides on venous refilling time as measured by light reflection rheography. Scripta Phlebologica1995;3:4-7. MacLennanWJ , WilsonJ , RattenhuberV , DiklandWJ , VanerdoncktJ , MoriauM . Hydroxyethylrutosides in elderly patients with chronic venous insufficiency. Its efficacy and tolerability. Gerontology1994;40(1):45-52. ">MacLennan 1994</a>; <a href="./references#CD003229-bbs2-0048" title="PlanchonB . Venous insufficiency and Daflon 500 mg [Insuffisance veineuse et Daflon 500 mg]. Artères et Veines1990;IX(4):376-80. ">Planchon 1990</a>), and four did not (<a href="./references#CD003229-bbs2-0021" title="FermosoJ , LegidoAG , Del PinoJ , ValienteR . Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Current Therapeutic Research, Clinical and Experimental1992;52(1):124-34. ">Fermoso 1992</a>; <a href="./references#CD003229-bbs2-0023" title="FrileuxC , GillyR . Activité thérapeutic de Daflon 500 mg dans l'insuffisance veineuse chronique des membres inférieurs. Journal Internationale de Medicine1994;Suppl 99:36-9. GillyR , PillionG , FrileuxC . Evaluation of a new venactive micronized flavonoid fraction (S5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology1994;9(2):67-70. ThiolletM , FrileuxC , GillyR . Evaluation of a new micronized diosmin in the treatment of chronic venous incompetence: a double-blind, placebo controlled trial. Journal of Vascular Surgery1992;15(2):447. ">Gilly 1994</a>; <a href="./references#CD003229-bbs2-0035" title="LaurentR , GillyR , FrileuxC . Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg. International Angiology1988;7(2 Suppl):39-43. ">Laurent 1988</a>; <a href="./references#CD003229-bbs2-0036" title="LazzariniA , DanieliL . Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers [Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche]. Rassegna Internazionale di Clinica e Terapia1982;62(12):825-44. ">Lazzarini 1982</a>). However, in two studies, trophic disorders were assessed subjectively as present or absent (<a href="./references#CD003229-bbs2-0021" title="FermosoJ , LegidoAG , Del PinoJ , ValienteR . Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Current Therapeutic Research, Clinical and Experimental1992;52(1):124-34. ">Fermoso 1992</a>; <a href="./references#CD003229-bbs2-0037" title="DiklandWJ . A clinical trial on the effect of hydroxyethylrutosides on venous refilling time as measured by light reflection rheography. Scripta Phlebologica1995;3:4-7. MacLennanWJ , WilsonJ , RattenhuberV , DiklandWJ , VanerdoncktJ , MoriauM . Hydroxyethylrutosides in elderly patients with chronic venous insufficiency. Its efficacy and tolerability. Gerontology1994;40(1):45-52. ">MacLennan 1994</a>), or as reported on semi‐quantitative four‐item scales (<a href="./references#CD003229-bbs2-0023" title="FrileuxC , GillyR . Activité thérapeutic de Daflon 500 mg dans l'insuffisance veineuse chronique des membres inférieurs. Journal Internationale de Medicine1994;Suppl 99:36-9. GillyR , PillionG , FrileuxC . Evaluation of a new venactive micronized flavonoid fraction (S5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology1994;9(2):67-70. ThiolletM , FrileuxC , GillyR . Evaluation of a new micronized diosmin in the treatment of chronic venous incompetence: a double-blind, placebo controlled trial. Journal of Vascular Surgery1992;15(2):447. ">Gilly 1994</a>; <a href="./references#CD003229-bbs2-0036" title="LazzariniA , DanieliL . Clinical controlled trial of aminaphtone in lower limbs' phlebopathies and phlebopathic ulcers [Sperimentazione clinica controllata del l´aminaftone flebopatie degli arti inferiori e nelle flebopatiche]. Rassegna Internazionale di Clinica e Terapia1982;62(12):825-44. ">Lazzarini 1982</a>; <a href="./references#CD003229-bbs2-0048" title="PlanchonB . Venous insufficiency and Daflon 500 mg [Insuffisance veineuse et Daflon 500 mg]. Artères et Veines1990;IX(4):376-80. ">Planchon 1990</a>). Therefore, although data from the examination of trophic alterations were analyzed, these results should be interpreted with caution. </p> <p>Most studies provided short‐term results (one to three months). Specificaly, for the primary outcome 'oedema in the lower limb,' the median time of follow‐up was 49 days for oedema measured as a dichotomous outcome and 60 days for oedema measures as a continuous outcome. Given the chronic nature of the disease, more long‐term data on the efficacy and safety of phlebotonics are needed (at least one‐year follow‐up). To achieve homogeneous data collection and to specify evidence on the efficacy of phlebotonics, measurement of signs and symptoms should be standardized. Although we have done a subgroup analysis by drugs, we noted that different doses were involved, and we are unable to comment on which is the optimal dose. </p> </section> <section id="CD003229-sec-0093"> <h3 class="title" id="CD003229-sec-0093">Quality of the evidence</h3> <p>Risk of bias of the included studies is somewhat unclear regarding randomisation and blinding because only a limited number of studies specifically reported details regarding these issues. It is difficult to determine whether this is a result of poor design or publication restrictions. As a result, among the 69 RCTs included in this review, only 39 explained the double‐blinding procedure in detail, 18 provided data on randomisation and 10 explained blinding of the randomisation. Furthermore, seven studies had attrition bias and nine selective reporting with high risk of bias. These issues were not addressed in the remaining included studies, and this adds uncertainty to the evidence. Only four studies were graded as having an overall low risk of bias (<a href="./references#CD003229-bbs2-0033" title="JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. Double-blind, placebo-controlled multicentre study. International Angiology2001;20(2 Suppl 1):239. JaegerK . Efficacy and safety of doxium in chronic venous insufficiency. OM PHARMA (LAB. ESTEVE). Study number: DX-1994/2. LabsKH , DegischerS , GambaG , JaegerKA , on behalf of the CVI Study Group. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phebology2004;19(3):123-9. ">Labs 2004</a>; <a href="./references#CD003229-bbs2-0040" title="Martinez-ZapataMJ , MorenoRM , GichI , UrrútiaG , BonfillX , Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. European Journal of Vascular and Endovascular Surgery2008;35(3):358-65. ">Martinez‐Zapata 2008</a>; <a href="./references#CD003229-bbs2-0052" title="RabeE , JaegerKA , BulittaM , PannierF . Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology2011;26:162–8. ">Rabe 2011</a>; <a href="./references#CD003229-bbs2-0064" title="VanscheidtW , RabeE , Naser-HijaziB , RameletAA , PartschH , DiehmC , et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa2002;31(3):185-90. ">Vanscheidt 2002a</a>). </p> <p>In the clinical area of CVI, results lack reliability if the RCT did not include a placebo group because of seasonal exacerbations (spring and summer) that might be self limiting and highly subjective symptoms. Consequently, an adequate control group is needed, and both randomisation and treatment should be appropriately blinded (preferably double‐blinded). For this reason, studies that did not include a control group and single‐blinded studies were excluded from the review. Among studies identified as double‐blinded, those with inappropriate blinding of treatments or randomisation were excluded from the meta‐analyses. </p> <p>We adopted a conservative approach in our review, which prioritised the ITT analysis in terms of both treatment losses and failures. On the other hand, we used change measures only if conditions of the compared groups at baseline were the same, to avoid bias in the assessment of results related to participants' baseline differences. </p> <p>We evaluated the certainty of the body of evidence using the GRADE approach (<a href="./references#CD003229-bbs2-0211" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and “Summary of findings” tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of interventions Version 5.1.0. London, UK: The Cochrane Collaboration. www.cochrane-handbook.org, 2011.">Schünemann 2011</a>), which is based on five considerations including risk of bias (study limitations), directness of the evidence, heterogeneity in the data, precision of effect estimates and additional considerations (including risk of publication bias) to assess the certainty of the body of evidence for a priori selected outcomes (in our review, these included the dichotomous variable of oedema in the lower legs and the continuous variables of oedema in the lower legs, QoL, participants with ulcer healing and participants with adverse events) (<a href="./full#CD003229-tbl-0001">summary of findings Table 1</a>). </p> <p>With this approach, the overall certainty of evidence is ranked from very low (paraesthesia (continuous variable) to moderate (dichotomous and continuous outcomes of oedema and adverse events; cramps, restless legs, swelling and paraesthesia (dichotomous variable). </p> <p>Reasons for downgrading the certainty of evidence for the outcome ulcer healing include the presence of selective reporting and incomplete outcome data; for the outcome QoL, we downgraded for incomplete outcome data and imprecision (wide confidence intervals); for the dichotomous variables measurement of oedema we downgraded for incomplete outcome data; and for the continuous variable oedema we downgraded for unclear risk of bias of one trial; for the outcome adverse events we downgraded for incomplete outcome data and indirectness (moderate heterogeneity). See <a href="./full#CD003229-tbl-0001">summary of findings Table 1</a>. </p> </section> <section id="CD003229-sec-0094"> <h3 class="title" id="CD003229-sec-0094">Potential biases in the review process</h3> <p>Any systematic review is influenced by the quality of included studies and reports. In this respect, we classified only four RCTs as having low risk of bias, and we considered most included studies to have moderate risk of potential bias. We excluded RCTs with high risk of bias. Therefore, conclusions about the results of these studies should be interpreted with caution. </p> <p>The heterogeneity of several analysis variables may be due to the following:</p> <p> <ul id="CD003229-list-0017"> <li> <p>Different diagnosis classification criteria have been applied; therefore, characteristics of the included population in terms of degree of progression of CVI might vary among studies. </p> </li> <li> <p>No standardisation is involved in measuring variables, given the different scales that have been used, some of which are not validated. Although the same criteria were applied to the data dichotomisation (participants without symptoms/signs or with mild symptoms/sign versus participants with moderate to severe symptoms/signs), these may not be equally relevant, as they result from the application of different scales. </p> </li> <li> <p>On the other hand, the same subjectivity of collected variables may represent differences among individuals and may influence the variability of results. </p> </li> <li> <p>In addition, efficacy of evaluated treatments may not be the same because different active principles were used. This explains observed differences among treatments in the subgroup analysis. </p> </li> </ul> </p> <p>All these considerations limit the validity of included clinical trials and the conclusions of this review. The existence of such heterogeneity restricts the importance of its detection in the process of generating hypotheses (i.e. phlebotonics could be effective for treatment of the pain, cramps, heaviness and swelling of CVI). </p> <p>Only 54% of included studies reported information on adverse events. However, to adequately assess adverse events related to phlebotonics, it is necessary to include observational study designs that were excluded from our review. </p> </section> <section id="CD003229-sec-0095"> <h3 class="title" id="CD003229-sec-0095">Agreements and disagreements with other studies or reviews</h3> <p>Several reviews have tried to evaluate the clinical benefit of phlebotonics. Some of these used poor methods, which did not include information on search strategies and data collection sources, extraction and statistical treatment (diosmine, escin and rutosides (<a href="./references#CD003229-bbs2-0190" title="DiehmC . The role of oedema protective drugs in the treatment of chronic venous insufficiency: a review of evidence based on placebo-controlled clinical trials with regard to efficacy and tolerance. Phlebology1996;11(1):23-9.">Diehm 1996b</a>); flavonoids, tribenosides, escin and calcium dobesilate (<a href="./references#CD003229-bbs2-0203" title="MarkwardtF . Pharmacology of oedema protective drugs. Phlebology1996;11(1):10-5.">Markwardt 1996</a>); rutosides (<a href="./references#CD003229-bbs2-0218" title="WadworthAN , FauldsD . Hydroxyethylrutosides. A review of its pharmacology and therapeutic efficacy in venous insufficiency and related disorders. Drugs1992;44(6):1013-32.">Wadworth 1992</a>); flavonoids (<a href="./references#CD003229-bbs2-0209" title="RabeE , GuexJJ , MorrisonN , RameletAA , Schuller-PetrovicS , ScuderiA , et al. Treatment of chronic venous disease with flavonoids: recommendations for treatment and further studies. [Review]. Phlebology2013;28(6):308-19.">Rabe 2013</a>)). Other reviews are more elaborate and were developed systematically (global phlebotonics (<a href="./references#CD003229-bbs2-0182" title="BoadaJN , NazcoGJ . Therapeutic effect of venotonics in chronic venous insufficiency. A meta-analysis. Clinical Drug Investigation1999;18(6):413-32.">Boada 1999</a>); calcium dobesilate (<a href="./references#CD003229-bbs2-0186" title="CiapponiA , LaffaireE , RoqueM . Calcium dobesilate for chronic venous insufficiency: a systematic review. Angiology2004;55(2):147-54.">Ciapponi 2004</a>); escin (<a href="./references#CD003229-bbs2-0205" title="PittlerMH , ErnstE . Horse-Chestnut seed extract for chronic venous insufficiency: a criteria-based systematic review. Archives of Dermatology1998;134(11):1356-60.">Pittler 1998</a>); rutosides (<a href="./references#CD003229-bbs2-0180" title="AzizZ , TangWL , ChongNJ , ThoLY . A systematic review of the efficacy and tolerability of hydroxyethylrutosides for improvement of the signs and symptoms of chronic venous insufficiency. Journal of Clinical Pharmacy and Therapeutics2015;40(2):177-85.">Aziz 2015</a>; <a href="./references#CD003229-bbs2-0208" title="PoynardT , ValterioC . Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. Vasa1994;23(3):244-50.">Poynard 1994</a>); flavonoids (<a href="./references#CD003229-bbs2-0198" title="KakkosSK , NicolaidesAN . Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms,signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol2018;37:143-54.">Kakkos 2018</a>)). Five reviews pursued data meta‐analysis (<a href="./references#CD003229-bbs2-0180" title="AzizZ , TangWL , ChongNJ , ThoLY . A systematic review of the efficacy and tolerability of hydroxyethylrutosides for improvement of the signs and symptoms of chronic venous insufficiency. Journal of Clinical Pharmacy and Therapeutics2015;40(2):177-85.">Aziz 2015</a>; <a href="./references#CD003229-bbs2-0182" title="BoadaJN , NazcoGJ . Therapeutic effect of venotonics in chronic venous insufficiency. A meta-analysis. Clinical Drug Investigation1999;18(6):413-32.">Boada 1999</a>; <a href="./references#CD003229-bbs2-0186" title="CiapponiA , LaffaireE , RoqueM . Calcium dobesilate for chronic venous insufficiency: a systematic review. Angiology2004;55(2):147-54.">Ciapponi 2004</a>; <a href="./references#CD003229-bbs2-0198" title="KakkosSK , NicolaidesAN . Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms,signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol2018;37:143-54.">Kakkos 2018</a>; <a href="./references#CD003229-bbs2-0208" title="PoynardT , ValterioC . Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. Vasa1994;23(3):244-50.">Poynard 1994</a>). </p> <p>One review specifically evaluated hydroxyethyl rutosides and the review authors included 15 randomised studies and applied a per‐protocol (PP) analysis. They stated that rutosides were better than control for controlling symptoms of pain, cramps and heaviness (<a href="./references#CD003229-bbs2-0180" title="AzizZ , TangWL , ChongNJ , ThoLY . A systematic review of the efficacy and tolerability of hydroxyethylrutosides for improvement of the signs and symptoms of chronic venous insufficiency. Journal of Clinical Pharmacy and Therapeutics2015;40(2):177-85.">Aziz 2015</a>). </p> <p>Another review analyzed rutosides and the review authors included 12 randomised, double‐blind, placebo‐controlled studies and applied an ITT analysis. They stated that rutosides were better than placebo for controlling symptoms of pain, cramps, heaviness, swelling and tiredness of affected legs. They did not mention CVI signs (<a href="./references#CD003229-bbs2-0208" title="PoynardT , ValterioC . Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. Vasa1994;23(3):244-50.">Poynard 1994</a>). </p> <p><a href="./references#CD003229-bbs2-0182" title="BoadaJN , NazcoGJ . Therapeutic effect of venotonics in chronic venous insufficiency. A meta-analysis. Clinical Drug Investigation1999;18(6):413-32.">Boada 1999</a> reviewed all drugs that have been evaluated for CVI through randomised, double‐blind, placebo‐controlled trials without concomitant compression procedures. These included traditional agents such as hidrosmine, diosmine, escin, rutosides and calcium dobesilate, along with other, less usual ones such as extract of <i>Centella asiatica</i>, benzarone, tribenoside, flunarizine, dihydroergotamine mesylate and mucopolysaccharide sulphate. The conclusion of the <a href="./references#CD003229-bbs2-0182" title="BoadaJN , NazcoGJ . Therapeutic effect of venotonics in chronic venous insufficiency. A meta-analysis. Clinical Drug Investigation1999;18(6):413-32.">Boada 1999</a> review was that phlebotonics might improve leg heaviness in patients with CVI. Review authors presented no conclusive data regarding other signs or symptoms, performed PP rather than ITT analysis and provided no information on individual phlebotonics (<a href="./references#CD003229-bbs2-0182" title="BoadaJN , NazcoGJ . Therapeutic effect of venotonics in chronic venous insufficiency. A meta-analysis. Clinical Drug Investigation1999;18(6):413-32.">Boada 1999</a>). </p> <p>The review led by <a href="./references#CD003229-bbs2-0186" title="CiapponiA , LaffaireE , RoqueM . Calcium dobesilate for chronic venous insufficiency: a systematic review. Angiology2004;55(2):147-54.">Ciapponi 2004</a> analyzed calcium dobesilate and the review authors included 10 double‐blind, randomised, placebo‐controlled studies and applied a PP analysis. They stated that calcium dobesilate was better than placebo for controlling cramps and discomfort. Subgroup analysis showed greater efficacy in more severe cases of the disease in terms of improving symptoms (pain, heaviness and swelling) and signs (leg volume). Sensitivity analysis based on the ITT analysis did not influence these results (<a href="./references#CD003229-bbs2-0186" title="CiapponiA , LaffaireE , RoqueM . Calcium dobesilate for chronic venous insufficiency: a systematic review. Angiology2004;55(2):147-54.">Ciapponi 2004</a>). </p> <p><a href="./references#CD003229-bbs2-0198" title="KakkosSK , NicolaidesAN . Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms,signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol2018;37:143-54.">Kakkos 2018</a> evaluated the efficacy of a micronized purified flavonoid fraction (diosmine) in CVD. The systematic review included seven double‐blind, randomised, placebo‐controlled studies. Their results showed a significant improvement for diosmine with respect to signs and symptoms related to CVD, QoL and treatment assessment by the physician. Although our review presents some differences because we pooled studies assessing diosmine and hidrosmine, except for QoL, the general results are in agreement with <a href="./references#CD003229-bbs2-0198" title="KakkosSK , NicolaidesAN . Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms,signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol2018;37:143-54.">Kakkos 2018</a>. </p> <p>With the exception of <a href="./references#CD003229-bbs2-0180" title="AzizZ , TangWL , ChongNJ , ThoLY . A systematic review of the efficacy and tolerability of hydroxyethylrutosides for improvement of the signs and symptoms of chronic venous insufficiency. Journal of Clinical Pharmacy and Therapeutics2015;40(2):177-85.">Aziz 2015</a> and <a href="./references#CD003229-bbs2-0198" title="KakkosSK , NicolaidesAN . Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms,signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol2018;37:143-54.">Kakkos 2018</a>, the above‐cited reviews were published some time ago and have not been updated. Our review provides an update regarding evidence on phlebotonics in general and by drug group. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003229-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Phlebotonics vs placebo, outcome: 1.1 Oedema in the lower legs (dichotomous variable)." data-id="CD003229-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Phlebotonics vs placebo, outcome: 1.1 Oedema in the lower legs (dichotomous variable). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003229-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD003229-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD003229-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 1: Oedema in the lower legs (dichotomous variable)" data-id="CD003229-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 1: Oedema in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 2: Ankle perimeter circumference (mm)" data-id="CD003229-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 2: Ankle perimeter circumference (mm) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 3: Volume of the leg (mL)" data-id="CD003229-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 3: Volume of the leg (mL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 4: Quality of life" data-id="CD003229-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 4: Quality of life</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 5: Ulcer healing" data-id="CD003229-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 5: Ulcer healing</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 6: Trophic disorders (dichotomous variable)" data-id="CD003229-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 6: Trophic disorders (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 7: Pain in the lower legs (dichotomous variable)" data-id="CD003229-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 7: Pain in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 8: Pain in the lower legs (continuous variable)" data-id="CD003229-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 8: Pain in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 9: Cramps in the lower legs (dichotomous variable)" data-id="CD003229-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 9: Cramps in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 10: Cramps in the lower legs (continuous variable)" data-id="CD003229-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 10: Cramps in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 11: Restless legs (dichotomous variable)" data-id="CD003229-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 11: Restless legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 12: Itching in the lower legs (dichotomous variable)" data-id="CD003229-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 12: Itching in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 13: Itching in the lower legs (continuous variable)" data-id="CD003229-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 13: Itching in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 14: Heaviness in the lower legs (dichotomous variable)" data-id="CD003229-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 14: Heaviness in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 15: Heaviness in the lower legs (continuous variable)" data-id="CD003229-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 15: Heaviness in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 16: Swelling in the lower legs (dichotomous variable)" data-id="CD003229-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 16: Swelling in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 17: Swelling in the lower legs (continuous variable)" data-id="CD003229-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 17: Swelling in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 18: Paraesthesia in the lower legs (dichotomous variable)" data-id="CD003229-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 18: Paraesthesia in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 19: Paraesthesia in the lower legs (continuous variable)" data-id="CD003229-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 19: Paraesthesia in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 20: Participant satisfaction (dichotomous variable)" data-id="CD003229-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 20: Participant satisfaction (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 21: Participant satisfaction (continuous variable)" data-id="CD003229-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 21: Participant satisfaction (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phlebotonics versus placebo, Outcome 22: Adverse events" data-id="CD003229-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Phlebotonics versus placebo, Outcome 22: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 1: Oedema in the lower legs (dichotomous variable)" data-id="CD003229-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 1: Oedema in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 2: Ankle perimeter circumference (mm)" data-id="CD003229-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 2: Ankle perimeter circumference (mm) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 3: Volume of the leg (mL)" data-id="CD003229-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 3: Volume of the leg (mL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 4: Quality of life" data-id="CD003229-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 4: Quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 5: Ulcer healing" data-id="CD003229-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 5: Ulcer healing </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 6: Trophic disorders (dichotomous variable)" data-id="CD003229-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 6: Trophic disorders (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 7: Pain in the lower legs (dichotomous variable)" data-id="CD003229-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 7: Pain in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 8: Pain in the lower legs (continuous variable)" data-id="CD003229-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 8: Pain in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 9: Cramps in the lower legs (dichotomous variable)" data-id="CD003229-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 9: Cramps in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 10: Cramps in the lower legs (continuous variable)" data-id="CD003229-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 10: Cramps in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 11: Restless legs (dichotomous variable)" data-id="CD003229-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 11: Restless legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 12: Itching in the lower legs (dichotomous variable)" data-id="CD003229-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 12: Itching in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 13: Itching in the lower legs (continuous variable)" data-id="CD003229-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 13: Itching in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 14: Heaviness in the lower legs (dichotomous variable)" data-id="CD003229-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 14: Heaviness in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 15: Heaviness in the lower legs (continuous variable)" data-id="CD003229-fig-0041" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 15: Heaviness in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 16: Swelling in the lower legs (dichotomous variable)" data-id="CD003229-fig-0042" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 16: Swelling in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 17: Swelling in the lower legs (continuous variable)" data-id="CD003229-fig-0043" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 17: Swelling in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 18: Paraesthesias in the lower legs (dichotomous variable)" data-id="CD003229-fig-0044" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 18: Paraesthesias in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 19: Paraesthesias in the lower legs (continuous variable)" data-id="CD003229-fig-0045" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 19: Paraesthesias in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 20: Participant satisfaction (dichotomous variable)" data-id="CD003229-fig-0046" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 20: Participant satisfaction (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 21: Participant satisfaction (continuous variable)" data-id="CD003229-fig-0047" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 21: Participant satisfaction (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-002.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 22: Adverse events" data-id="CD003229-fig-0048" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-002.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis excluding studies that allowed the use of elastic stockings, Outcome 22: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-002.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 1: Oedema in the lower legs (dichotomous variable)" data-id="CD003229-fig-0049" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 1: Oedema in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 2: Ankle perimeter circumference (mm)" data-id="CD003229-fig-0050" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 2: Ankle perimeter circumference (mm) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 3: Volume of the leg (mL)" data-id="CD003229-fig-0051" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 3: Volume of the leg (mL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 4: Quality of life" data-id="CD003229-fig-0052" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 4: Quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 5: Patients with ulcer (dichotomous variable)" data-id="CD003229-fig-0053" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 5: Patients with ulcer (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 6: Trophic disorders (dichotomous variable)" data-id="CD003229-fig-0054" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 6: Trophic disorders (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 7: Pain in the lower legs (dichotomous variable)" data-id="CD003229-fig-0055" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 7: Pain in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 8: Pain in the lower legs (continuous variable)" data-id="CD003229-fig-0056" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 8: Pain in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 9: Cramps in the lower legs (dichotomous variable)" data-id="CD003229-fig-0057" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 9: Cramps in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 10: Cramps in the lower legs (continuous variable)" data-id="CD003229-fig-0058" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 10: Cramps in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 11: Restless legs (dichotomous variable)" data-id="CD003229-fig-0059" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 11: Restless legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 12: Itching in the lower legs (dichotomous variable)" data-id="CD003229-fig-0060" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 12: Itching in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 13: Itching in the lower legs (continuous variable)" data-id="CD003229-fig-0061" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 13: Itching in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 14: Heaviness in the lower legs (dichotomous variable)" data-id="CD003229-fig-0062" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 14: Heaviness in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 15: Heaviness in the lower legs (continuous variable)" data-id="CD003229-fig-0063" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 15: Heaviness in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 16: Swelling in the lower legs (dichotomous variable)" data-id="CD003229-fig-0064" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 16: Swelling in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 17: Swelling in the lower legs (continuous variable)" data-id="CD003229-fig-0065" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 17: Swelling in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 18: Paraesthesias in the lower legs (dichotomous variable)" data-id="CD003229-fig-0066" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 18: Paraesthesias in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 19: Paraesthesias in the lower legs (continuous variable)" data-id="CD003229-fig-0067" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 19: Paraesthesias in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 20: Participant satisfaction (dichotomous variable)" data-id="CD003229-fig-0068" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 20: Participant satisfaction (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 21: Participant satisfaction (continuous variable)" data-id="CD003229-fig-0069" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.21</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 21: Participant satisfaction (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-003.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sensitivity analysis of published studies only, Outcome 22: Adverse events" data-id="CD003229-fig-0070" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-003.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.22</div> <div class="figure-caption"> <p>Comparison 3: Sensitivity analysis of published studies only, Outcome 22: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-003.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 1: Oedema in the lower legs (dichotomous variable)" data-id="CD003229-fig-0071" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 1: Oedema in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 2: Ankle perimeter circumference (mm)" data-id="CD003229-fig-0072" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 2: Ankle perimeter circumference (mm) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 3: Quality of life" data-id="CD003229-fig-0073" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 3: Quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 4: Pain in the lower legs (dichotomous variable)" data-id="CD003229-fig-0074" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 4: Pain in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 5: Pain in the lower legs (continuous variable)" data-id="CD003229-fig-0075" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 5: Pain in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 6: Cramps in the lower legs (continuous variable)" data-id="CD003229-fig-0076" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 6: Cramps in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 7: Itching in the lower legs (dichotomous variable)" data-id="CD003229-fig-0077" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 7: Itching in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 8: Itching in the lower legs (continuous variable)" data-id="CD003229-fig-0078" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 8: Itching in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 9: Heaviness in the lower legs (dichotomous variable)" data-id="CD003229-fig-0079" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 9: Heaviness in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-004.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 10: Heaviness in the lower legs (continuous variable)" data-id="CD003229-fig-0080" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-004.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 10: Heaviness in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-004.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 11: Swelling in the lower legs (dichotomous variable)" data-id="CD003229-fig-0081" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-004.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 11: Swelling in the lower legs (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-004.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 12: Swelling in the lower legs (continuous variable)" data-id="CD003229-fig-0082" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-004.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 12: Swelling in the lower legs (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-004.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 13: Participant satisfaction (dichotomous variable)" data-id="CD003229-fig-0083" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-004.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 13: Participant satisfaction (dichotomous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-004.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 14: Participant satisfaction (continuous variable)" data-id="CD003229-fig-0084" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-004.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 14: Participant satisfaction (continuous variable) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003229-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/urn:x-wiley:14651858:media:CD003229:CD003229-CMP-004.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 15: Adverse events" data-id="CD003229-fig-0085" src="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_t/tCD003229-CMP-004.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis based on low risk of bias, Outcome 15: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/media/CDSR/CD003229/image_n/nCD003229-CMP-004.15.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003229-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Do phlebotonics improve signs and symptoms of venous insufficiency when compared with placebo?</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phlebotonics compared with placebo for venous insufficiency</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with venous insufficiency<br/><b>Settings:</b> hospital and ambulatory settings<br/><b>Intervention:</b> phlebotonics<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects *</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(RCTs)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with phlebotonics</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Oedema in the lower legs</b> </p> <p><b>(dichotomous</b> </p> <p><b>variable)</b> </p> <p>Follow‐up: 1‐6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>575 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>403 per 1000</b><br/>(362 to 449) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.70</b> <br/>(0.63 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1245<br/>(13 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phebotonics probably slightly reduce oedema in the lower limb compared to placebo</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Oedema in the lower legs</b> </p> <p><b>(ankle circumference, mm)</b> </p> <p>Follow‐up: 1‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ankle circumference in the lower legs in the phlebotonic groups was <b>4.27 mm lower</b> (5.61 to 2.93 lower) than in the placebo groups </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010<br/>(15 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phlebotonics probably slightly reduce ankle perimeter circumference compared to placebo</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><b>(CIVIQ and other questionnaires)</b> </p> <p>Follow‐up: mean 2‐12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The QoL in the phlebotonic groups was <b>0.06 SMD lower</b> (0.22 lower to 0.1 higher) than in the placebo groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1639<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phebotonics probably make little or no difference to QoL compared with placebo</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ulcer healing</b> </p> <p><b>(dichotomous variable)</b> </p> <p>Follow‐up: 1‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>381 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>358 per 1000</b><br/>(301 to 430) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/>(0.79 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>461<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phlebotonics may make little or no difference to ulcer healing compared to placebo</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 1‐12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>158 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>180 per 1000</b><br/>(161 to 200) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.14</b> <br/>(1.02 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5789<br/>(37 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phlebotonics probably slightly increase adverse events compared to placebo</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>CIVIQ</b> : Chronic Venous Insufficiency International Questionnaire; <b>QoL</b> : quality of life; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The certainty of the evidence was downgraded (1 level) to moderate because of overall risk of bias (10 studies had an unclear risk of bias and two had a high risk of bias)<br/><sup>b</sup>The certainty of the evidence was downgraded (1 level) to moderate because of overall risk of bias (11 studies had an unclear risk of bias and one had a high risk of bias)<br/><sup>c</sup>The certainty of the evidence was downgraded (1 level) to moderate because of overall risk of bias (one study had an unclear risk of bias and two had a high risk of bias)<br/><sup>d</sup>The certainty of the evidence was downgraded (2 levels) to low because of overall risk of bias (four studies had an unclear risk of bias and two had a high risk of bias) and imprecision (low number of events)<br/><sup>e</sup>The certainty of the evidence was downgraded (1 level) to moderate because of overall risk of bias (28 RCTs had unclear risk of bias and four RCTs had high risk of bias) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Do phlebotonics improve signs and symptoms of venous insufficiency when compared with placebo?</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003229-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Results of all outcomes analysed (all phlebotonics)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Variables</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dichotomous</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Continuous</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.70 (0.63 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema (mm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐4.27 (‐5.61 to ‐2.93)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema (volume)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.24 (‐0.33 to ‐0.15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulcer cured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trophic disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.87 (0.81 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.35 (‐0.54, ‐0.17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cramps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.72 (0.58 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restless legs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.81 (0.72 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Itching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heaviness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.63 (0.50 to 0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paraesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.67 (0.50 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global assessment by the participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.14 (1.02 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Note: No measures of effect are specified when I<sup>2</sup> was &gt; 75% for the subgroup </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>RR: risk ratio<br/>MD: mean difference<br/>NS: non‐significant<br/>RR: risk ratio<br/>SMD: standardized mean difference </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Results of all outcomes analysed (all phlebotonics)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003229-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Results by pharmacological group: aminaftone</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Variables</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dichotomous</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Continous</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.53 (0.28 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.17 (‐0.61 to 0.28)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulcer cured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trophic disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.43 (0.23 to 0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cramps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.56 (0.31 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Itching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.53 (0.31 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heaviness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.32 (0.17 to 0.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of live</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐10.00 (‐17.01 to ‐2.99)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Note: Only 1 study was analyzed</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>MD: mean difference<br/>NS: non‐significant<br/>RR: risk ratio<br/>SMD: standardized mean difference </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Results by pharmacological group: aminaftone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003229-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results by pharmacological group: calcium dobesilate</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Variables</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dichotomous</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Continuous</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema (mm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema (volume)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.38 (‐0.51 to ‐0.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulcer cured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.53 (0.35 to 0.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cramps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.65 (0.50 to 0.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restless legs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.73 (0.59 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Itching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heaviness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.19 (0.08 to 0.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paraesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global assessment by the participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.52 (‐0.71 to ‐0.33)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.22 (1.0 to 1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Note: No measures of effect are specified when I<sup>2</sup> was &gt; 75% for the subgroup </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>NS: non‐significant<br/>RR: risk ratio<br/>SMD: standardized mean difference </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results by pharmacological group: calcium dobesilate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003229-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Results by pharmacological group: Centella asiatica </span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Variables</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dichotomous</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Continuous</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heaviness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global assessment by the participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.28 (0.14 to 0.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Note: Only 1 study was analyzed</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>NS: non‐significant<br/>RR: risk ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Results by pharmacological group: Centella asiatica </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003229-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Results by pharmacological group: diosmine, hidrosmine</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Variables</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dichotomous</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Continuous</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.63 (0.46 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema (mm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐5.98 (‐7.78 to ‐4.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulcer cured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trophic disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.87 (0.81 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.23 (‐0.41 to ‐0.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cramps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.83 (0.70 to 0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.46 (‐0.78 to ‐0.14)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restless legs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Itching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heaviness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.69 (‐1.02 to ‐0.36)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.70 (0.52 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.92 (‐1.26 to ‐0.58)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paraesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global assessment by the participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.81 (‐1.14 to ‐0.47)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Note: No measures of effect are specified when I<sup>2</sup> was &gt; 75% for the subgroup </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>MD: mean difference<br/>NS: non‐significant<br/>RR: risk ratio<br/>SMD: standardized mean difference </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Results by pharmacological group: diosmine, hidrosmine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003229-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Results by pharmacological group: French maritime pine bark extract</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Variables</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dichotomous</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Continuous</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.66 (0.48 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐1.39 (‐2.09 to ‐0.69)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heaviness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐1.50 (‐2.21 to ‐0.79)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐1.65 (‐2.38 to ‐0.92)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Note: Only 1 study was analyzed</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>NS: non‐significant<br/>RR: risk ratio<br/>SMD: standardized mean difference </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Results by pharmacological group: French maritime pine bark extract</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003229-tbl-0008"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Results by pharmacological group: grape seed extract</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Variables</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dichotomous</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Continuous</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Note: Only 1 study was analyzed</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>NS: non‐significant</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Results by pharmacological group: grape seed extract</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003229-tbl-0009"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Results by pharmacological group: rutosides</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Variables</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dichotomous</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Continuous</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.72 (0.64 to 0.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema (mm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema (volume)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.15 (‐0.16 to ‐0.03)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulcer cured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trophic disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.71 (‐1.23 to ‐0.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cramps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR ‐0.83 (‐1.50 to ‐0.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restless legs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Itching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.58 (‐1.10 to ‐0.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heaviness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.60 (0.48 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Swelling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.67 (0.50 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paraesthesias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.55 (0.37 to 0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global assessment by the participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.22 (1.04 to 1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Note: No measures of effect are specified when I<sup>2</sup> was &gt; 75% </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>NS: non‐significant<br/>RR: risk ratio<br/>SMD: standardized mean difference </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Results by pharmacological group: rutosides</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/full#CD003229-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003229-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Phlebotonics versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Oedema in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.63, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.28, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.48, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.46, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 Grape seed extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.58, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.5 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.64, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Ankle perimeter circumference (mm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.27 [‐5.61, ‐2.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.69 [‐4.84, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.98 [‐7.78, ‐4.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.45 [‐5.06, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Volume of the leg (mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.33, ‐0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.61, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>826</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐0.51, ‐0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.26, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.22, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.64 [‐1.10, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Calcium dobesilate at 3 months of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.16, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.12, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Ulcer healing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.79, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.18, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.69, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.69, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.87, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Trophic disorders (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.81, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.41, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.81, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.71, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Pain in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.23, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.35, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.63, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.4 French maritime pine bark extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.48, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.5 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.48, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Pain in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐0.54, ‐0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.31, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>846</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.41, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 French maritime pine bark extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.39 [‐2.09, ‐0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.4 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐1.23, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Cramps in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1793</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.58, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.31, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.50, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.70, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.4 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.47, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Cramps in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.29, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.78, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.83 [‐1.50, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Restless legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.72, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.59, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.70, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.72, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Itching in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.31, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.51, 5.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.21, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Itching in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.11, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.58 [‐1.10, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Heaviness in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.17, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.08, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.3 Centella asiatica</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.32, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.4 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.35, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.5 French maritime pine bark extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.76, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.6 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.48, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Heaviness in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.23, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.69 [‐1.02, ‐0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.3 French maritime pine bark extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐2.21, ‐0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.4 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.11 [‐1.87, ‐0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Swelling in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.50, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.08, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.52, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.3 French maritime pine bark extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.64, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.4 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.50, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Swelling in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.24, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.92 [‐1.26, ‐0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.3 French maritime pine bark extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.65 [‐2.38, ‐0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.4 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.73 [‐3.50, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Paraesthesia in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.50, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.51, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.62, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.37, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Paraesthesia in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.44, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.1 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.44, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.2 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.96, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Participant satisfaction (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.36, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.43, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.3 Centella asiatica</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.14, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.4 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.30, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Participant satisfaction (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.71, ‐0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.81 [‐1.14, ‐0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.18 [‐1.96, ‐0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.02, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.06, 6.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.00, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.3 Centella asiatica</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.58, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.4 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.72, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.5 Grape seed extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.19, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.6 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.04, 1.43]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Phlebotonics versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003229-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sensitivity analysis excluding studies that allowed the use of elastic stockings</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Oedema in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.60, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.28, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.48, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.46, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 Grape seed extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.58, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.5 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>540</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.58, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Ankle perimeter circumference (mm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.59 [‐6.02, ‐3.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐4.95, 3.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.90 [‐7.72, ‐4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.28 [‐6.06, ‐0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Volume of the leg (mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.42, ‐0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.61, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>587</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.33 [‐0.49, ‐0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.47, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.41, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.64 [‐1.10, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.23, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.12, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Ulcer healing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.27, 3.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.18, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.15, 14.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Trophic disorders (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.79, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.41, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.81, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Pain in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.60, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.23, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.35, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.3 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.63, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.4 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.61, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Pain in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.42, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>846</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.41, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.96 [‐1.33, ‐0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Cramps in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.57, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.31, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.50, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.3 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.69, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.4 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.50, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Cramps in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐1.15, ‐0.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.78, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.2 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.83 [‐1.50, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Restless legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.72, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.59, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.70, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.73, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Itching in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.31, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.51, 5.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.21, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Itching in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.1 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Heaviness in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.17, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.08, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.3 Centella asiatica</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.32, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.4 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.29, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.5 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.38, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Heaviness in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.1 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.69 [‐1.02, ‐0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.2 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.27 [‐2.22, ‐0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Swelling in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>952</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.53, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.08, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.52, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.58, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.17 Swelling in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.1 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.92 [‐1.26, ‐0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.2 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.73 [‐3.50, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.18 Paraesthesias in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.64, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.58, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.61, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.51, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.19 Paraesthesias in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19.1 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.20 Participant satisfaction (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.53, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.43, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.68, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.28, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.21 Participant satisfaction (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21.1 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21.2 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.22 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.95, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.06, 6.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>935</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.82, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.3 Centella asiatica</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.58, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.4 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.74, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.5 Grape seed extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.19, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.6 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.08, 2.19]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sensitivity analysis excluding studies that allowed the use of elastic stockings</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003229-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis of published studies only</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Oedema in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.63, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.28, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.48, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.46, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.4 Grape seed extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.58, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.5 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.64, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Ankle perimeter circumference (mm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1796</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.61 [‐6.77, ‐0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.17 [‐8.37, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.98 [‐7.78, ‐4.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.18 [‐9.79, 5.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Volume of the leg (mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.34 [‐0.44, ‐0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.61, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>826</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐0.51, ‐0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.47, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.22, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.64 [‐1.10, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.16, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.3 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.12, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Patients with ulcer (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.78, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.18, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.70, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.84, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Trophic disorders (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.81, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.41, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.81, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.71, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Pain in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.23, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.35, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.3 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.63, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.4 French maritime pine bark extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.48, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.5 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.45, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Pain in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1075</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.34, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>846</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.41, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.3 French maritime pine bark extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.39 [‐2.09, ‐0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.4 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐1.23, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Cramps in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.31, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.50, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.3 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.70, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.4 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1060</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.45, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Cramps in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.29, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.78, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.83 [‐1.50, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Restless legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.72, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.59, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.70, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.72, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Itching in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.31, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.51, 5.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.21, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.13 Itching in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.1 Calccium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.11, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.2 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.58 [‐1.10, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.14 Heaviness in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.17, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.08, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.3 Centella asiatica</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.32, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.4 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.35, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.5 French maritime pine bark extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.76, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.6 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.49, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.15 Heaviness in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.23, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.69 [‐1.02, ‐0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.3 French maritime pine bark extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐2.21, ‐0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.4 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.27 [‐2.22, ‐0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.16 Swelling in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.49, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.08, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.52, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16.3 French maritime pine bark extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.64, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16.4 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.49, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.17 Swelling in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.24, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.15 [‐1.50, ‐0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17.3 French maritime pine bark extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.65 [‐2.38, ‐0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17.4 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.73 [‐3.50, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.18 Paraesthesias in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.48, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.51, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.62, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.35, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.19 Paraesthesias in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.1 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.20 Participant satisfaction (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.20.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.61, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.20.2 Centella asiatica</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.14, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.20.3 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.59, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.20.4 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.26, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.21 Participant satisfaction (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.71, ‐0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21.2 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.81 [‐1.14, ‐0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21.3 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.18 [‐1.96, ‐0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.22 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4830</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.99, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22.1 Aminaftone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.06, 6.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22.2 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.00, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22.3 Centella asiatica</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.58, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22.4 Diosmine, Hidrosmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.72, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22.5 Grape seed extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.19, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22.6 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.02, 1.76]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis of published studies only</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003229-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sensitivity analysis based on low risk of bias</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Oedema in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Ankle perimeter circumference (mm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.34 [‐8.79, 4.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.34 [‐8.79, 4.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>617</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐2.15, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Calcium dobesilate at 3 months of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>617</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐2.15, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Pain in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Pain in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Cramps in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Itching in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Itching in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Heaviness in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.1 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.10 Heaviness in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.11 Swelling in the lower legs (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.1 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.12 Swelling in the lower legs (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.13 Participant satisfaction (dichotomous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.81, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.81, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.14 Participant satisfaction (continuous variable) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.15 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.97, 2.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.1 Calcium dobesilate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.76, 3.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.2 Rutosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.00, 3.34]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sensitivity analysis based on low risk of bias</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003229.pub4/references#CD003229-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003229.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003229-note-0021">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003229-note-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003229-note-0019">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD003229-note-0017">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD003229-note-0016">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD003229-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD003229-note-0020">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003229-note-0013">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003229-note-0014">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003229\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003229\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003229\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003229\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003229\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003229\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003229\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003229\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003229\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003229\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003229\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003229\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003229\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003229\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003229\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003229\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003229\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003229\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003229.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003229.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003229.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003229.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003229.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726125029"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003229.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726125032"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003229.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8bf719969379',t:'MTc0MDcyNjEyNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 